Compounds > cardiovascular agents
Page last updated: 2024-08-03 11:44:27

cardiovascular agents

Description

Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. [MeSH]

Cross-References

ID SourceID
PubMed CID25063946
SCHEMBL ID9907037
MeSH IDM0003472

Synonyms (10)

Synonym
cardiovascular agents
934841-17-5
(3s,5s)-tert-butyl 3-isopropyl-5-((2s,4s)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-2-oxopyrrolidine-1-carboxylate
AKOS016003341
SCHEMBL9907037
tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate
DTXSID60648583
cid 25063946
A937555
(3s,5s)-tert-butyl3-isopropyl-5-((2s,4s)-4-isopropyl-5-oxotetrahydrofuran-2-yl)-2-oxopyrrolidine-1-carboxylate

Research

Studies (16,344)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903949 (24.16)18.7374
1990's1395 (8.54)18.2507
2000's3535 (21.63)29.6817
2010's6226 (38.09)24.3611
2020's1239 (7.58)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,480 (8.39%)5.53%
Reviews4,350 (24.65%)6.00%
Case Studies766 (4.34%)4.05%
Observational341 (1.93%)0.25%
Other10,708 (60.69%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetylcarnitine
1
O-acylcarnitinehuman metabolite2011201113.0low000010
dinitrochlorobenzene
1
C-nitro compound;
monochlorobenzenes		allergen;
epitope;
sensitiser		1979197945.0low010000
2,3-diphosphoglycerate
1
bisphosphoglyceric acid;
tetronic acid derivative		human metabolite2013201311.0low000010
gamma-aminobutyric acid
11
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule		1998201520.4low105510
aminolevulinic acid
1
4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		2009200915.0low000100
5-hydroxytryptophan
2
hydroxytryptophanhuman metabolite;
neurotransmitter		1963196560.0low020000
acetic acid
3
monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent		200420209.7low000120
acetaldehyde
1
aldehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent		2001200123.0low000100
acetamide
1
acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia		1960196064.0low010000
adenine
6
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		199920229.3low001041
agmatine
1
guanidines;
primary amino compound		Escherichia coli metabolite;
mouse metabolite		2012201212.0low000010
allantoin
1
imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary		2010201014.0low000100
ammonium hydroxide
4
azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant		1994201816.0low101120
quinacrine
1
acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor		1957195767.0low010000
beta-alanine
1
amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter		2013201311.0low000010
benzene
4
aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent		1951195272.2low040000
betaine
6
amino-acid betaine;
glycine derivative		fundamental metabolite2006201314.0low100330
bromide
5
halide anion;
monoatomic bromine		1953196068.0low050000
1-butanol
4
alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent		1954202028.0low011020
carbamates
20
amino-acid anion1950201053.0low1171200
carbon monoxide
5
carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent		2008202110.8low000221
formic acid
1
monocarboxylic acidantibacterial agent;
astringent;
metabolite;
protic solvent;
solvent		2010201014.0low000100
carnitine
32
amino-acid betainehuman metabolite;
mouse metabolite		1993202216.1low40612131
methane
2
alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas		1955202036.5low010010
choline
17
cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite		1951196469.2low0170000
citric acid, anhydrous
4
tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite		1963201834.8low020020
chlorine
13
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		1953201631.0low052240
coumarin
5
coumarinsfluorescent dye;
human metabolite;
plant metabolite		1954201436.6low121020
salicylic acid
3
monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite		2004201714.0low000210
phloroglucinol
1
benzenetriol;
phenolic donor		algal metabolite1962196262.0low010000
gallic acid
2
trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite		2002201217.0low000110
hydrogen sulfide
16
gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent		200820218.8low0004111
3-hydroxybutyric acid
1
(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid		human metabolite2009200915.0low000100
bupropion
1
aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic		2003200321.0low000100
3-chlorobenzoic acid
1
monochlorobenzoic aciddrug metabolite1958195866.0low010000
guaiacol
12
guaiacolsdisinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite		1954196366.0low0120000
n(g),n(g')-dimethyl-l-arginine
12
alpha-amino acid2003201713.8low300660
phosphonoacetic acid
1
monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor		1992199232.0low001000
creatine
2
glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical		2005202111.0low000101
lactic acid
46
2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite		1954201717.0low84311280
dihydroxyacetone
1
ketotriose;
primary alpha-hydroxy ketone		antifungal agent;
Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201720177.0low000010
dimethyl sulfoxide
5
sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger		1994201620.2low002120
ethanolamine
2
ethanolamines;
primary alcohol;
primary amine		Escherichia coli metabolite;
human metabolite;
mouse metabolite		1957201040.5low010100
formaldehyde
3
aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1952199357.0low021000
formamide
1
carboximidic acid;
formamides;
monocarboxylic acid amide;
one-carbon compound		solvent1955195569.0low010000
gamma-butyrobetaine
6
amino-acid betaineEscherichia coli metabolite;
human metabolite		2006201314.0low100330
glutaric acid
1
alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		Daphnia magna metabolite;
human metabolite		1959195965.0low010000
glycine
19
alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical		1952201345.8low0102520
glycerol
17
alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent		1954202153.8low0140021
carbonic acid
2
carbon oxoacid;
chalcocarbonic acid		mouse metabolite1951198954.0low020000
hydrogen carbonate
2
carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1961199247.5low011000
dalteparin
10
1993201817.7low302620
dalteparin
8
1999201817.4low201610
histamine
25
aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter		1951201451.4low1182320
hydrogen
3
elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite		1958201329.7low010020
hydrogen
2
elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite		1958201239.0low010010
imidazole
2
imidazole1988201124.5low010010
indole
1
indole;
polycyclic heteroarene		Escherichia coli metabolite1956195668.0low010000
iodine
4
diatomic iodinenutrient1954200145.0low021100
pipecolic acid
1
piperidinemonocarboxylic acid1957195767.0low010000
2,3,4,5-tetrahydroxypentanal
1
hydroxyaldehyde;
pentose;
polyol		202120213.0low000001
thioctic acid
4
dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector		201020208.5low100130
malonic acid
1
alpha,omega-dicarboxylic acidhuman metabolite1964196460.0low010000
pyruvaldehyde
1
2-oxo aldehyde;
propanals		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201720177.0low000010
methanol
4
alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite		1958201425.2low010030
inositol
1
cyclitol;
hexol		1962196262.0low010000
melatonin
5
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		200920209.8low100140
croton oil
2
N-acyl-hexosamine1955198852.5low020000
acetanilide
5
acetamides;
anilide		analgesic1959196263.4low050000
nickel
3
metal allergen;
nickel group element atom		epitope;
micronutrient		2008201314.0low000210
niacinamide
4
pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor		1963200743.8low030100
niacin
12
pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent		1952201549.9low080310
nitrates
117
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		1949202326.4low9263526264
nitroxyl
4
nitrogen oxoacid201320216.5low000031
nitrites
21
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite1957201738.4low0122340
nitrous oxide
2
gas molecular entity;
nitrogen oxide		analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent		1999201616.5low001010
orotic acid
1
pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite		2006200618.0low000100
oxamic acid
2
dicarboxylic acid monoamideEscherichia coli metabolite1957200045.5low011000
palmitic acid
2
long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite		2004200718.5low000200
parathion
1
C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
avicide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
mouse metabolite		1957195767.0low010000
pentachlorophenol
1
aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes		human xenobiotic metabolite1955195569.0low010000
phenethylamine
2
alkaloid;
aralkylamine;
phenylethylamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite		1955196365.0low020000
phosphorylcholine
6
phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite		2002201416.3low400510
diphosphoric acid
1
acyclic phosphorus acid anhydride;
phosphorus oxoacid		Escherichia coli metabolite202020204.0low000010
propylene glycol
1
glycol;
propane-1,2-diols		allergen;
human xenobiotic metabolite;
mouse metabolite;
protic solvent		1958195866.0low010000
1-propanol
3
propan-1-ols;
short-chain primary fatty alcohol		metabolite;
protic solvent		1964200236.7low011100
purine
6
purine1951200060.0low051000
pyridoxal phosphate
2
methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2001200322.0low000200
pyrogallol
3
benzenetriol;
phenolic donor		plant metabolite1962201329.3low010110
pyruvic acid
1
2-oxo monocarboxylic acidcofactor;
fundamental metabolite		1958195866.0low010000
thiosulfates
2
divalent inorganic anion;
sulfur oxide;
sulfur oxoanion		human metabolite201120208.5low100020
dithionite
1
sulfur oxide;
sulfur oxoanion		1954195470.0low010000
sulfites
1
divalent inorganic anion;
sulfur oxide;
sulfur oxoanion		1954195470.0low010000
spermine
1
polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent		1998199826.0low001000
succinic acid
6
alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid		anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent		1951201644.2low030210
sulfur dioxide
1
sulfur oxideEscherichia coli metabolite;
food bleaching agent;
refrigerant		201620168.0low000010
taurine
3
amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite		2000201616.3low001110
thiamine
13
primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1950201963.5low1120010
trimethyloxamine
3
tertiary amine oxideEscherichia coli metabolite;
metabolite;
osmolyte		201320188.3low100030
uracil
6
pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		1962202113.8low310041
uric acid
7
uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite		1958201734.9low031210
urea
23
isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1952202318.0low6501116
xanthine
3
xanthineSaccharomyces cerevisiae metabolite1996201023.0low002100
2-amino-5-phosphonovalerate
5
non-proteinogenic alpha-amino acidNMDA receptor antagonist1998201617.4low002120
2-amino-5-phosphonovalerate
3
non-proteinogenic alpha-amino acidNMDA receptor antagonist1998200523.7low002100
8-hydroxy-2-(di-n-propylamino)tetralin
2
phenols;
tertiary amino compound;
tetralins		serotonergic antagonist1987200030.5low011000
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
1
non-proteinogenic alpha-amino acid2000200024.0low001000
4-iodo-2,5-dimethoxyphenylisopropylamine
1
amphetamines;
dimethoxybenzene;
organoiodine compound		2000200024.0low001000
gallopamil
1
benzenes;
organic amino compound		1982198242.0low010000
vanilmandelic acid
1
2-hydroxy monocarboxylic acid;
aromatic ether;
phenols		human metabolite2013201311.0low000010
menthol
1
p-menthane monoterpenoid;
secondary alcohol		volatile oil component1993199331.0low001000
mandelic acid
3
2-hydroxy monocarboxylic acid;
benzenes		antibacterial agent;
human xenobiotic metabolite		1951195671.0low030000
1,2-dioctanoylglycerol
1
1988198836.0low010000
1,3-dipropyl-8-cyclopentylxanthine
2
oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor		1998200423.0low001100
1,3-dipropyl-8-(4-sulfophenyl)xanthine
1
1998199826.0low001000
1-anilino-8-naphthalenesulfonate
3
aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe1959201034.0low010200
14,15-epoxy-5,8,11-eicosatrienoic acid
1
long-chain fatty acid2008200816.0low000100
17-octadecynoic acid
1
acetylenic fatty acid;
long-chain fatty acid;
monounsaturated fatty acid;
terminal acetylenic compound		EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor;
EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor;
P450 inhibitor		2000200024.0low001000
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
1
oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor2007200717.0low000100
2,4,5-trichlorophenoxyacetic acid
1
chlorophenoxyacetic acid;
trichlorobenzene		defoliant;
phenoxy herbicide;
synthetic auxin		1986198638.0low010000
2,4-dichlorophenoxyacetic acid
1
chlorophenoxyacetic acid;
dichlorobenzene		agrochemical;
defoliant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
environmental contaminant;
phenoxy herbicide;
synthetic auxin		1986198638.0low010000
2,4-dinitrophenol
1
dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor		1955195569.0low010000
2-aminoethoxydiphenyl borate
1
organoboron compound;
primary amino compound		calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener		2006200618.0low000100
3,4-methylenedioxyamphetamine
1
benzodioxoles2012201212.0low100010
3-nitropropionic acid
1
C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin		202120213.0low000001
4-aminopyridine
20
aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker		1981200937.9low0190100
5,5-dimethyl-1-pyrroline-1-oxide
1
1-pyrroline nitronesneuroprotective agent;
spin trapping reagent		1988198836.0low010000
phenytoin
12
imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent		1949199159.0low0111000
5,8,11,14-eicosatetraynoic acid
1
long-chain fatty acid2009200915.0low000100
5-dimethylamiloride
1
2008200816.0low000100
ethylisopropylamiloride
1
aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound		anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker		2000200024.0low001000
5-hydroxydecanoate
4
medium-chain fatty acid1990200326.0low002200
7-nitroindazole
4
1993200923.2low002200
8-(4-sulfophenyl)theophylline
3
1997200124.3low001200
8-phenyltheophylline
1
1996199628.0low001000
tacrine
2
acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor1998200124.5low001100
2,2'-azobis(2-amidinopropane)
1
monoazo compound1998199826.0low001000
acebutolol
2
aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent		1987201025.5low010100
acemetacin
1
carboxylic ester;
indol-3-yl carboxylic acid;
monocarboxylic acid;
monochlorobenzenes;
N-acylindole		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug		1981198143.0low010000
acetaminophen
12
acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		1964201319.2low011640
acetazolamide
8
monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		1959201424.5low120240
adiphenine
1
diarylmethane1963196361.0low010000
albuterol
3
phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic		1994199828.7low103000
alendronate
1
1,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor		2014201410.0low000010
alfuzosin
1
monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent		2003200321.0low000100
alpha-methyltyrosine methyl ester
1
1981198143.0low010000
alprazolam
1
organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic		1986198638.0low010000
diatrizoic acid
1
acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic		1962196262.0low010000
amifostine anhydrous
4
diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent		1998200721.8low002200
pimagedine
2
guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor		2000200621.0low001100
p-aminohippuric acid
1
N-acylglycineDaphnia magna metabolite2000200024.0low001000
theophylline
42
dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent		1954202141.5low32110821
amiodarone
33
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug1980202319.6low2451662
dan 2163
1
aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic		2013201311.0low000010
amitriptyline
6
carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic		1986201621.2low012120
amlodipine
29
dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent		1993202416.5low4061472
amobarbital
3
barbiturates1953195869.3low030000
antipyrine
2
pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		1961200740.0low010100
2-amino-4-phosphonobutyric acid
1
2014201410.0low000010
acetovanillone
3
acetophenones;
aromatic ketone;
methyl ketone		antirheumatic drug;
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
plant metabolite		2011201511.3low000030
arecoline
1
enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist		1962196262.0low010000
aspirin
283
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		1953202316.0low4114329513210
astemizole
2
benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist		201520206.5low000020
atenolol
29
ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic		1981202318.5low8261452
azathioprine
5
aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug		1990200725.0low003200
baclofen
4
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant		1986199829.5low013000
bay-k-8644
5
(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester		1987199831.6low023000
benzyl benzoate
1
benzoate ester;
benzyl ester		acaricide;
plant metabolite;
scabicide		1953195371.0low010000
bepridil
2
pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent		1993200027.5low002000
berberine
5
alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker		2001202211.6low000221
bethanechol
1
carbamate ester;
quaternary ammonium ion		muscarinic agonist1995199529.0low001000
biperiden
5
piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic		1957195966.0low050000
bisbenzimidazole
1
bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome		2001200123.0low000100
bisindolylmaleimide i
3
2001201714.3low000120
bisoprolol
20
secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent		1993202210.3low5024113
buflomedil
2
aromatic ketone1985198638.5low120000
bupivacaine
1
aromatic amide;
piperidinecarboxamide;
tertiary amino compound		2014201410.0low000010
caffeine
47
purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic		1952201849.2low0332570
verapamil
61
aromatic ether;
nitrile;
polyether;
tertiary amino compound		1981202226.9low420191291
calmidazolium
1
imidazolium ionapoptosis inducer;
calmodulin antagonist		2011201113.0low000010
camphor, (+-)-isomer
2
bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite1956195767.5low020000
candesartan cilexetil
1
biphenyls1999199925.0low101000
candesartan
6
benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		2003202013.3low000330
carbamazepine
3
dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic		1991201122.0low001110
carisoprodol
22
carbamate estermuscle relaxant1960196463.3low0220000
carvedilol
24
carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent		2000202413.2low60110121
celecoxib
1
organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		2009200915.0low000100
celiprolol
1
aromatic ketone1995199529.0low101000
chelerythrine
3
benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		1997200524.3low002100
chloral hydrate
3
aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic		1962198454.0low030000
chlorambucil
1
aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent		2001200123.0low000100
chlordiazepoxide
12
benzodiazepine1962196560.5low0120000
chlormezanone
11
1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant		1959196264.2low0110000
chloroquine
4
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		1979201919.2low010120
chlorothiazide
2
benzothiadiazineantihypertensive agent;
diuretic		1959196263.5low020000
chlorphenesin carbamate
1
carbamate ester;
monochlorobenzenes;
secondary alcohol		muscle relaxant1963196361.0low010000
chlorpromazine
25
organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug		1954198164.6low0250000
chlorthalidone
2
isoindoles;
monochlorobenzenes;
sulfonamide		2009201512.0low000110
chlorzoxazone
11
1,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative		1958200758.1low0100100
cifenline
1
diarylmethane2005200519.0low000100
cilostazol
38
lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent		200220219.9low90011261
cimetidine
6
aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1982200733.5low041100
eucalyptol
1
2009200915.0low000100
citalopram
1
2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound		2008200816.0low000100
clenbuterol
3
amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent		2005201116.7low100210
clioquinol
3
monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator		1962196461.0low030000
clofibrate
2
aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist		1984200828.0low010100
clofibric acid
5
aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist		2002200818.6low000500
clomipramine
1
dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor		2000200024.0low001000
clonazepam
1
1,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator		202120213.0low000001
clonidine
61
clonidine;
imidazoline		1979202033.5low63714730
cyclandelate
14
carboxylic ester;
secondary alcohol		vasodilator agent1952196167.6low0140000
cyclocreatine
1
1995199529.0low001000
cycrimine
2
piperidines;
tertiary alcohol;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist		1955195569.0high020000
decamethonium
19
quaternary ammonium ionmuscle relaxant;
nicotinic acetylcholine receptor agonist		1950196271.4low0190000
deferiprone
1
4-pyridonesiron chelator;
protective agent		2004200420.0low000100
deferoxamine
3
acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore		1993200426.0low002100
desipramine
2
dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor		201420178.5low000020
amphetamine
4
primary amine1953200640.5low021100
diazepam
12
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic		1962200642.8low073200
diazoxide
5
benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent		2003201815.6low100410
dibucaine
2
aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic1956196464.0low020000
diclofenac
5
amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		1988201620.8low111120
ddt
1
benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant		1956195668.0low010000
dicyclomine
3
carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic		1953196565.0low030000
diflunisal
1
monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug		202120213.0low000001
dilazep
3
benzoate ester;
diazepane;
diester;
methoxybenzenes		cardioprotective agent;
platelet aggregation inhibitor;
vasodilator agent		1988199134.7low021000
dimethoate
2
monocarboxylic acid amide;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic		1961201138.0low010010
diphenhydramine
8
ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative		1953197963.6low080000
dipyridamole
33
piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent		1961201930.1low61111650
disopyramide
11
monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug1980200937.4low082100
valproic acid
2
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		1999200721.0low001100
domperidone
2
benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist		1990202118.5low001001
donepezil
1
aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent		2009200915.0low000100
doxapram
1
morpholines;
pyrrolidin-2-ones		central nervous system stimulant1984198440.0low010000
doxazosin
2
aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent		2000202412.0low001001
doxepin
1
dibenzooxepine;
tertiary amino compound		antidepressant1999199925.0low001000
droperidol
2
aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic		1982198242.0low020000
e 4031
2
sulfonamide1998199925.5low002000
edrophonium
6
phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor		1952198362.5low060000
enoxacin
1
1,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor		1993199331.0low001000
erythrosine
4
2002201119.2low000310
etanidazole
1
C-nitro compound;
imidazoles;
monocarboxylic acid amide		alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent		2001200123.0low000100
ethaverine
2
isoquinolines1954195470.0low020000
ether
17
ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant		1954196267.1low0170000
profenamine
2
phenothiazines;
tertiary amino compound		adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist		1956195668.0low020000
eicosapentaenoic acid ethyl ester
3
201420206.7low000030
famotidine
1
1,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		2009200915.0low000100
felodipine
1
dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent		2002200222.0low100100
fendiline
1
diarylmethane2014201410.0low000010
fenofibrate
3
aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic		2004201116.3low000210
fenoldopam
3
benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent		1983201324.0low010110
fentanyl
3
anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic		1982200033.0low012000
flecainide
4
aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug1999202012.0low001030
flufenamic acid
1
aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		2010201014.0low000100
flumazenil
3
ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist		1993200624.7low002100
fluorouracil
12
nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic		1990201325.2low409210
fluoxetine
1
(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound		201720177.0low100010
foscarnet
1
carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor		1992199232.0low001000
furosemide
29
chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic		1984202220.6low857881
furosemide
30
chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic		1984202220.1low857891
gabapentin
2
gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic		2006200618.0low100200
gentamicin
4
1979201222.2low010210
glutaral
1
dialdehydecross-linking reagent;
disinfectant;
fixative		2012201212.0low000010
glutethimide
2
piperidines1958195965.5low020000
glyburide
15
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		1990201522.8low106810
guaifenesin
19
methoxybenzenes1952196468.3low0190000
guanethidine
3
azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent		1964201842.0low020010
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
5
isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor2003201116.4low100410
fasudil
4
isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent		2003200917.2low100400
halothane
3
haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic1961199641.3low012000
heptaminol
1
tertiary alcohol1962196262.0low010000
4-fluorohexahydrosiladifenidol
1
1998199826.0low001000
hexamethonium
160
quaternary ammonium salt1951200070.1low01582000
hexobarbital
1
barbiturates1952195272.0low010000
hexylresorcinol
1
resorcinols1954195470.0low010000
alpha-methylhistamine
1
aralkylamino compound;
imidazoles		animal metabolite;
H3-receptor agonist		2010201014.0low000100
hydralazine
71
azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent		1952201944.6low34022090
hydrochlorothiazide
18
benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic		1962201919.4low631770
hydroxychloroquine
4
aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug		2004202011.5low000130
hydroxyurea
1
one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent		201720177.0low000010
hydroxyzine
3
hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist		1960198455.3low030000
mk 473
1
2010201014.0low000100
ibuprofen
11
monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic		1992201816.3low101550
phenelzine
2
primary amine1963196460.5low020000
lidocaine
40
benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic		1955202334.3low2218443
mephentermine
1
amphetamines1961196163.0low010000
alverine
5
tertiary amineantispasmodic drug1955196566.4medium050000
idebenone
1
1,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor		201820186.0low000010
imipramine
4
dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor		1963200941.8low021100
amrinone
5
bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor1981199138.2low041000
indapamide
2
indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic		201320198.0low000020
indomethacin
198
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		1957202018.8low13634113450
inositol niacinate
1
inositol nicotinate1962196262.0low010000
iodixanol
1
organoiodine compoundradioopaque medium2000200024.0low001000
iodoacetamide
1
1957195767.0low010000
iohexol
7
benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic		2011201810.3low100070
iopromide
7
dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic		201120239.6low200061
iothalamic acid
2
organic molecular entity1963201634.5low010010
iproniazid
1
carbohydrazide;
pyridines		1964196460.0low010000
avapro
2
azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		201120237.0low000011
1-methyl-3-isobutylxanthine
5
3-isobutyl-1-methylxanthine1986201627.6low022010
isocarboxazid
2
benzenes1963196361.0low020000
isoflurane
5
organofluorine compoundinhalation anaesthetic1987201521.4low011210
isoniazid
2
carbohydrazideantitubercular agent;
drug allergen		1954195569.5low020000
2-propanol
1
secondary alcohol;
secondary fatty alcohol		protic solvent2011201113.0low000010
2-propanol
2
secondary alcohol;
secondary fatty alcohol		protic solvent1959201139.0low010010
isoproterenol
82
catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent		1952202125.3low7211916242
isoxsuprine
9
alkylbenzene1959196462.2low090000
ketamine
3
cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic		1987201521.7low010110
ketanserin
2
aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist		1990200029.0low002000
ketoconazole
1
dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine		2006200618.0low000100
ketoprofen
1
benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic		201520159.0low000010
khellin
6
furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent		1953196268.7low060000
kynurenic acid
1
monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite		201520159.0low000010
labetalol
7
benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound		1981202321.0low013111
lamotrigine
2
1,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic		2008201711.5low000110
beta-lapachone
1
benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite		2009200915.0low000100
lidoflazine
4
diarylmethane1988199134.2low013000
linopirdine
1
indoles2002200222.0low000100
lomefloxacin
1
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent		1993199331.0low001000
lorazepam
1
benzodiazepine1999199925.0low001000
losartan
24
biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist		1992202313.5low2055122
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
1
chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector		2011201113.0low000010
manidipine
1
diarylmethane2011201113.0low000010
edaravone
1
pyrazoloneantioxidant;
radical scavenger		2007200717.0low000100
mecamylamine
6
primary aliphatic amine1956201042.3low031200
meclizine
1
diarylmethane1964196460.0low010000
meclofenamic acid
3
aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug		1978200531.3low011100
memantine
1
adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist		2005200519.0low000100
meperidine
11
ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic		1951196365.9low0110000
mephenesin
8
aromatic ether;
glycerol ether		1952196467.8low080000
mepivacaine
4
piperidinecarboxamidedrug allergen;
local anaesthetic		1956199853.8low031000
meprobamate
15
organic molecular entity1954196464.8low0150000
mescaline
4
methoxybenzenes;
phenethylamine alkaloid;
primary amino compound		hallucinogen1952195571.0low040000
metformin
27
guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic		1963202311.7low2123192
methadone
5
benzenes;
diarylmethane;
ketone;
tertiary amino compound		1955201334.6low020120
methantheline
5
xanthenes1952195470.8low050000
methenamine
1
polyazaalkane;
polycyclic cage;
tetramine		antibacterial drug1964196460.0low010000
methocarbamol
26
aromatic ether;
carbamate ester;
secondary alcohol		1957196463.8low0260000
methylphenidate
1
beta-amino acid ester;
methyl ester;
piperidines		2009200915.0low000100
methyprylon
1
organic molecular entity1956195668.0low010000
metoclopramide
3
benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic		1964202135.0low020001
metolazone
1
organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor		1989198935.0low010000
metoprolol
44
aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic		1996202112.1low80510263
metronidazole
1
C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic		2010201014.0low000100
metyrapone
2
aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor		1959196064.5low020000
mexiletine
5
aromatic ether;
primary amino compound		anti-arrhythmia drug1985200727.4low020300
mianserin
1
dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist		201620168.0low000010
miconazole
1
dichlorobenzene;
ether;
imidazoles		2001200123.0low000100
midazolam
4
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		1998201718.5low002110
midodrine
3
amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent		2012201610.3low000030
milrinone
18
bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent		1984202018.9low133480
mirtazapine
1
benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist		201620168.0low000010
mitoxantrone
4
dihydroxyanthraquinoneanalgesic;
antineoplastic agent		1998200920.5low201300
modafinil
1
monocarboxylic acid amide;
sulfoxide		2013201311.0low100010
molsidomine
8
ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent		1981201624.9low014210
moxisylyte
1
monoterpenoid1990199034.0low001000
deoxyepinephrine
4
catecholamine1987200131.0low021100
apnea
8
purine nucleoside1953199460.4low071000
nabumetone
1
methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug		1993199331.0low001000
nafronyl
1
naphthalenes1985198539.0low110000
naphazoline
1
naphthalenes1952195272.0low010000
nefazodone
1
aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor		202120213.0low000001
neostigmine
9
quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor		1951200456.3low070200
nialamide
1
organonitrogen compound;
organooxygen compound		1963196361.0low010000
nicardipine
10
benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound		1985201823.0low114320
niclosamide
1
benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor		2009200915.0low000100
nifedipine
32
C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent		1981201130.4low51016510
nimodipine
5
2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent		2009202111.2low000221
nitrazepam
1
1,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative		1965196559.0low010000
nitrendipine
1
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent		1994199430.0low001000
nitroglycerin
79
nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic		1962202226.2low13241914202
ns 1619
1
(trifluoromethyl)benzenes;
benzimidazoles;
phenols		potassium channel opener201720177.0low000010
nylidrin
1
alkylbenzene1953195371.0low010000
octopamine
1
phenylethanolamines;
tyramines		neurotransmitter2003200321.0low000100
ofloxacin
2
3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline		1992200426.0low101100
olprinone
1
bipyridines2001200123.0low000100
omeprazole
2
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		201620177.5low100020
ondansetron
1
carbazoles1992199232.0low001000
orphenadrine
1
ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic		1963196361.0low010000
oxazepam
1
1,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic		1989198935.0low110000
oxethazaine
1
amino acid amide1962196262.0low010000
oxidopamine
3
benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin		1996201516.7low001020
oxprenolol
1
aromatic ether1997199727.0low001000
oxybutynin
1
acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic		2004200420.0low000100
oxybutynin
1
acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic		201920195.0low100010
quinone
1
1,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite		1982198242.0low010000
papaverine
26
benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent		1953201557.1low0221210
pargyline
2
aromatic amine1964198052.0low020000
pd 98059
5
aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		2001201116.2low000410
pentobarbital
6
barbituratesGABAA receptor agonist1957201543.2low040110
pentoxifylline
6
oxopurine1985201816.8low111130
perhexiline
56
piperidinescardiovascular drug1982202317.0medium1011027162
phenacetin
5
acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug		1953196464.4low050000
phenindione
1
aromatic ketone;
beta-diketone		anticoagulant1963196361.0low010000
phenobarbital
10
barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative		1952201550.4low071110
phenoxybenzamine
8
aromatic amine1953200054.6low062000
phenprobamate
3
benzenes1960196263.0low030000
phenyl biguanide
1
guanidinescentral nervous system drug1990199034.0low001000
phenylbutazone
5
pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug		1959198857.6low050000
moxonidine
2
organohalogen compound;
pyrimidines		1999200124.0low001100
picotamide
1
benzamides2001200123.0low000100
pilsicainide
1
organic heterobicyclic compound;
secondary carboxamide		anti-arrhythmia drug;
sodium channel blocker		2006200618.0low000100
pimobendan
3
benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		1990202119.7low001101
pinacidil
3
pyridines1988200626.7low011100
pindolol
2
indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent		1994199728.5low002000
pioglitazone
10
aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic		2006201613.2low500640
pipenzolate
2
diarylmethane1957195767.0high020000
piperazine
4
azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug1957196364.2low040000
piperidolate
2
diarylmethane1957195866.5high020000
piracetam
3
organonitrogen compound;
organooxygen compound		1978201424.0low110110
pirbuterol
2
pyridines1981198143.0low120000
pirenzepine
2
pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist		1998200224.0low001100
potassium chloride
16
inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer1965202224.8low034621
4-aminobenzoic acid
8
aminobenzoate;
aromatic amino-acid anion		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		1955201458.9low170010
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
1
arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde		purinergic receptor P2X antagonist2001200123.0low000100
ono 1078
1
chromones1995199529.0low001000
prazosin
12
aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor		1981200134.5low174100
proadifen
2
diarylmethane2008201114.5low000110
probenecid
1
benzoic acids;
sulfonamide		uricosuric drug1959195965.0low010000
probucol
17
dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug		1995201812.1low7023120
procainamide
22
benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker		1953201351.9low0181210
procaine
39
benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug		1950202261.4low0361011
prochlorperazine
1
N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic		1964196460.0low010000
procyclidine
2
pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist		1952195371.5low020000
promethazine
6
phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative		1957196363.7low060000
propafenone
3
aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug2011201113.0low000030
propantheline
1
xanthenes1954195470.0low010000
propofol
5
phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative		2001201917.2low200410
propranolol
67
naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic		1979202026.4low8291012160
puupehenone
1
201620168.0low000010
pyrilamine
3
aromatic ether;
ethylenediamine derivative		H1-receptor antagonist1999200720.7low001200
quipazine
1
piperazines;
pyridines		1993199331.0low001000
stenopril
1
1987198737.0medium010000
riluzole
1
benzothiazoles2013201311.0low000010
risperidone
1
1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist		2001200123.0low000100
rofecoxib
1
butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		2006200618.0low000100
rolipram
1
pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor		1993199331.0low001000
ropinirole
1
indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist		201520159.0low000010
salicyl alcohol
1
aromatic primary alcohol;
hydroxybenzyl alcohol		human urinary metabolite1951195173.0low010000
sarpogrelate
1
hemisuccinate;
stilbenoid		2013201311.0low100010
sb 239063
2
imidazoles2011201113.0low000020
secobarbital
4
barbituratesanaesthesia adjuvant;
GABA modulator;
sedative		1954196465.0low040000
sevoflurane
2
ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor		1999201716.0low001010
linsidomine
1
morpholines1998199826.0low001000
sodium fluoride
1
fluoride saltmutagen2012201212.0low000010
sotalol
7
ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic		1993201520.0low102410
stearic acid
1
long-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite		202120213.0low000001
succinylcholine
85
quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent		1951196569.6low0850000
sulfamethoxypyridazine
1
pyridazines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor		1964196460.0low010000
sulfanilamide
3
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		1953195967.7low030000
sulfasalazine
1
1963196361.0low010000
sulfisoxazole
1
isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen		1964196460.0low010000
sulforaphane
2
isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite		201320207.5low100020
sulmazole
3
imidazopyridine;
sulfoxide		adenosine A1 receptor antagonist;
cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor		1984199536.3low121000
sulpiride
4
benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist		1982201329.2low020110
sulthiame
1
organic molecular entity1961196163.0low010000
sumatriptan
2
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent		1991199929.0low002000
suramin
3
naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug		2001201318.0low000210
temazepam
2
benzodiazepine1999201417.5low001010
terbutaline
2
phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent		1996202115.5low001001
terfenadine
2
diarylmethane2006202011.0low000110
tetracaine
6
benzoate ester;
tertiary amino compound		local anaesthetic1956201549.8low050010
tetraethylammonium
16
quaternary ammonium ion1950200949.8low0100600
thalidomide
1
phthalimides;
piperidones		2007200717.0low100100
theobromine
3
dimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent		1958195965.7low030000
ticlopidine
56
monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		1998201714.8low50330230
tiopronin
1
N-acyl-amino acid1990199034.0low001000
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate
1
trihydroxybenzoic acid2002200222.0low000100
nikethamide
1
pyridinecarboxamide1991199133.0low001000
tolazoline
6
imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent		1950196466.0low060000
tolbutamide
3
N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker		1963200435.7low011100
tolmetin
1
aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug		1993199331.0low001000
tolperisone
2
aromatic ketone1962196461.0low020000
tranexamic acid
1
amino acid2010201014.0low000100
trapidil
6
triazolopyrimidines1983201034.0low150100
trazodone
2
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor		1993199828.5low002000
triamterene
2
pteridinesdiuretic;
sodium channel blocker		2002201814.0low000110
triazolam
1
triazolobenzodiazepinesedative1996199628.0low101000
triclosan
2
aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic		1952200545.5low010100
trifluoperazine
2
N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug		1963202132.0low010001
trihexyphenidyl
6
amine1952195868.3low060000
trimethobenzamide
1
benzamides;
tertiary amino compound		antiemetic1964196460.0low010000
troglitazone
2
chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent		2005200718.0low000200
tyramine
2
monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter		1964200042.0low011000
urapidil
1
piperazines2012201212.0low000010
urethane
4
carbamate esterfungal metabolite;
mutagen		1951201429.0low010120
valethamate
2
alkylbenzene1955195867.5medium020000
vesnarinone
1
organic molecular entity2001200123.0low000100
vinca
2
alkaloid1961196262.5low020000
w 7
1
1999199925.0low001000
pirinixic acid
4
aryl sulfide;
organochlorine compound;
pyrimidines		2004201016.8low000400
xylazine
5
1,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative		1982198740.2low050000
zardaverine
1
organofluorine compound;
pyridazinone		anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug		1993199331.0low001000
zolpidem
4
imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative		1993201619.8low002110
corticosterone
3
11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1965201924.3low010020
prednisolone
21
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic		1958201652.8low0162120
estriol
2
16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite		1964196460.0low020000
lysergic acid diethylamide
34
ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound		dopamine agonist;
hallucinogen;
serotonergic agonist		1953199067.3low0331000
reserpine
35
alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic		1955200757.9low0313100
phentolamine
10
imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent		1953200141.1low163100
sorbitol
7
glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent		1961201447.0low150020
alloxan
1
pyrimidonehyperglycemic agent;
metabolite		1981198143.0low010000
thymidine
4
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite		1997201019.0low001300
benzimidazole
1
benzimidazole;
polycyclic heteroarene		202120213.0low000001
hydroxyproline
5
4-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite		2005201513.8low000320
thyroxine
14
2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone		1952202034.4low253330
dextroamphetamine
1
1-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent		1965196559.0low010000
carbachol
11
ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic		1958201527.7low026210
spironolactone
42
3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic		1964202216.4low22021172
aldosterone
20
11beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite		1988202316.8low2121232
pentolinium tartrate
27
tartrate saltantihypertensive agent1954196467.1low0270000
penicillamine
2
non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen		1979200432.5low010100
prednisone
19
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug		1957202044.7low1122140
etiocholanolone
4
17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid		human metabolite;
mouse metabolite		2006200916.5low100400
dehydroepiandrosterone
3
17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite		1963202026.0low010020
adrenochrome
1
indoles1963196361.0low010000
camylofine
5
alpha-amino acid ester1952195968.8medium050000
penicillin g
2
penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope		1954198554.5low020000
metaraminol
2
phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent		200720239.0low000101
pilocarpine
2
pilocarpineantiglaucoma drug1953197958.0low020000
pentylenetetrazole
1
organic heterobicyclic compound;
organonitrogen heterocyclic compound		1955195569.0low010000
triiodothyronine
4
2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone		1964201327.2low211110
pheniprazine
1
amphetamines1963196361.0low010000
biguanides
2
guanidines1990200725.5low001100
alanine
3
alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite		1955199954.3low021000
serine
4
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2010201413.0low000310
chloramphenicol
5
C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor		1958198556.8low050000
aspartic acid
2
aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter		1960200939.5low010100
glutamine
5
amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		2005202114.4low000311
lysine
4
aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		1999202013.0low001120
cyanides
3
pseudohalide anionEC 1.9.3.1 (cytochrome c oxidase) inhibitor1952201148.3low020010
physostigmine
4
carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic		1955199853.8low031000
sucrose
1
glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent		2001200123.0low000100
tubocurarine
15
bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist		1950196564.7low0150000
apomorphine
3
aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug		1964200833.0low010200
fencarbamide
2
1963196460.5high020000
aminopyrine
21
pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		1954198863.0low0210000
adenosine diphosphate
15
adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite		1983201629.6low172510
uridine
2
uridinesdrug metabolite;
fundamental metabolite;
human metabolite		1990199034.0low002000
uridine monophosphate
1
pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite		201820186.0low000010
bromodeoxyuridine
1
pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent		2010201014.0low000100
galactose
1
D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite		2014201410.0low000010
carbostyril
4
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite1989199531.0low013000
phenylephrine
30
phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent		1978202319.2low32107101
levodopa
3
amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug		1986201917.0low010020
edetic acid
6
ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector		1957201433.3low021120
tyrosine
7
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		1964201123.0low010420
cysteamine
1
amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent		1961196163.0low010000
acepromazine
1
aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound		phenothiazine antipsychotic drug1984198440.0low010000
methoxamine
3
amphetaminesalpha-adrenergic agonist;
antihypotensive agent		1964201030.3low010200
adenosine monophosphate
5
adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		2000202018.2low002210
methylene blue
5
organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer		1996201618.6low002120
zoxazolamine
9
benzoxazole1956196364.8low090000
leucine
9
amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		1955201553.8low070110
aniline
1
anilines;
primary arylamine		1955195569.0low010000
lactose
3
lactose1965201230.7low010110
methionine
5
aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical		2002201515.0low100410
phenylalanine
1
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		201520159.0low000010
desoxycorticosterone
8
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1953201342.1low050120
colchicine
24
alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen		1958202214.3low223559
etimizol
1
1995199529.0low001000
gallamine triethiodide
34
1951200467.0low0330100
cycloheximide
1
antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor		1997199727.0low001000
egtazic acid
3
diether;
tertiary amino compound;
tetracarboxylic acid		chelator2002201017.0low000300
barbituric acid
3
barbituratesallergen;
xenobiotic		1953195868.7low030000
chloroform
1
chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant		1964196460.0low010000
gliotoxin
1
dipeptide;
organic disulfide;
organic heterotetracyclic compound;
pyrazinoindole		antifungal agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
immunosuppressive agent;
mycotoxin;
proteasome inhibitor		2009200915.0low000100
benziodarone
2
aromatic ketone1962196262.0low020000
chlorisondamine
2
isoindoles1956199847.0low011000
tubercidin
1
antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite		1998199826.0low001000
mannitol
8
mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent		1964202230.9low030221
cytarabine
1
beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent		1996199628.0low001000
ornithine
3
non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite		2011201610.7low100030
isopropamide iodide
1
diarylmethane1964196460.0low010000
valine
10
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		1963201620.5low111530
threonine
1
amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2010201014.0low000100
dichlorodiphenyldichloroethane
1
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		xenobiotic metabolite1956195668.0low010000
cordycepin
1
3'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic		2008200816.0low000100
tryptophan
5
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		1960196461.2low050000
4-chlorobenzoic acid
1
monochlorobenzoic acidbacterial xenobiotic metabolite1958195866.0low010000
arginine
47
arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical		1993201717.1low60824150
methyl bromide
1
bromohydrocarbon;
bromomethanes;
methyl halides		algal metabolite;
fumigant insecticide;
marine metabolite		1957195767.0low010000
ethane
1
alkane;
gas molecular entity		plant metabolite;
refrigerant		1953195371.0low010000
boranes
2
boranes;
mononuclear parent hydride		1982202122.5low010001
propane
4
alkane;
gas molecular entity		food propellant1952201931.2low020020
ethyl chloride
1
chloroethanesantipruritic drug;
inhalation anaesthetic;
local anaesthetic		1954195470.0low010000
ethylamine
1
primary aliphatic aminehuman metabolite1997199727.0low001000
acetonitrile
1
aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent		2014201410.0low000010
tetramethylammonium
1
quaternary ammonium ion1952195272.0low010000
methanesulfonic acid
3
alkanesulfonic acid;
one-carbon compound		Escherichia coli metabolite1953201547.3low020010
trifluoroacetic acid
1
fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent		2014201410.0low000010
chloropicrin
1
C-nitro compound;
one-carbon compound;
organochlorine compound		antifungal agrochemical;
fumigant insecticide;
nematicide		1953195371.0low010000
caramiphen
2
benzenes1951195272.5low020000
dimethyl sulfate
1
alkyl sulfatealkylating agent;
immunosuppressive agent		1952195272.0low010000
tromethamine
2
primary amino compound;
triol		buffer1952199351.5low011000
acetyl triethyl citrate
1
2011201113.0medium000010
quinic acid
1
2014201410.0low000010
pentaerythritol tetranitrate
4
pentaerythritol nitrateexplosive;
vasodilator agent		1954196463.5low040000
dichloroacetic acid
5
monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite		2001201915.0low000320
pantothenic acid
3
pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite		1958196362.7low030000
methylmethacrylate
1
enoate ester;
methyl ester		allergen;
polymerisation monomer		2002200222.0low000100
taurocholic acid
2
amino sulfonic acid;
bile acid taurine conjugate		human metabolite2005200618.5low000200
methylprednisolone
6
6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic		1958202124.8low212021
9,10-anthraquinone
1
anthraquinone2007200717.0low000100
diethyl phthalate
1
diester;
ethyl ester;
phthalate ester		neurotoxin;
plasticiser;
teratogenic agent		201520159.0low000010
propoxycaine
1
benzoate ester1955195569.0low010000
isosorbide dinitrate
46
glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent		1981202118.8low54820131
n-vinyl-2-pyrrolidinone
3
pyrrolidin-2-ones1952201251.7low020010
quinoxalines
6
mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene		1963201223.5low010410
2-naphthylamine
1
naphthylaminecarcinogenic agent1951195173.0low010000
diphenyl
4
aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative		1953201949.5low030010
phenylpiperazine
1
202020204.0low000010
xanthenes
4
xanthene1961201728.2low010210
phenothiazine
5
phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger		1952196067.0low050000
synephrine
1
ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite		2009200915.0low000100
methyl acrylate
2
enoate ester1997199727.0low002000
butyl methacrylate
1
enoate ester201720177.0low000010
benzenesulfonic acid
1
benzenesulfonic acids201520159.0low000010
cumene
1
alkylbenzene1999199925.0low001000
4-(dimethylamino)benzaldehyde
1
benzaldehydes;
substituted aniline;
tertiary amino compound		chromogenic compound1953195371.0low010000
2-diethylaminoethanol
2
ethanolamines;
primary alcohol;
tertiary amino compound		1951195173.0low020000
quinuclidines
2
quinuclidines;
saturated organic heterobicyclic parent		1962198849.0low020000
pyridostigmine bromide
2
pyridinium salt2004201315.5low000110
phenylurethane
1
1951195173.0low010000
1,2-dihydrostilbene
1
diphenylethane1962196262.0low010000
chlorphenesin
1
glycol;
monochlorobenzenes;
propane-1,2-diols		antibacterial drug;
antifungal drug;
muscle relaxant		1963196361.0low010000
citronellal
1
aldehyde;
monoterpenoid		antifungal agent;
metabolite		202120213.0low000001
acrolein
1
enalherbicide;
human xenobiotic metabolite;
toxin		2001200123.0low000100
allylamine
2
alkylamine2000201516.5low101010
3-hydroxybutanal
1
201720177.0low000010
biuret
1
condensed ureas1958195866.0low010000
acetic anhydride
1
acyclic carboxylic anhydridemetabolite;
reagent		1999199925.0low001000
succinic anhydride
1
cyclic dicarboxylic anhydride;
tetrahydrofurandione		1999199925.0low001000
propylene carbonate
1
201920195.0low000010
cyclohexanol
2
cyclohexanols;
secondary alcohol		solvent1958200940.5low010100
3-hydroxypyridine
1
monohydroxypyridine1984198440.0low010000
triethylene glycol dimethacrylate
1
2002200222.0low000100
n-butylamine
1
primary aliphatic amine1961196163.0low010000
diethylamine
1
secondary aliphatic amine1951195173.0low010000
pyrroles
41
pyrrole;
secondary amine		1954202123.5low6651992
tetrahydrofuran
1
cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent1953195371.0low010000
furan
1
furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product		1953195371.0low010000
thiophenes
11
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent1981201916.7low110730
succinamide
1
2003200321.0low000100
succinonitrile
1
1952195272.0low010000
cyclohexane
5
cycloalkane;
volatile organic compound		non-polar solvent1952196465.4low050000
piperidine
1
azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine		base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent		1965196559.0low010000
heptanol
1
heptanol;
primary alcohol		flavouring agent;
fragrance;
gap junctional intercellular communication inhibitor;
plant metabolite		201620168.0low000010
carbitol
1
diether;
glycol ether;
hydroxypolyether;
primary alcohol		protic solvent2011201113.0low000010
ergotamine
77
peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent		1951200766.2low0751100
methylergonovine
39
ergoline alkaloid1951201166.5low0380010
phenformin
1
biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent		1963196361.0low010000
tecnazene
1
aromatic fungicide;
C-nitro compound;
tetrachlorobenzene		antifungal agrochemical2009200915.0low000100
framycetin
2
aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite		1958196463.0low020000
isoquinoline
1
azaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene		1952195272.0low010000
tropine
1
1954195470.0low010000
vanillic acid
1
methoxybenzoic acid;
monohydroxybenzoic acid		plant metabolite1957195767.0low010000
triethylamine
1
tertiary amine2014201410.0low000010
2,5-norbornadiene
1
2002200222.0low000100
pyrazolanthrone
1
anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector		2010201014.0low000100
1-naphthylamine
1
naphthylaminehuman xenobiotic metabolite1993199331.0low001000
2-naphthol
3
naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger		1951201637.7low011010
cupric acetate
1
2006200618.0low000100
n-heptane
1
alkane;
volatile organic compound		non-polar solvent;
plant metabolite		1957195767.0low010000
sodium cyanide
1
cyanide salt;
one-carbon compound;
sodium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor1999199925.0low001000
tetraphenylborate
1
1959195965.0low010000
yohimbine
10
methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist		1982201735.4low181010
2-chloroadenosine
1
purine nucleoside1998199826.0low001000
diphenhydramine hydrochloride
4
hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative		1954198552.2low040000
potassium cyanide
1
cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin		1989198935.0low010000
methohexital
1
acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic		2000200024.0low001000
catechin
17
catechinantioxidant;
plant metabolite		1988201912.9low0115100
thiamine pyrophosphate
2
organic chloride salt;
vitamin B1		1958195866.0low020000
quinazolines
11
azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines		1954200939.0low171300
indazoles
5
indazole1993202119.2low002201
benzoxazoles
7
1,3-benzoxazoles;
mancude organic heterobicyclic parent		1963202113.7low010051
adamantane
2
adamantanes;
polycyclic alkane		1986200827.0low010100
cyclopentane
10
cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent1951201344.7low160220
isoxazoles
8
isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		1999202117.9low103401
oxazoles
4
1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		1963201630.2low012010
thiazoles
20
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		1951202123.2low419451
pyrimidine
2
diazine;
pyrimidines		Daphnia magna metabolite1952200048.0low011000
pyrazines
14
diazine;
pyrazines		Daphnia magna metabolite1982201419.4low013550
triphenyltetrazolium
1
organic cation1998199826.0low001000
methylphenazonium methosulfate
1
azaheterocycle sulfate salt;
phenazines		2001200123.0low000100
calcium gluconate
1
calcium saltnutraceutical201920195.0low000010
ephedrine
8
phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		1953202353.0low060101
muscarine
2
monosaccharide1999200223.5low001100
hydrazine
6
azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor1961201336.0low030210
benzoquinonium
7
aromatic amine1951195771.1high070000
hemicholinium 3
1
1959195965.0low010000
monocrotaline
7
pyrrolizidine alkaloid1982202113.9low010141
aminophylline
9
mixturebronchodilator agent;
cardiotonic drug		1959201630.3low042030
phenyramidol
1
aminopyridine1960196064.0low010000
galantamine
1
benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite		2005200519.0low000100
aminoimidazole carboxamide
3
aminoimidazole;
monocarboxylic acid amide		mouse metabolite1996201417.3low101110
methysergide
21
ergoline alkaloid1962200452.3low0172200
citrulline
4
amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite		1998201517.0low002020
betamethasone
2
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent		1995201320.0low001010
prenylamine
11
diarylmethane1961199357.0low0101000
4-fluoroamphetamine
1
202120213.0low000001
dicyandiamido
1
guanidines;
nitrile		curing agent;
explosive;
fertilizer;
flame retardant;
nitrification inhibitor		1952195272.0low010000
hydantoins
9
imidazolidine-2,4-dione1949201563.3low080010
fluorobenzenes
6
monofluorobenzenesNMR chemical shift reference compound2003201515.7low100420
n-pentyl nitrite
2
nitrite estersvasodilator agent1963196460.5low020000
dextropropoxyphene
1
1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic		1964196460.0low010000
oxamide
1
dicarboxylic acid diamide1957195767.0low010000
chenodeoxycholic acid
1
bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite		2009200915.0low000100
boldine
1
aporphine alkaloid2002200222.0low000100
rhein
1
dihydroxyanthraquinone2009200915.0low000100
2-bromolysergic acid diethylamide
1
1959195965.0low010000
plumbagin
1
hydroxy-1,4-naphthoquinone;
phenols		anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite		201620168.0low000010
imperatorin
3
psoralensEC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite		1962201927.0low010110
dihydralazine
1
phthalazines1985198539.0low010000
bicuculline
5
benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin		1998201616.6low002120
bufotenin
1
tertiary amine;
tryptamine alkaloid		coral metabolite;
hallucinogen		1956195668.0low010000
benzohydroxamic acid
1
2012201212.0low000010
arecaidine
1
citraconoyl group1962196262.0low010000
beclamide
2
benzenes1958196264.0low020000
alpha-aminopyridine
22
1981202136.9low0200011
1,3-propanediol
5
propane-1,3-diolsmetabolite;
protic solvent		1952196466.2low050000
thiazolidines
1
thiazolidine1998199826.0low001000
oleanolic acid
3
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite2003202011.0low000120
dihydroergotamine
68
ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent		1951198568.6low1680000
podophyllotoxin
1
furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator		2007200717.0low000100
hesperidin
6
3'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen2008201612.7low400330
dihydrotestosterone
1
17beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite		2012201212.0low000010
dimenhydrinate
1
diarylmethane1950195074.0low010000
copper gluconate
1
organic molecular entity1963196361.0low010000
hexylcaine
1
benzoate ester1948194876.0low010000
cumic acid
1
cumic acidplant metabolite1950195074.0low010000
methamphetamine
3
amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic		1953201634.7low011010
pentamethonium
4
quaternary ammonium ionantihypertensive agent;
vasodilator agent		1952195670.5low040000
butyramide
1
butanamides;
primary fatty amide		1962196262.0low010000
malondialdehyde
26
dialdehydebiomarker1980201817.5low1257120
myristic acid
1
long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite		2007200717.0low000100
thiphenamil
5
diarylmethane1951199163.6medium041000
paeonol
1
methoxybenzenes;
phenols		metabolite1985198539.0low010000
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol
1
terpineol;
tertiary alcohol		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiparasitic agent;
apoptosis inducer;
plant metabolite;
volatile oil component		2002200222.0low000100
congo red
1
bis(azo) compound1955195569.0low010000
3-hydroxyflavone
6
flavonols;
monohydroxyflavone		1964201522.7low010230
levulinic acid
1
oxopentanoic acid;
straight-chain saturated fatty acid		plant metabolite1983198341.0low010000
glycopyrrolate
1
organic bromide salt;
quaternary ammonium salt		2012201212.0low000010
phenylglyoxylic acid
1
2-oxo monocarboxylic acidbiomarker;
human xenobiotic metabolite		1956195668.0low010000
trimecaine
1
amino acid amide1958195866.0low010000
acetylcysteine
7
acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary		1993202014.7low001330
bendazole
1
benzimidazoles1959195965.0low010000
bulbocapnine
5
aporphine alkaloid;
aromatic ether;
oxacycle;
phenols		EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor;
EC 1.4.3.22 (diamine oxidase) inhibitor;
plant metabolite		1958196263.2low050000
c.i. 42510
1
1954195470.0low010000
benzydamine
1
aromatic ether;
indazoles;
tertiary amino compound		analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug		1988198836.0low010000
erythromycin
1
cyclic ketone;
erythromycin		1996199628.0low001000
formal glycol
3
cyclic acetal;
dioxolane		1953196166.7low030000
isosorbide
2
organic molecular entity2002200520.5low100200
chromonar
1
coumarins1981198143.0low010000
2-piperidone
1
delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor1956195668.0low010000
perfluoropentane
1
fluoroalkane;
fluorocarbon		radioopaque medium;
ultrasound contrast agent		2014201410.0low000010
hydroxyethyl methacrylate
1
enoate esterallergen;
polymerisation monomer		2002200222.0low000100
deoxycytidine
2
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2010201312.5low000110
2'-deoxyadenosine
1
purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2004200420.0low000100
canrenone
2
steroid lactone2003201316.0low000110
cytidine diphosphate choline
1
nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite		2000200024.0low001000
rhodamine 6g
1
2011201113.0low000010
dimethoxon
1
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor		2011201113.0low000010
tetramethylpyrazine
11
alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent		1982201418.5low012350
durapatite
2
2008200915.5low000200
sodium hydroxide
1
alkali metal hydroxide2009200915.0low000100
arsenic trioxide
2
201320188.5low000020
vancomycin
1
glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite		2000200024.0low101000
glycyrrhizic acid
2
enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite		2007201214.5low000110
d-alpha tocopherol
24
alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite		1980201324.6low22111010
selenomethionine
1
selenoamino acid;
selenomethionines		plant metabolite1994199430.0low101000
vincamine
1
alkaloid ester;
hemiaminal;
methyl ester;
organic heteropentacyclic compound;
vinca alkaloid		antihypertensive agent;
metabolite;
vasodilator agent		1980198044.0low010000
decane
1
alkane1955195569.0low010000
cyclopropanecarboxylic acid
1
cyclopropanes;
monocarboxylic acid		1952195272.0low010000
phenyltrimethylammonium
1
quaternary ammonium ion1952195272.0low010000
dronabinol
2
benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic		1996201021.0low001100
bamifylline
1
oxopurine2008200816.0low000100
amiloride
4
aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker		1996200822.5low002200
buthiazide
1
benzothiadiazine2008200816.0low000100
diallyl trisulfide
1
organic trisulfideanti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
antioxidant;
antiprotozoal drug;
apoptosis inducer;
estrogen receptor antagonist;
insecticide;
platelet aggregation inhibitor;
vasodilator agent		2011201113.0low000010
diallyl disulfide
2
organic disulfideantifungal agent;
antineoplastic agent;
plant metabolite		2000201815.0low101010
aminorex
1
benzenes1982198242.0low010000
fluorescein
1
2-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium		1999199925.0low001000
alpha-terpineol
1
terpineolplant metabolite2010201014.0low000100
ethamsylate
1
organosulfur compound;
sulfonic acid derivative		201520159.0low000010
acadesine
1
1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor		2014201410.0low100010
ddms
1
chlorophenylethane;
monochlorobenzenes		2000200024.0low001000
fluorescein-5-isothiocyanate
1
fluorescein isothiocyanate2009200915.0low000100
sabinene
1
thujeneplant metabolite1964196460.0low010000
mannose
1
D-aldohexose;
D-mannose;
mannopyranose		metabolite2014201410.0low000010
palmatine
1
berberine alkaloid;
organic heterotetracyclic compound		plant metabolite2010201014.0low000100
tranylcypromine
3
2-phenylcyclopropan-1-amine1963200845.7low020100
streptomycin
4
antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor		1951200455.5low030100
carbonates
2
carbon oxoanion1989202119.0low010001
fructosamine
2
2009201711.0low000110
trimetazidine
36
aromatic amine1998202212.3low50117144
floxacillin
1
penicillin allergen;
penicillin		antibacterial drug1996199628.0low001000
vidarabine
1
beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic		2007200717.0low000100
diadenosine tetraphosphate
1
diadenosyl tetraphosphateEscherichia coli metabolite;
mouse metabolite		1999199925.0low001000
iodinated glycerol
3
dioxolane1963201329.0low010110
isometheptene
1
secondary amino compound1955195569.0low010000
olsalazine
1
azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug		1992199232.0low001000
n-methylaspartate
4
amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent2000200821.2low002200
trimethaphan
1
sulfonium compoundanaesthesia adjuvant;
antihypertensive agent;
nicotinic antagonist;
vasodilator agent		1960196064.0low010000
iridium
1
cobalt group element atom;
platinum group metal atom		201820186.0low100010
manganese
3
elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient		1994201421.0low001110
mercury
1
elemental mercury;
zinc group element atom		neurotoxin1950195074.0low010000
platinum
18
elemental platinum;
nickel group element atom;
platinum group metal atom		201020197.8low6001170
silver
1
copper group element atom;
elemental silver		Escherichia coli metabolite1985198539.0low010000
tantalum
1
vanadium group element atom2007200717.0low000100
technetium
4
manganese group element atom1986200925.5low111200
titanium
7
titanium group element atom1999202011.7low301150
cadmium
1
cadmium molecular entity;
zinc group element atom		2001200123.0low000100
chromium
16
chromium group element atom;
metal allergen		micronutrient199620199.5low2011140
gadolinium
2
f-block element atom;
lanthanoid atom		1996201419.0low001010
gold
4
copper group element atom;
elemental gold		1958201827.8low110210
helium
2
monoatomic helium;
noble gas atom;
s-block element atom		food packaging gas201520168.5low000020
xenon
1
monoatomic xenon;
noble gas atom;
p-block element atom		2014201410.0low000010
aluminum chloride
1
aluminium coordination entityLewis acid2013201311.0low000010
magnesium sulfate
9
magnesium salt;
metal sulfate;
organic magnesium salt		anaesthetic;
analgesic;
anti-arrhythmia drug;
anticonvulsant;
calcium channel blocker;
cardiovascular drug;
fertilizer;
tocolytic agent		1964201822.2low111610
acetylglucosamine
4
N-acetyl-D-glucosamineepitope201120219.8low000031
sodium nitrate
1
inorganic nitrate salt;
inorganic sodium salt		fertilizer;
NMR chemical shift reference compound		1954195470.0low010000
cesium chloride
2
inorganic caesium salt;
inorganic chloride		phase-transfer catalyst;
vasoconstrictor agent		1998201617.0low001010
hypochlorous acid
1
chlorine oxoacid;
reactive oxygen species		EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
human metabolite		1990199034.0low001000
camptothecin
2
delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite		1999201318.0low001010
ferric chloride
1
iron coordination entityastringent;
Lewis acid		2014201410.0low000010
potassium nitrate
2
inorganic nitrate salt;
potassium salt		fertilizer1953195470.5low020000
copper sulfate
1
metal sulfateemetic;
fertilizer;
sensitiser		1990199034.0low001000
sodium thiosulfate
2
inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent		201120208.5low100020
deuterium
2
dihydrogen1994200524.5low001100
thallium chloride
1
inorganic chloride;
thallium molecular entity		1981198143.0low010000
sulfonyl chloride
1
sulfuryl halide2007200717.0low000100
poloxalene
2
epoxide1987201423.5low010010
ozone
1
elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer		202020204.0low000010
sodium selenite
1
inorganic sodium salt;
selenite salt		nutraceutical1994199430.0low101000
barium chloride
2
barium salt;
inorganic chloride		potassium channel blocker1990200924.5low001100
trolamine salicylate
9
1952201847.9low061110
ethionine
1
S-ethylhomocysteineantimetabolite;
carcinogenic agent		1961196163.0low010000
febarbamate
1
barbiturates1961196163.0medium010000
tiletamine hydrochloride
1
1958195866.0low010000
clemastine
1
monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist		201520159.0low000010
cephalexin
1
beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug2002200222.0low000100
isosorbide-5-mononitrate
9
glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent		1993202114.4low102151
tetradecanoylphorbol acetate
4
acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator		1998200621.0low001300
sodium bisulfide
3
2009201612.7low000210
fluorides
1
halide anion;
monoatomic fluorine		1985198539.0low010000
hypnorm
1
2000200024.0low001000
deslanoside
1
12beta-hydroxy steroid;
14beta-hydroxy steroid;
cardenolide glycoside;
tetrasaccharide derivative		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
metabolite		1979197945.0low110000
calcium dobesilate
4
1991200922.0low102200
iodine
11
halide anion;
monoatomic iodine		human metabolite1951196171.1low0110000
daunorubicin
10
aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite		1996201021.3low204600
razoxane
125
N-alkylpiperazine1992201322.6medium230665270
carbimazole
1
1,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug		2001200123.0low000100
bromocriptine
2
indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist		1986201623.0low010010
phenyl acetate
12
benzenes;
phenyl acetates		1953201154.1low091110
cetylpyridinium chloride anhydrous
1
chloride salt;
organic chloride salt		antiseptic drug;
surfactant		1961196163.0low010000
triamcinolone
7
11beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug		1959196462.4low070000
tris(2,3-dibromopropyl)phosphate
4
trialkyl phosphate1952196168.2low040000
tributyl phosphate
1
trialkyl phosphate2005200519.0low000100
fludrocortisone
6
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug		1959201936.7low030030
ursodeoxycholic acid
2
bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite		1987199931.0low011000
metipranolol
1
acetate ester;
aromatic ether;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist		1996199628.0low001000
dimethophrine
1
methoxybenzenes;
phenols		1984198440.0medium110000
4-methoxyamphetamine
11
1952202228.1low130422
du-21220
1
benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound		201920195.0low000010
dihydro-beta-erythroidine
3
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound		nicotinic antagonist1953201049.7low020100
8-bromo cyclic adenosine monophosphate
2
3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist		2010201810.0low000110
transferrin
1
1990199034.0low001000
glutamic acid
4
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		2003201417.0low000310
glucaric acid
1
glucaric acidantineoplastic agent2011201113.0low000010
adenosine diphosphate ribose
1
ADP-sugarEscherichia coli metabolite;
mouse metabolite		2014201410.0low000010
amoxicillin
1
penicillin allergen;
penicillin		antibacterial drug1996199628.0low001000
timolol
2
timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist		2002201814.0low000110
tramadol
1
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor		2005200519.0low000100
mixidine
2
1980198044.0high020000
dinitramine
1
C-nitro compound1953195371.0low010000
dehydrocorydalin
1
alkaloid1989198935.0low010000
zidovudine
1
azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor		2006200618.0low000100
paclitaxel
732
taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent		1995202310.1low2110320544381
alinidine
47
1980200635.9high63212300
etoposide
2
beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor		2001200521.0low000200
substance p
6
peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent		1993201222.5low003210
dobutamine
59
catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent		1979202319.9low1161618163
trimazosin
1
N-arylpiperazine1981198143.0low110000
methyldopa
4
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent		1964202035.8low030010
tocainide
1
monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker		1986198638.0low010000
bezafibrate
1
aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic		202120213.0low000001
sq-11725
3
201520206.3low000030
diltiazem
155
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent		1981202420.6low3236258293
nonachlazine
1
1983198341.0low010000
vecuronium bromide
4
organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist		1994200126.5low303100
ng-nitroarginine methyl ester
53
alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor1996202218.3low10113282
amafolone
1
1981198143.0low010000
pirfenidone
1
pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		201920195.0low100010
torsemide
1
aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic		201620168.0low000010
epirubicin
8
aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor		1996201321.9low505210
idarubicin
1
anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative		201820186.0low000010
propiconazole
1
conazole fungicide;
cyclic ketal;
dichlorobenzene;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic		1955195569.0low010000
paroxetine
4
aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor		201320169.8low100040
captopril
11
alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1981201823.6low224320
suxethonium
1
1961196163.0medium010000
salsoline
1
isoquinolines1956195668.0low010000
nicorandil
34
nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent		1988202312.4low2138184
pergolide
1
diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist		1983198341.0low010000
colforsin
12
acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist		1988201924.2low026310
bucindolol
2
2004201116.5low000110
alfentanil
1
monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug		1994199430.0low101000
sulotroban
1
1988198836.0low010000
fomesafen
18
aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide		1952201546.4low0114210
dazoxiben
1
1984198440.0low010000
lovastatin
4
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug		1993201023.8low203100
magnocurarine
1
isoquinolines1953195371.0medium010000
flordipine
1
(trifluoromethyl)benzenes1984198440.0medium010000
enoximone
3
aromatic ketone1984200430.7low011100
simvastatin
32
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug		1999201913.0low70211190
pravastatin
5
3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic		1996200823.6low203200
cabergoline
1
N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist		2012201212.0low000010
atomoxetine hydrochloride
1
hydrochlorideadrenergic uptake inhibitor;
antidepressant		201720177.0low000010
quinapril
1
dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		201620168.0low000010
raloxifene hydrochloride
1
hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator		2007200717.0low000100
cicletanine
1
organochlorine compound2000200024.0low001000
dopexamine
2
catecholamine2000201218.0low101010
cilazapril, anhydrous
1
dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		2009200915.0low000100
ranolazine
120
aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol		1990202210.5medium250134787
finasteride
1
3-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor		1993199331.0low001000
mk 458
1
hydrochlorideanticonvulsant;
antiparkinson drug;
dopamine agonist		2003200321.0low000100
esmolol
3
aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound		2009201512.0low000120
temafloxacin
1
amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound		1993199331.0low001000
sparfloxacin
1
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		2007200717.0low000100
clopidogrel
55
methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		1999202213.6low50128251
mibefradil
3
tetralinsT-type calcium channel blocker1999200921.0low001200
remifentanil
1
alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative		2001200123.0low100100
atorvastatin
36
aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic		2002202311.7low90013194
duloxetine hydrochloride
1
duloxetine hydrochlorideantidepressant2005200519.0low000100
irinotecan
1
carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug		2013201311.0low000010
valsartan
40
biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		199920237.9low7014314
3-iodobenzylguanidine
3
organoiodine compound1996201620.0low102010
simendan
35
200420239.0low5006236
tirofiban
5
L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist		2003201116.4low000320
capecitabine
2
carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug		2010201312.5low000110
xemilofiban
1
1999199925.0low001000
adenosine
153
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		1980202124.4low15710528121
safranal
1
monoterpenoid201620168.0low000010
3-n-butylphthalide
1
benzofurans2013201311.0low100010
cathinone
1
2-aminopropiophenone;
monoamine alkaloid		central nervous system stimulant;
psychotropic drug		1982198242.0low010000
n-ethyl-3-piperidyl benzilate
1
1954195470.0medium010000
colestipol
1
2002200222.0low100100
cyamemazine
1
phenothiazines2013201311.0low000010
venlafaxine hydrochloride
1
hydrochloride2014201410.0low000010
hydrochlorothiazide-triamterene
1
2002200222.0low000100
rolofylline
3
oxopurine2008201314.0low100210
glucose, (beta-d)-isomer
23
D-glucopyranoseepitope;
mouse metabolite		198520229.9low5212144
anisodamine
1
201620168.0low100010
dihydrochalcone
1
dihydrochalconesplant metabolite1960196064.0low010000
fenofibric acid
1
aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite		2004200420.0low000100
ursolic acid
5
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite		2003202012.6low000140
thiazolyl blue
1
organic bromide saltcolorimetric reagent;
dye		2014201410.0low000010
baicalin
1
dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug		201820186.0low100010
plerixafor
1
azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant		2006200618.0low000100
allicin
2
botanical anti-fungal agent;
sulfoxide		antibacterial agent201320169.5low000020
diacetylfluorescein
1
2011201113.0low000010
epigallocatechin gallate
6
flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite		200820189.8low000150
fluorexon
2
xanthene dyefluorochrome2002200222.0low000200
aica ribonucleotide
1
1-(phosphoribosyl)imidazolecarboxamide;
aminoimidazole		cardiovascular drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		2010201014.0low000100
neocuproine
1
phenanthrolineschelator;
copper chelator		1990199034.0low001000
pyrrolidine dithiocarbamate
1
dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger		2007200717.0low000100
4-nitrobenzylthioinosine
4
purine nucleoside1989199832.0low013000
cephalosporin c
1
cephalosporinfungal metabolite1981198143.0low010000
prenylamine lactate
1
1961196163.0low010000
zatebradine
49
benzazepine1984200631.5high2741100
octimibate
1
1997199727.0low001000
caroverine
1
quinoxaline derivative1963196361.0low010000
motapizone
3
1986199335.7medium121000
milnacipran
1
acetamides2011201113.0low000010
ro 22-4839
1
1987198737.0medium010000
lubeluzole
8
benzothiazoles1996200625.2medium206200
telmisartan
7
benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic		200620229.0low100232
benzylaniline
2
1957195767.0medium020000
1,7-phenanthroline
7
phenanthroline1962201427.0low021220
triazoles
7
1,2,3-triazole1991202122.3low004111
sesamol
1
benzodioxoles2011201113.0low000010
ibopamine
3
benzoate ester;
phenols		1988200129.0low011100
medetomidine
1
imidazoles2000200024.0low001000
fluorodeoxyglucose f18
3
2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose		2008201611.7low000120
sertraline
3
dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor		1993202114.7low001011
rilmenidine
1
isourea1999199925.0low001000
zoledronic acid
1
1,1-bis(phosphonic acid);
imidazoles		bone density conservation agent2011201113.0low000010
tianeptine
2
dibenzothiazepine;
monocarboxylic acid;
organochlorine compound		2004200917.5low200200
drospirenone
1
3-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin		2013201311.0low000010
ryodipine
2
1985199335.0low111000
glycine amide
2
amino acid amide;
glycine derivative		1953195570.0low020000
aprofen
1
1957195767.0low010000
cromakalim
8
1988200130.1low016100
falipamil
22
1981200636.6high2156100
uk 68798
4
aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker		1992202115.8low002011
dexrazoxane
2
razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent		201320169.5low000020
dicolinium iodide
2
1953196465.5medium020000
nicametate
1
aromatic carboxylic acid;
pyridines		1998199826.0low001000
bufuralol
1
benzofurans2000200024.0low001000
buquineran
1
1984198440.0low010000
butoprozine
1
1980198044.0low010000
carbazeran
3
1981198939.3medium130000
mioflazine
11
1984199135.4high065000
nipradilol
1
organic molecular entity2004200420.0low100100
perindoprilat
3
dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1998200124.3low102100
dehydrosanol
1
benzothiadiazine1965196559.0low010000
cyclarbamate
1
carbamate ester1964196460.0medium010000
terlipressin
1
polypeptide2008200816.0low000100
methotrimeprazine
1
phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist		1963196361.0low010000
4-o-methyl-12-o-tetradecanoylphorbol 13-acetate
1
2004200420.0low000100
magnolol
2
biphenyls2007201911.0low000110
sesamin
1
benzodioxoles;
furofuran;
lignan		antineoplastic agent;
neuroprotective agent;
plant metabolite		202020204.0low000010
coptisine
1
alkaloidmetabolite2010201014.0low000100
nobiletin
1
methoxyflavoneantineoplastic agent;
plant metabolite		201720177.0low000010
lycorine
1
indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor		202020204.0low000010
picropodophyllin
1
furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor		2007200717.0low000100
1,2-bis(3,5-dioxopiperazin-1-yl)ethane
3
1997200026.0medium003000
gliclazide
1
2008200816.0low000100
agroclavine
2
ergot alkaloid1954195470.0low020000
bilobalide
2
sesquiterpene lactone2002201018.0low100200
oxazolidin-2-one
1
carbamate ester;
oxazolidinone		metabolite2010201014.0low000100
o-methylisourea
1
1999199925.0low001000
1-benzylpiperazine
1
N-alkylpiperazineenvironmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic		1965196559.0low010000
rivastigmine
1
carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent		1998199826.0low001000
rosiglitazone
7
aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug		2004201814.9low100430
hydroxyguanidine
1
guanidines;
one-carbon compound		antineoplastic agent;
antiviral agent		1999199925.0low001000
s20098
1
acetamides201620168.0low100010
1-ethyl-2-benzimidazolinone
1
imidazoles2012201212.0low000010
biocytin
2
azabicycloalkane;
L-alpha-amino acid zwitterion;
L-lysine derivative;
monocarboxylic acid amide;
non-proteinogenic L-alpha-amino acid;
thiabicycloalkane;
ureas		mouse metabolite2010201511.5low000110
ketorolac tromethamine
1
organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor		1993199331.0low001000
clarithromycin
1
macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic		1993199331.0low001000
aminaftone
1
naphthols2014201410.0low100010
nicotine
13
3-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic		1953201936.4low251430
fibrinogen
16
iditolfungal metabolite1955201821.2low423560
7-ketocholesterol
1
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
7-oxo steroid;
cholestanoid		neuroprotective agent2013201311.0low000010
homocysteine
13
amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite		2002201515.4low300940
alpha,beta-methyleneadenosine 5'-triphosphate
2
nucleoside triphosphate analogue2001200421.5low000200
deacetyldiltiazem
2
benzothiazepine1989199830.5low011000
4-hydroxyphenylglycine
1
hydroxy-amino acidbacterial metabolite2006200618.0low000100
zofenopril
1
aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent		201820186.0low000010
1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine
1
1998199826.0low001000
mci 9038
2
peptide2001200421.5low000200
arginine methyl ester
1
alpha-amino acid ester2012201212.0low000010
quinidine gluconate
1
D-gluconate adduct1984198440.0low010000
glucuronic acid
2
D-glucuronic acidalgal metabolite2012201610.0low000020
trimeperidine
2
1955195569.0low020000
diosgenin
2
3beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite		2013201410.5low000020
1,1'-binaphthyl-2,2'-diyl hydrogen phosphate
1
1997199727.0low001000
coumarin 6
1
7-aminocoumarinsfluorochrome2011201113.0low000010
denitro-kt-1
1
1991199133.0medium001000
leucinocaine mesylate
7
1955196165.9high070000
phenglutarimide
1
piperidines1958195866.0low010000
cobalt
5
cobalt group element atom;
metal allergen		micronutrient2008201910.4low100230
p-methoxy-n-methylphenethylamine
1
aromatic ether;
secondary amino compound		metabolite1964196460.0low010000
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid
1
polyamino carboxylic acid;
tetracarboxylic acid		chelator2009200915.0low000100
yttrium radioisotopes
1
2011201113.0low100010
desethylamiodarone
1
aromatic ketone201520159.0low000010
enkephalin, d-penicillamine (2,5)-
2
heterodetic cyclic peptidedelta-opioid receptor agonist1998199925.5low002000
arginyl-glycyl-aspartic acid
3
oligopeptide2009201911.7low000210
1,4-dihydropyridine
3
1984200134.0low020100
cremophor el
1
2011201113.0low000010
alphaxalone
1
corticosteroid hormone201820186.0low000010
sr141716
4
amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist		2000201017.2low001300
bosentan anhydrous
11
primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist		2001201714.6low000560
bicuculline methiodide
3
1998201614.3low001020
eudragit rs
2
201320179.0low000020
fluo-3
1
xanthene dyefluorochrome2001200123.0low000100
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate
1
beta-carbolines1999199925.0low001000
fpl 55712
1
aromatic ketone1987198737.0low010000
paxilline
1
diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker		2007200717.0low000100
ergosine
1
ergot alkaloidfungal metabolite1962196262.0low010000
cgp 35348
2
1998200124.5low001100
dihydroergocristine
1
ergot alkaloidadrenergic antagonist;
vasodilator agent		1955195569.0low010000
propionylcarnitine
5
O-acylcarnitineanalgesic;
antirheumatic drug;
cardiotonic drug;
human metabolite;
peripheral nervous system drug		1993201619.2low202120
methoctramine
1
hydrochloridemuscarinic antagonist1998199826.0low001000
1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol
2
1996201021.0low001100
perindopril
10
alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1996202313.6low401351
ethacizine
1
phenothiazines202020204.0low000010
afdx 116
1
benzodiazepine2002200222.0low000100
procyanidin
5
proanthocyanidin1988201819.2low011120
n(g)-iminoethylornithine
2
L-alpha-amino acid2011201312.0low000020
triptolide
1
diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite		202120213.0low000001
1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)-
2
2000200820.0low001100
cobaltiprotoporphyrin
1
2007200717.0low000100
ml 9
1
1999199925.0low001000
schizandrin b
1
2010201014.0low000100
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
6
2-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent		1984200828.0low030300
exp3174
1
biphenylyltetrazole;
imidazoles;
organochlorine compound		metabolite2013201311.0low000010
tadalafil
2
benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		2007201214.5low000110
thromboxanes
5
1980200435.0low040100
landiolol
2
morpholines2012201212.0low100020
tanshinone
15
abietane diterpenoidanticoronaviral agent1985202214.8low011481
1-(carboxymethylthio)tetradecane
1
straight-chain fatty acid2009200915.0low000100
icrf 193
1
1997199727.0low001000
ginkgolide a
1
diterpene lactone2010201014.0low100100
stachydrine
2
alkaloid;
amino-acid betaine;
N-methyl-L-alpha-amino acid		food component;
human blood serum metabolite;
plant metabolite		201020209.0low000110
dioscin
2
hexacyclic triterpenoid;
spiroketal;
spirostanyl glycoside;
trisaccharide derivative		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 1.14.18.1 (tyrosinase) inhibitor;
hepatoprotective agent;
metabolite		2013201410.5low000020
caprylates
1
fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite		2011201113.0low000010
ah 6809
1
xanthones2009200915.0low000100
tropacine
3
1955195569.0medium030000
zd 7114
1
2011201113.0low000010
ezogabine
1
carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline		anticonvulsant;
potassium channel modulator		2009200915.0low000100
hydroxypropylmethylcellulose acetate succinate
1
2001200123.0low000100
bms 180448
3
1996200423.7low001200
pd 142893
1
1999199925.0low001000
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin
1
1982198242.0low010000
3-quinuclidinyl-4-iodobenzilate
1
1988198836.0low010000
7-propyl spirolactone
1
2003200321.0low000100
saccharolactone
1
aldarolactone;
delta-lactone		2011201113.0low000010
astragaloside a
3
201220216.3low000021
peroxynitrous acid
1
nitrogen oxoacid201720177.0low000010
imatinib mesylate
1
methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor		2007200717.0low000100
mk 0663
1
bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		201720177.0low000010
bay x 1005
1
2010201014.0low000100
argipressin, beta-mercapto-beta,beta cyclopentamethylenepropionic acid(1)-
1
1996199628.0low001000
bdf 9148
1
1995199529.0low001000
proctolin
2
1997200324.0low001100
angiotensin ii, des-phe(8)-
10
amino acid zwitterion;
angiotensin		vasodilator agent2000202110.1low001081
2-chloro-n(6)cyclopentyladenosine
2
1999200522.0low001100
heliox
1
201620168.0low000010
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-
1
organic molecular entity2005200519.0low100100
n,n-dimethylarginine
12
dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor2003201713.8low300660
polytrimethylene carbonate
2
2011201411.5low000020
cgp 28392
1
aromatic ether1987198737.0low010000
3-(2,2,2-trimethylhydrazine)propionate
78
ammonium betainecardioprotective agent;
EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor;
neuroprotective agent		1989202216.1high1811428341
benzoylarginine ethyl ester
1
2012201212.0low000010
tak 044
2
2000200521.5low001100
6-methoxy-n-(3-sulfopropyl)quinolinium
1
2010201014.0low000100
zd 7288
71
1993201818.2medium001734200
glabridin
1
hydroxyisoflavansantiplasmodial drug2013201311.0low000010
icrf 198
5
1997201319.0high001220
methotrexate
6
dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent		2004201910.5low100240
sb 211475
1
2000200024.0medium001000
bmy 45778
1
bisoxazolepartial prostacyclin agonist1997199727.0low001000
ly 293558
1
2000200024.0low001000
n(6)-2-(4-amino-3-iodophenyl)ethyladenosine
1
1996199628.0medium001000
ta 993
1
1998199826.0medium001000
picrocrocin
1
beta-D-glucoside201620168.0low000010
mdl 73404
7
1991199630.4high007000
bmy 42393
1
1997199727.0low001000
fk 633
1
1999199925.0low001000
omega-n-methylarginine
9
amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		1998201222.9low007110
dk-ah 268
2
1994200226.0medium001100
ivabradine
362
aromatic ether;
benzazepine;
carbobicyclic compound;
tertiary amino compound		cardiotonic drug199420237.9high73023330027
butyryl-n-trihexylcitrate
3
201120189.3high100030
ino 2628-cz
2
1988199234.0high011000
proline
5
amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		2003202013.2low000320
cucurbitaceae
1
1961196163.0low010000
3,3',4'-trihydroxyflavone
1
hydroxyflavan2012201212.0low000010
6-chloro-2-pyridylmethyl nitrate
1
1988198836.0medium010000
2-(1-octynyl)adenosine
1
201520159.0low000010
levofloxacin
1
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor		2004200420.0low100100
tanshinone vi
1
1994199430.0medium001000
ezetimibe
6
azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite		2002202113.7low000321
conivaptan
5
benzazepineaquaretic;
vasopressin receptor antagonist		1999201615.0low001220
cariporide
3
1999200423.3low002100
tezosentan
4
2003201316.8low000310
ribulose
1
ribuloseEscherichia coli metabolite;
human metabolite		201720177.0low000010
moxifloxacin
6
aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug2003201513.3low100330
clevidipine
1
dihydropyridine2010201014.0low000100
xamoterol
2
morpholines2001201118.0low000110
n-n-propyl-n-n-butyl-beta-dopamine
3
1981199038.3medium021000
naproxen
2
methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		201420188.0low000020
hydroxyl radical
2
oxygen hydride;
oxygen radical;
reactive oxygen species		1985200927.0low010100
methyl 5-aminolevulinate
1
delta-amino acid esterantineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug		2009200915.0low000100
telbivudine
1
pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		2008200816.0low000100
atrasentan
3
pyrrolidines2004200818.7low000300
diplacin
2
1952195471.0medium020000
cryptotanshinone
2
abietane diterpenoidanticoronaviral agent1985200827.5low010100
succinylmonocholine
3
acylcholine1953195570.3medium030000
leonurine
1
trihydroxybenzoic acid2012201212.0low000010
deacetyltrimepranol
1
1996199628.0medium001000
r 64719
1
1991199133.0low001000
1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane
1
2005200519.0low000100
angiotensin ii (3-7)
1
202120213.0low000001
gp 531
1
1996199628.0medium001000
antibiotic ps 6
1
carbapenems1980198044.0medium010000
avasimibe
1
monoterpenoid2004200420.0low000100
dihydroergocornine
4
ergot alkaloid1951195669.8medium040000
symmetric dimethylarginine
2
amino acid zwitterion;
dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor2011201212.5low000020
varenicline
2
2008201612.0low000110
biotin
1
biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite		201820186.0low000010
angiotensin ii
63
amino acid zwitterion;
angiotensin II		human metabolite1962202119.2low441820201
lixivaptan
1
2008200816.0low000100
dimethylethylsilylimidazole
1
202220222.0medium000001
atropine
50
1952202143.3low1336461
benzofurocaine
1
1987198737.0low010000
sb 203580
2
imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent		2001201018.5low000200
zm 241385
1
diamino-1,3,5-triazine1996199628.0low001000
cilengitide
1
oligopeptide201920195.0low000010
roxifiban
3
1999200024.3low003000
xv 459
1
2000200024.0low001000
lu 135252
1
2003200321.0low000100
piboserod
1
202120213.0low000001
organophosphonates
3
divalent inorganic anion;
phosphite ion		1992200424.3low001200
orbofiban
1
1999199925.0low001000
a 2545
1
2001200123.0medium000100
scutellarin
5
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor		201120218.4low000041
propargylglycine
1
2009200915.0low000100
emd 60263
1
1994199430.0low001000
mk 912
1
1999199925.0low001000
1-(1-pyrrolidinylmethyl)-2-naphthol
1
1992199232.0medium001000
mdl 74270
1
1991199133.0medium001000
dibenzheptropine
2
organic tricyclic compound1963196560.0low020000
dronedarone
3
1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic		201620196.3low000030
ramelteon
2
indanes201820205.0low000020
darunavir
3
carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor		2008202010.3low000120
dabigatran
1
aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines		anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor		2013201311.0low000010
tbc-11251
3
benzodioxoles2003201017.3low100300
tolvaptan
14
benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist		2004201414.6low700860
nolomirole
1
2012201212.0medium100010
sorafenib
2
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor		201920195.0low000020
alagebrium
3
2004201117.7low100210
succinobucol
3
benzoate ester;
phenols		2010201810.3low000120
regadenoson
1
purine nucleoside201920195.0low100010
lacosamide
1
N-acyl-amino acid201720177.0low000010
erythritol
1
butane-1,2,3,4-tetrolantioxidant;
human metabolite;
plant metabolite		1965196559.0low010000
deoxycholic acid
1
bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite1987198737.0low010000
cortisone
14
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1953198563.9low0140000
sodium sulfide
2
201620168.0low000020
benzofurans
12
1962201528.8low242150
hydroxydione
1
20-oxo steroid;
21-hydroxy steroid;
3-oxo-5beta-steroid;
primary alpha-hydroxy ketone		human xenobiotic metabolite1956195668.0low010000
lupeol
1
pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite		201620168.0low000010
cyclovirobuxine d
6
1982200633.7medium232100
noscapine
1
aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite		1962196262.0low010000
wortmannin
1
acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent		2007200717.0low000100
piperitenone
1
p-menthadien-3-one2001200123.0low000100
2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide
1
2001200123.0low000100
ritonavir
3
1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic		2008202210.3low000111
dihydropyridines
9
1984201227.6low024120
4-aminopiperidine
1
201820186.0low000010
leupeptins
1
2009200915.0low000100
lithium chloride
2
inorganic chloride;
lithium salt		antimanic drug;
geroprotector		2010201014.0low000200
glycogen
4
1952200038.0low013000
fibrin
13
peptide1994201912.7low0012100
bradykinin
29
oligopeptidehuman blood serum metabolite;
vasodilator agent		1970202221.0low0310961
glucosamine
2
D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite		201320169.5low100020
elastin
7
oligopeptide200820189.7low000160
carnosine
1
amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent		201920195.0low100010
mevalonic acid
2
3,5-dihydroxy-3-methylpentanoic acid2004201912.5low000110
oxytocin
19
heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent		1952201453.8low0150220
3,4-dihydroxyphenyllactic acid
4
2-hydroxy monocarboxylic acid;
catechols		2009201911.8low000220
inositol 1,4,5-trisphosphate
2
myo-inositol trisphosphatemouse metabolite2006201215.0low000110
ouabain
13
11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite		1956201230.3low044410
tartaric acid
7
tartaric acidEscherichia coli metabolite1952200662.6low060100
nitroarginine
14
guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid		1993200821.9low0031100
adenosine 5'-o-(3-thiotriphosphate)
1
nucleoside triphosphate analogue1999199925.0low001000
elymoclavine
1
alkaloid1958195866.0low010000
strychnine
11
monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide		1952198462.2low0110000
quinidine
42
cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker		1948202246.1low0326211
digitoxin
7
cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor1947199059.3low061000
digitoxin
70
cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor1946201862.7low0654010
pancuronium
2
acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist		1994199927.5low102000
rocuronium
1
3alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent		1999199925.0low001000
trimethaphan camsylate
1
1960196064.0low010000
ryanodine
1
2014201410.0low000010
convallatoxin
1
14beta-hydroxy steroid;
19-oxo steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
steroid aldehyde;
steroid lactone		metabolite;
vasodilator agent		1992199232.0low001000
ginsenoside re
2
12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
nephroprotective agent;
neuroprotective agent;
plant metabolite		201220208.0low000020
ginsenoside rg1
2
12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		neuroprotective agent;
pro-angiogenic agent		201520168.5low000020
lysergamide
1
ergoline alkaloid1955195569.0low010000
stevioside
1
beta-D-glucoside;
bridged compound;
diterpene glycoside;
ent-kaurane diterpenoid;
tetracyclic diterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
hypoglycemic agent;
plant metabolite;
sweetening agent		2014201410.0low000010
visnadin
1
coumarins1953195371.0low010000
gingerol
1
beta-hydroxy ketone;
guaiacols		antineoplastic agent;
plant metabolite		2005200519.0low000100
ecgonine
1
tropane alkaloid1955195569.0low010000
lignans
9
1986202018.7low012330
schizandrin c
1
tannin2010201014.0low000100
bq 123
2
cyclic peptide2003200818.5low000200
n-formylmethionine leucyl-phenylalanine
3
tripeptide1996200721.0low001200
teprotide
1
peptide1981198143.0low010000
sodium arsenite
1
arsenic molecular entity;
inorganic sodium salt		antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide		201520159.0low000010
eplerenone
15
3-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent		2003201814.9low200870
ergonovine
89
ergot alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		diagnostic agent;
fungal metabolite;
oxytocic;
toxin		1950201763.5low0813320
medigoxin
2
cardenolide glycoside1985199434.5low011000
betadex
4
cyclodextrin2005202111.2low000211
acetyl coenzyme a
1
acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite		202120213.0low000001
e-z cinnamic acid
1
cinnamic acidplant metabolite2011201113.0low000010
ergosterol
1
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite		1962196262.0low010000
tretinoin
1
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		201820186.0low000010
arachidonic acid
13
icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite		1984201521.2low130640
alpha-cyclodextrin
1
cyclodextrin202020204.0low100010
prostaglandin h2
1
olefinic compound;
oxylipin;
prostaglandins H;
secondary alcohol		mouse metabolite1985198539.0low010000
farnesol
1
farnesolplant metabolite202120213.0low000001
3-hydroxy-3-methylglutaryl-coenzyme a
1
3-hydroxy-3-methylglutaryl-CoA;
3-hydroxy fatty acyl-CoA		human metabolite;
mouse metabolite		2012201212.0low000010
resveratrol
24
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		2003202111.3low1008142
retinol
4
retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite		1963199353.0low031000
oleic acid
2
octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent		1990200626.0low001100
tacrolimus
15
macrolide lactambacterial metabolite;
immunosuppressive agent		2008201713.4low2001050
ferulic acid
1
ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite		2011201113.0low000010
pectins
2
D-galactopyranuronic acid1961202133.0low010001
cerivastatin
1
dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)		2010201014.0low000100
cocaine
13
benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		1955201531.6low034510
eicosapentaenoic acid
12
icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical		2002202010.8low2002100
alpha-methyl-4-carboxyphenylglycine
1
non-proteinogenic alpha-amino acidmetabotropic glutamate receptor antagonist1998199826.0low001000
mycophenolic acid
3
2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic		1998201520.0low002010
clindamycin
1
201720177.0low000010
lycopene
1
acyclic caroteneantioxidant;
plant metabolite		2013201311.0low000010
zithromax
2
macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic		1993201520.0low001010
geranylgeranyl pyrophosphate
1
geranylgeranyl diphosphatemouse metabolite2007200717.0low000100
apstatin
1
1999199925.0low001000
2-butenal
1
enal201820186.0low000010
t0901317
2
2010201113.5low000110
y 27632
2
aromatic amide2007201413.5low000110
adenosine-5'-(n-ethylcarboxamide)
1
adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		1990199034.0low001000
prostaglandin d2
3
prostaglandins Dhuman metabolite;
mouse metabolite		1985200923.0low010200
diethylstilbestrol
2
olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen		1954195967.5low020000
eptifibatide
3
homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor		2003200520.0low100300
h 89
2
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide2000200123.5low001100
imidazolidines
1
azacycloalkane;
imidazolidines;
saturated organic heteromonocyclic parent		1998199826.0low001000
texas red
1
organic heteroheptacyclic compoundfluorochrome2004200420.0low000100
iridoids
1
2013201311.0low000010
kt 5720
1
carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor2009200915.0low000100
dactinomycin
2
actinomycinmutagen1999201019.5low001100
gamma-sitosterol
1
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite		2014201410.0low000010
enkephalin, leucine
5
pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite		1982199930.2low014000
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
1
amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor2009200915.0low000100
schizandrin
2
1991201521.0low001010
riboflavin
1
flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite		1992199232.0low001000
sodium bicarbonate
6
one-carbon compound;
organic sodium salt		antacid;
food anticaking agent		1992201922.0low003210
potassium perchlorate
1
2011201113.0low000010
ammonium acetate
1
acetate salt;
ammonium salt		buffer;
food acidity regulator		2011201113.0low000010
dipyrone
1
organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug		2009200915.0low000100
carbenoxolone sodium
2
triterpenoid201520206.5low000020
anethole
1
anetholeflavouring agent2007200717.0low000100
geraniol
1
3,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol		allergen;
fragrance;
plant metabolite;
volatile oil component		201820186.0low000010
glycosides
11
1950202149.7low080021
chalcone
5
chalconeEC 3.2.1.1 (alpha-amylase) inhibitor2003201615.0low100320
isomethyleugenol
1
isomethyleugenol201520159.0low000010
stilbenes
33
stilbene1953202024.9low07011150
flavin-adenine dinucleotide
1
flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group		2003200321.0low000100
cocaethylene
1
benzoate ester1995199529.0low001000
norcocaine
1
benzoate ester1995199529.0low001000
cannabidiol
1
olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite		2007200717.0low000100
buprenorphine
1
morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic		2013201311.0low000010
lypressin
1
cyclic peptide2008200816.0low000100
arginine vasopressin
11
vasopressincardiovascular drug;
hematologic agent;
mitogen		1959201631.5low032420
sea 0400
1
201520159.0low000010
pyrophosphate
2
diphosphate ion1964202032.0low010010
gw9662
1
benzamides2004200420.0low000100
bz-423
1
1963196361.0low010000
methylatropine
3
1998200025.0low003000
omapatrilat
24
dipeptide1997201221.8medium1061710
xe 991, anthracenone
1
anthracenes2009200915.0low000100
tram 34
1
organochlorine compound2011201113.0low000010
fludarabine
1
purine nucleoside2007200717.0low000100
nsc 4347
1
2013201311.0low000010
n(6)-cyclopentyladenosine
3
1995200226.0low002100
sesquiterpenes
3
1958201629.3low010110
dienestrol
1
1954195470.0low010000
etomidate
4
ethyl ester;
imidazoles		intravenous anaesthetic;
sedative		1953195371.0low040000
mercaptopurine
1
aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent		1957195767.0low010000
methylthiouracil
1
pyrimidone1964196460.0low010000
bemesetron
1
1990199034.0low001000
thioinosine
4
1989199832.0low013000
cotinine
2
N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite		2002200520.5low100200
flunarizine
2
diarylmethane1985199136.0low111000
curcumin
6
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		2004202113.2low000411
benztropine
4
diarylmethane1956196066.0low040000
thiouracil
2
nucleobase analogue;
thiocarbonyl compound		antithyroid drug;
metabolite		1958195965.5low020000
methimazole
2
1,3-dihydroimidazole-2-thionesantithyroid drug1960196064.0low020000
urb 597
1
biphenyls2010201014.0low000100
cinnarizine
1
diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist		1985198539.0low110000
capsaicin
4
capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker		1995201621.2low002110
drotaverin
1
isoquinolines1963196361.0low010000
chlorogenic acid
1
cinnamate ester;
tannin		food component;
plant metabolite		2014201410.0low000010
1,3-dimethylthiourea
1
2009200915.0low000100
thiourea
5
one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore		1953201328.2low011210
D-fructopyranose
4
cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent1997201713.8low001030
digoxin
106
cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope		1963202320.0low8191727349
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole
1
benzoic acid;
imidazolines;
organic radical		apoptosis inhibitor;
radical scavenger		2011201113.0low000010
tamoxifen
3
stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator		1994200821.0low001200
hydroxypropyl-gamma-cyclodextrin
1
2005200519.0low000100
nadp
3
2004201017.3low000300
1,1-diphenyl-2-picrylhydrazyl
4
2000201715.0low001120
methyl-thiohydantoin-tryptophan
1
organonitrogen compound;
organooxygen compound		201720177.0low000010
ace-011
1
202320231.0low100001
rhyncophylline
1
2012201212.0low000010
thiopental
3
barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic		1953200140.3low111100
ranitidine
3
C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic		1989201423.3low011010
lithium
9
alkali metal atom1979202035.7low062010
thiobutabarbital
1
1997199727.0low001000
cobaltous chloride
1
cobalt salt;
inorganic chloride		allergen;
calcium channel blocker;
sensitiser;
two-colour indicator		201520159.0low000010
nitrogen dioxide
1
nitrogen oxide2012201212.0low100010
tinofedrine
1
alkylbenzene1981198143.0medium010000
monooctanoin
1
1-monoglyceride;
octanoate ester;
rac-1-monoacylglycerol		2011201113.0low000010
orlistat
1
beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor		2012201212.0low000010
quinine
23
cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic		1951201862.7low0220010
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester
1
2010201014.0low000100
8-bromoguanosino-3',5'-cyclic monophosphorothioate
1
201820186.0low000010
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
1
2012201212.0low000010
u-50488
1
dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist		1999199925.0low001000
chlordiazepoxide, clidinium drug combination
1
1962196262.0low010000
sr 144528
1
bridged compound;
monochlorobenzenes;
pyrazoles;
secondary carboxamide		CB2 receptor antagonist;
EC 2.3.1.26 (sterol O-acyltransferase) inhibitor		2000200024.0low001000
nitinol
29
200720209.9low8005240
argipressin, deaminopenicillamine(1)-val(4)-
1
1996199628.0low001000
sc 52608
3
1994199529.7high003000
18-crown-6 2,3,11,12-tetracarboxylic acid
1
2014201410.0low000010
ergotoxine
8
1952196069.4medium080000
cytellin
1
2014201410.0low000010
ginsenosides
10
200920208.6low000280
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine
3
adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid		adenosine A2A receptor agonist;
anti-inflammatory agent		1997200821.0low001200
sodium dodecyl sulfate
2
organic sodium saltdetergent;
protein denaturant		1995202016.5low001010
crocin
1
201620168.0low000010
l 663536
1
aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist		2007200717.0low000100
flavan-3-ol
1
hydroxyflavonoid201520159.0low000010
6-cyano-7-nitroquinoxaline-2,3-dione
7
quinoxaline derivative1998201618.7low003220
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone
1
201720177.0low000010
fg 9041
1
quinoxaline derivative2012201212.0low000010
alpha-chymotrypsin
1
2009200915.0low100100
naphthoquinones
4
1954201640.5low020110
am 630
1
N-acylindole2010201014.0low000100
sb 408124
1
organohalogen compound;
quinolines		201520159.0low000010
osteoprotegerin
1
long-chain fatty acid201620168.0low000010
flosequinan
4
quinolines1993200128.0low003100
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
1
benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor2008200816.0low000100
rhodamine 123
1
organic cation;
xanthene dye		fluorochrome2006200618.0low000100
quercetin 3-o-glucuronide
1
beta-D-glucosiduronic acid;
quercetin O-glycoside		antidepressant;
antioxidant;
metabolite		2011201113.0low000010
sphingosine
8
sphing-4-eninehuman metabolite;
mouse metabolite		1995201415.8low101430
quercetin
7
7-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger		1963201820.9low110240
bilirubin
5
biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite		1964201622.2low010130
dinoprostone
15
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		1984201325.7low063420
dinoprost
5
monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite		1986200626.8low021200
apigenin
4
trihydroxyflavoneantineoplastic agent;
metabolite		200920219.8low000121
luteolin
1
3'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist		201720177.0low000010
7,3'-dihydroxy-4'-methoxyisoflavone
1
4'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite		202020204.0low000010
linoleic acid
1
octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite		2005200519.0low000100
calcitriol
2
D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical		2005202011.5low000110
scopoletin
1
hydroxycoumarinplant growth regulator;
plant metabolite		1983198341.0low010000
vitamin k semiquinone radical
9
1953202030.1low140050
beta carotene
3
carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A		1996201321.7low202010
leukotriene b4
3
dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent		1989199631.0low012000
thromboxane a2
14
epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite1980201825.9low054230
8,11,14-eicosatrienoic acid
3
fatty acid 20:3;
long-chain fatty acid		fungal metabolite;
human metabolite;
nutraceutical		2008201513.3low000210
alprostadil
15
prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent		1984201327.1low490240
vitamin d 2
2
hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide		1962200540.5low010100
cholecalciferol
2
D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite		2004201216.0low000110
rutin
13
disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite		1953201439.7low173210
kaempferol
1
7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite		2001200123.0low000100
prostaglandin g2
1
prostaglandins Ghuman metabolite;
mouse metabolite		1985198539.0low010000
6-ketoprostaglandin f1 alpha
6
prostaglandins Falphahuman metabolite;
mouse metabolite		1987201424.0low120310
11-dehydro-thromboxane b2
1
thromboxanehuman metabolite201820186.0low000010
arachidonic acid omega-9 hydroperoxide
1
HPETEmouse metabolite1990199034.0low001000
alpha-linolenic acid
5
linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical		1989201519.0low011120
prostaglandin f1
1
prostaglandins Falphahuman metabolite1996199628.0low001000
genistein
3
7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		1999200820.3low001200
paricalcitol
1
hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug2005200519.0low000100
astaxanthine
2
carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite		2011201411.5low000020
fucoxanthin
1
2012201212.0low000010
chanoclavine
1
benzoindole;
ergot alkaloid;
organic heterotricyclic compound;
primary alcohol;
secondary amino compound		1964196460.0low010000
toxiferine
5
alkaloid1960196263.2low050000
esculetin
2
hydroxycoumarinantioxidant;
plant metabolite;
ultraviolet filter		2001200421.5low000200
humulene
2
alpha-humulene1979200731.0low010100
petasin
1
alicyclic ketone;
enoate ester;
enone;
sesquiterpenoid		anti-allergic agent;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} activator;
plant metabolite;
vasodilator agent		1958195866.0low010000
baicalein
1
trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger		2008200816.0low000100
chrysin
1
7-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite		202020204.0low000010
diosmetin
2
3'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent		201020209.0low000110
diosmin
18
dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant		1973202016.3low323580
mangiferin
1
C-glycosyl compound;
xanthones		anti-inflammatory agent;
antioxidant;
hypoglycemic agent;
plant metabolite		201720177.0low000010
mangostin
1
aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite		201720177.0low000010
3-methylquercetin
1
7-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite		2002200222.0low000100
myricitrin
2
alpha-L-rhamnoside;
glycosyloxyflavone;
monosaccharide derivative;
pentahydroxyflavone		anti-allergic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite		201520178.0low000020
scutellarein
1
tetrahydroxyflavonemetabolite201620168.0low000010
daidzein
1
7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite		201920195.0low000010
rosmarinic acid
1
rosmarinic acidgeroprotector;
plant metabolite		2013201311.0low000010
salvianolic acid a
2
stilbenoid2011201710.0low000020
shogaol
1
enone;
monomethoxybenzene;
phenols		2005200519.0low000100
acteoside
1
catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite		1999199925.0low001000
rottlerin
1
aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite		2009200915.0low000100
coenzyme q10
10
ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite		1994201719.2low604240
anandamide
3
endocannabinoid;
N-acylethanolamine 20:4		human blood serum metabolite;
neurotransmitter;
vasodilator agent		2002201017.7low000300
ethyl linoleate
1
long-chain fatty acid ethyl esteranti-inflammatory agent;
plant metabolite		2014201410.0low000010
geranylgeranylacetone
1
201820186.0low000010
tranilast
2
amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent		2002201615.0low100110
glyceryl 2-arachidonate
1
2-acylglycerol 20:4;
endocannabinoid		human metabolite2000200024.0low001000
menatetrenone
1
menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent		2012201212.0low100010
isotretinoin
1
retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent		201620168.0low000010
misoprostol
1
2000200024.0low001000
ozagrel
2
cinnamic acids1996200026.0low002000
thromboxane b2
11
thromboxanes Bhuman metabolite;
mouse metabolite		1985201829.2low171120
20-hydroxy-5,8,11,14-eicosatetraenoic acid
2
HETE;
hydroxy monocarboxylic acid		human metabolite;
mouse metabolite		2000201417.0low001010
4-hydroxy-2-nonenal
2
4-hydroxynon-2-enal;
4-hydroxynonenal		2011201610.5low100020
n-oleoylethanolamine
1
endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist		201820186.0low000010
menaquinone 6
1
2012201212.0low100010
sphingosine 1-phosphate
7
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent		1995201316.6low001420
codeine
2
morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic		1964198947.5low020000
perhexiline maleate
4
1999201617.0low001210
phenylephrine hydrochloride
1
hydrochloride1962196262.0low010000
rutin sulfate
1
2000200024.0low001000
acetyldigitoxin
1
cardenolide glycosideanti-arrhythmia drug;
cardiotonic drug;
enzyme inhibitor		1984198440.0low010000
erythrityl tetranitrate
2
nitrate esterexplosive;
vasodilator agent		1962196361.5low020000
iodopyracet
1
1964196460.0low010000
levetiracetam
2
pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic		2008201413.0low100110
naloxone
3
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist		1982200633.0low020100
sirolimus
990
antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		2003202311.0low2910031763439
topiramate
2
cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker		201420178.5low000020
menaquinone 7
1
menaquinonebone density conservation agent;
cofactor;
Escherichia coli metabolite;
human blood serum metabolite;
Mycoplasma genitalium metabolite		2012201212.0low100010
alvocidib
1
dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		201620168.0low000010
morphine
16
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		1951202140.8low193211
as 605240
1
quinoxaline derivative;
thiazolidinediones		anti-inflammatory agent;
antirheumatic drug;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor		2010201014.0low000100
a 192621
4
2000200820.0low001300
bibo 3457
1
1999199925.0low001000
bibp 3226
1
1999199925.0low001000
cicaprost
2
monoterpenoid1984199733.5low011000
clobetasol
1
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist		2007200717.0low000100
deamino arginine vasopressin
1
heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist		2014201410.0low000010
iloprost
111
carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent		1981202134.0low21917571
lacidipine
1
cinnamate ester;
tert-butyl ester		2012201212.0low000010
taprostene
15
benzoic acids1984201130.3high8311010
lysophosphatidic acid
1
1-acyl-sn-glycerol 3-phosphate2003200321.0low000100
cytochalasin b
1
cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor		1999199925.0low001000
neurokinin a
1
1999199925.0low001000
ono 3708
1
2000200024.0low001000
pd 123319
4
imidazopyridineangiotensin receptor antagonist;
endothelin receptor antagonist;
vasoconstrictor agent		2004201713.0low000220
sb 234551
1
2000200024.0medium001000
spirapril
1
azaspiro compound;
dicarboxylic acid monoester;
dipeptide;
dithioketal;
ethyl ester;
pyrrolidinecarboxylic acid;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		1992199232.0low001000
sq 29548
1
2001200123.0low000100
sulprostone
2
prostanoid1988201323.5low010010
biliverdine
1
2008200816.0low000100
syringin
1
beta-D-glucoside;
dimethoxybenzene;
monosaccharide derivative;
primary alcohol		hepatoprotective agent;
plant metabolite		1986198638.0low010000
andrographolide
1
carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol		anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite		202020204.0low000010
icariin
3
flavonols;
glycosyloxyflavone		antioxidant;
bone density conservation agent;
EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
phytoestrogen		1997201517.7low001110
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone
1
agonist2013201311.0low000010
malealdehyde
1
but-2-enedial2011201113.0low000010
ag-490
1
catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor		2010201014.0low000100
semaxinib
1
olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist		202120213.0low000001
su 11248
2
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		201020218.5low000101
mitoguazone
1
guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor		1985198539.0low010000
fosbretabulin
1
2014201410.0low000010
lead
1
carbon group element atom;
elemental lead;
metal atom		neurotoxin2001200123.0low000100
tin
1
carbon group element atom;
elemental tin;
metal atom		micronutrient2006200618.0low000100
12-hydroxy-5,8,10,14-eicosatetraenoic acid
1
1990199034.0low001000
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
11
1984201523.4low024320
antimony
1
metalloid atom;
pnictogen		1990199034.0low001000
cesium
15
alkali metal atom1989201624.3low027420
barium
9
alkaline earth metal atom;
elemental barium		1963200334.6low043200
mevinphos
1
201720177.0low000010
strontium
1
alkaline earth metal atom1962196262.0low010000
bismuth
2
metal atom;
pnictogen		1957196364.0low020000
thallium
3
boron group element atom1981199636.3low121000
arsenic
1
metalloid atom;
pnictogen		micronutrient2013201311.0low000010
naltrexone
1
cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic		1997199727.0low001000
dextromethorphan
1
6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic		2004200420.0low100100
dextrorphan
1
morphinane alkaloid2004200420.0low100100
lisinopril
14
dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor1996201913.6low201490
ramipril
18
azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug		1996202312.1low304383
indinavir sulfate
1
dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor2005200519.0low000100
sulfur
8
chalcogen;
nonmetal atom		macronutrient1951201458.1low061010
veratrine
1
alkaloid1954195470.0low010000
puerarin
5
C-glycosyl compound;
isoflavonoid		200620207.6low000140
enalapril
18
dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug		1992201919.6low607650
thevetine
1
1981198143.0low010000
murexine
1
1955195569.0low010000
n-(p-coumaroyl)serotonin
1
carboxamide;
hydroxyindoles		201620168.0low000010
sinomenine
1
morphinane alkaloid2012201212.0low000010
fumarates
14
butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite		1958201819.1low220390
cysteine
7
cysteiniumfundamental metabolite1957201620.3low011140
thyronines
1
thyronine2000200024.0low001000
phosphorus
5
monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient1956201435.4low031010
ramiprilat
3
azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid;
dipeptide		bradykinin receptor B2 agonist;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor		1999200024.3low003000
imidapril
1
dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		1998199826.0low001000
ici 118551
2
aromatic ether;
indanes;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist2009201114.0low000110
trandolapril
1
dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		2008200816.0low000100
enkephalin, ala(2)-mephe(4)-gly(5)-
4
1998200523.5low003100
strontium radioisotopes
1
2011201113.0low100010
troxerutin
1
2014201410.0low100010
pregabalin
1
gamma-amino acidanticonvulsant;
calcium channel blocker		201720177.0low000010
tiotropium bromide
1
2005200519.0low000100
oxyfedrine
2
aromatic ketone1985200330.0low010100
cafedrine, theodrenaline drug combination
5
1980201521.2high110310
ro 48-3657
1
N-acylglycine2007200717.0low100100
oxyhyponitrite
1
2013201311.0low000010
aliskiren
12
monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent2007201811.3low200390
naltrindole
1
isoquinolines1997199727.0low001000
guanabenz
2
dichlorobenzene1986199931.5low011000
resiniferatoxin
1
carboxylic ester;
diterpenoid;
enone;
monomethoxybenzene;
organic heteropentacyclic compound;
ortho ester;
phenols;
tertiary alpha-hydroxy ketone		analgesic;
neurotoxin;
plant metabolite;
TRPV1 agonist		2010201014.0low000100
carbocyanines
2
cyanine dye;
organic iodide salt		fluorochrome2009200915.0low000200
epimedin b
1
flavonoids;
glycoside		1997199727.0low001000
epimedin c
2
flavonoids;
glycoside		1997200622.5low001100
n-feruloylserotonin
1
aromatic ether;
cinnamamides;
hydroxyindoles;
phenols;
secondary carboxamide		plant metabolite201620168.0low000010
ammonium sulfate
2
ammonium salt;
inorganic sulfate salt		fertilizer2010201014.0low000200
magnesium citrate
1
magnesium saltlaxative201820186.0low000010
ajmaline
6
1962201439.3low041010
barium titanate(iv)
1
201620168.0low000010
ono 1301
2
2013201410.5low000020
tetrodotoxin
15
azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker		1979201819.6low023640
selenium
2
chalcogen;
nonmetal atom		micronutrient1996199827.0low002000
oxalates
2
1990201919.5low001010
1,1-diethyl-2-hydroxy-2-nitrosohydrazine
1
organic anion2013201311.0low000010
pyroantimonate
1
1990199034.0low001000
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
2
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid2004200917.5low000200
raubasine
1
yohimban alkaloid1985198539.0low110000
dihydroergotoxine
46
1951198564.0low1460000
dizocilpine maleate
3
maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		2001201417.3low000210
pregnanediol
3
1956195767.7low030000
caldaret
1
2008200816.0low100100
eniporide
1
1999199925.0low001000
bongkrekic acid
1
ether;
olefinic compound;
tricarboxylic acid		apoptosis inhibitor;
ATP/ADP translocase inhibitor;
bacterial metabolite;
EC 2.5.1.18 (glutathione transferase) inhibitor;
toxin		2009200915.0low000100
nileprost
1
1988198836.0medium010000
hesperidin methylchalcone
2
2010201113.5low200110
hexahydroubiquinone-4
1
1982198242.0medium010000
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid
1
HPETEhuman xenobiotic metabolite1985198539.0low010000
sphingosine phosphorylcholine
1
2014201410.0low100010
kt 362
1
1999199925.0low001000
2,3,5,4'-tetrahydroxystilbene 2-o-glucopyranoside
2
2011201610.5low000020
e 4080
1
1992199232.0medium001000
14-hydroxydocosahexaenoate
1
1989198935.0low010000
pregna-4,17-diene-3,16-dione
1
3-hydroxy steroidandrogen1989198935.0low010000
disufenton sodium
20
2006200916.8medium3002000
comfrey
1
201820186.0low000010
2-(amino)oleic acid
1
2006200618.0low000100
everolimus
470
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		200620238.8medium157004141118
hydroxysafflor yellow a
3
2008201611.7low000120
1-oleoyl-2-palmitoylphosphatidylcholine
1
2004200420.0low000100
17,20-dimethylisocarbacyclin
1
1997199727.0medium001000
salvianolic acid B
3
1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol		anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite		2011201511.3low000030
technetium tc 99m pyrophosphate
1
1996199628.0low001000
glucuronyl glucosamine glycan sulfate
4
2014201410.0low000040
(melle-4)cyclosporin
1
2008200816.0low000100
beta-escin
14
triterpenoid saponin1963202212.9low310283
tanespimycin
1
1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor		201720177.0low000010
beta-escin
18
1963202117.7low024273
s-nitroso-n-acetylpenicillamine
2
nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent		2004201514.5low000110
nitrofurantoin
2
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent		1964200440.0low010100
sb 334867-a
1
naphthyridine derivative201620168.0low000010
shellac
1
2013201311.0low100010
butylscopolammonium bromide
5
1952196469.6low050000
gadolinium dtpa
2
gadolinium coordination entityMRI contrast agent2007200717.0low000200
morphinans
1
isoquinoline alkaloid fundamental parent;
morphinane alkaloid		2012201212.0low000010
ergoline
14
diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound		1952201262.4low0130010
adenosine-3',5'-cyclic phosphorothioate
1
nucleoside 3',5'-cyclic phosphorothioate2000200024.0low001000
sq-23377
1
cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite		1996199628.0low001000
beraprost
1
enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent		2010201014.0low000100
u 62840
4
carbotricyclic compound;
carboxylic acid		antihypertensive agent;
cardiovascular drug;
human blood serum metabolite;
platelet aggregation inhibitor;
vasodilator agent;
vitamin K antagonist		1993201822.5low002110
hexarelin
1
2012201212.0low000010
lu 208075
3
diarylmethane2004200619.3low000300
xct790
1
cinnamamides202120213.0low000001
rebaudioside a
1
beta-D-glucoside;
rebaudioside;
tetracyclic diterpenoid		sweetening agent202120213.0low000001
isoborneol
1
borneol2007200717.0low000100
bromopyruvate
1
2-oxo monocarboxylic acid anion202120213.0low000001
staurosporine
2
ammonium ion derivative1997200025.5low002000
4-oxo-6-((pyrimidin-2-ylthio)methyl)-4h-pyran-3-yl 4-nitrobenzoate
1
nitrobenzoic acid2012201212.0low000010
bufalin
1
14beta-hydroxy steroid;
3beta-hydroxy steroid		animal metabolite;
anti-inflammatory agent;
antineoplastic agent;
cardiotonic drug		202020204.0low000010
hypericum
2
penicillanic acids2002200819.0low000200
phosphocreatine
9
phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite		1983201128.0low134110
chlorhexidine
1
biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent		2007200717.0low000100
guanoxabenz
1
1999199925.0low001000
ep 045
1
1985198539.0low010000
cgp 56999a
1
201620168.0low000010
ono4819
1
benzyl ether2004200420.0low000100
atl 146e
1
2008200816.0low000100
bay 58-2667
1
aromatic ether;
benzoic acids;
dicarboxylic acid;
tertiary amino compound		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent		2011201113.0low000010
amoxicillin-potassium clavulanate combination
2
1996200623.0low001100
sacubitril
3
biphenyls202220222.0low000003
bemethyl
1
1990199034.0low001000
bms 191095
2
2001200521.0low000200
kb r7943
1
2004200420.0low000100
zd 7155
1
2008200816.0low000100
omacor
3
2002201117.7low100210
etomoxir
6
aromatic ether1998201618.7low001410
n(6)-cyclohexyladenosine
1
1996199628.0low001000
istaroxime
4
2006200916.5low100400
ah 1058
2
2000200123.5high001100
ave 0991
1
2010201014.0low000100
novolimus
8
201620206.5high100080
cgs 35066
1
2004200420.0low000100
mocetinostat
11
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		1987201522.0low024320
k201 compound
3
1999200522.7low002100
fimasartan
1
biphenyls2013201311.0low000010
ticagrelor
1
aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor		2014201410.0low000010
zotarolimus
171
lactam;
macrolide		2007202310.3high6600391266
lipid a
1
dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite1997199727.0low001000
dapagliflozin
7
aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201920223.3low300034
ginsenoside rb1
1
ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger		2009200915.0low000100
sk&f 107647
1
2000200024.0low001000
tgx 221
1
pyridopyrimidine2008200816.0low000100
rs 79948-197
1
1999199925.0low001000
zibotentan
1
phenylpyridine202020204.0low100010
avosentan
1
2005200519.0low100100
vernakalant
1
alcohol;
phenols		201720177.0low000010
darapladib
5
2008201314.0low200320
s 5682
1
201620168.0low000010
bedoradrine
1
2006200618.0low000100
cgp 20712a
2
2009201114.0low000110
epiyangambin
1
2001200123.0low000100
n-(1-methylethyl)-1,1,2-trimethylpropylamine
2
2009200915.0low000200
n-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide
1
2009200915.0low000100
pazopanib
1
aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist		202120213.0low000001
ave 9488
1
2008200816.0medium000100
prasugrel hydrochloride
3
2008201513.0low000210
apixaban
3
aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		200820198.7low100120
lepadiformine
2
2001200123.0low000200
aleglitazar
1
201620168.0low000010
sb-611812
1
2009200915.0low000100
edoxaban
2
chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor		201320179.0low100020
angiotensin amide
1
oligopeptide1962196262.0low010000
cgs 24012
1
1998199826.0low001000
etamicastat
1
2006200618.0low000100
etc-1002
2
alpha,omega-dicarboxylic acidantilipemic drug;
EC 2.3.3.8 (ATP citrate synthase) inhibitor;
prodrug		202320231.0low000002
oxadiazoles
3
1981200727.3low010200
ucn 1028 c
3
1997200025.0low003000
ribose
4
D-ribose;
ribopyranose		1988200825.0low111200
acebutolol
2
alpha-D-glucosyl-(1->4)-D-mannopyranose201620215.5low000011
tafamidis
4
1,3-benzoxazoles;
dichlorobenzene;
monocarboxylic acid		central nervous system drug201920214.0low000031
palytoxin
1
polyoltoxin1981198143.0low010000
krp-203
1
2013201311.0low000010
wp1066
1
2012201212.0low000010
nystatin a1
1
nystatins1957195767.0low010000
bay 63-2521
4
aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator		2011201610.0low000040
mitoquinone
1
201520159.0low000010
ridaforolimus
2
macrolide lactam201820205.0low100020
dorsomorphin
1
aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor		202020204.0low000010
anacetrapib
1
2010201014.0low000100
sitagliptin phosphate
2
200820229.0low100101
veratridine
1
2013201311.0low000010
ginsenoside rd
1
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		anti-inflammatory drug;
apoptosis inducer;
immunosuppressive agent;
neuroprotective agent;
plant metabolite;
vulnerary		2009200915.0low000100
omecamtiv mecarbil
10
ureas201020226.1low200163
ru 66647
1
2005200519.0low000100
trametinib
1
acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		201920195.0low000010
bay 60-6583
1
aminopyridine;
aromatic ether;
aryl sulfide;
cyanopyridine;
cyclopropanes;
monocarboxylic acid amide		adenosine A2B receptor agonist;
anti-inflammatory agent;
cardioprotective agent		2012201212.0low000010
losartan potassium
25
1996202213.8low20112111
d-arg-dmt-lys-phe-nh2
2
201720186.5low100020
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc
1
amino tetrasaccharide;
glucosamine oligosaccharide		epitope1999199925.0low001000
td-5108
1
202120213.0low000001
empagliflozin
6
aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201720204.7low200060
calcimycin
3
benzoxazole1984201128.0low011010
indocyanine green
3
1,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye		2003201417.0low000210
scopolamine hydrobromide
9
1953196464.6low090000
pituitrin
17
1959202122.5low131751
syntometrine
1
1963196361.0low010000
amlodipine, atorvastatin drug combination
1
2005200519.0low000100
thienopyridine
3
2005201615.0low100210
phytosterols
4
1994201319.2low101210
rifamycins
1
2005200519.0low000100
clove
1
1959195965.0low010000
dihydroergocryptine
1
1955195569.0low010000
ginsenoside rb3
1
12beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		antidepressant;
antioxidant;
cardioprotective agent;
neuroprotective agent;
NMDA receptor antagonist;
plant metabolite		202020204.0low000010
esorubicin
1
1990199034.0low001000
bleomycetin
1
2010201014.0low000100
icatibant
7
1999200821.7low004300
nad
5
organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite		1987201819.8low011120
sc 25152
1
2003200321.0medium000100
mdv 3100
1
(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent		202020204.0low000010
macitentan
1
aromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides		antihypertensive agent;
endothelin receptor antagonist;
orphan drug		2013201311.0low000010
imidazoleacetic acid ribotide
1
imidazoles;
monocarboxylic acid;
N-glycosyl compound;
ribose monophosphate		2006200618.0medium000100
cytochrome c-t
7
2004201415.4low000610
bivalirudin
3
polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor		2008201911.3low000120
atrial natriuretic factor
49
polypeptide1993202117.5low40132691
nociceptin
1
organic molecular entity;
polypeptide		human metabolite;
rat metabolite		1999199925.0low001000
exchanger inhibitory peptide
1
2004200420.0low000100
tachykinin neuropeptide gamma
1
1999199925.0low001000
glucagon-like peptide 1 (7-36)amide
1
2010201014.0low000100
glucagon
6
peptide hormone1980200933.3low041100
anthopleurin-a
2
1979198144.0low020000
sauvagine
1
2002200222.0low000100
neuropeptide y
6
1999201716.2low001320
ularitide
4
2004201615.8low000310
s6c sarafotoxin
1
2008200816.0low000100
iberiotoxin
1
2001200123.0low000100
angiotensinogen
3
2000201516.3low001110
tannins
1
2013201311.0low000010
oligonucleotides
6
2007202110.2low200312
liraglutide
3
lipopeptide;
polypeptide		glucagon-like peptide-1 receptor agonist;
neuroprotective agent		200920198.3low000120
glucagon-like peptide 1
8
2009201512.8low000530
incretins
7
2009201810.1low000250
natriuretic peptide, c-type
7
1996201918.0low202410
cellulose
5
glycoside2011201710.2low000050
endothelin-1
37
1996201618.2low1052750
phosphatidylcholines
9
1,2-diacyl-sn-glycero-3-phosphocholine1999201615.7low201350
atractyloside
4
1957200854.2low030100
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
1
21-hydroxy steroid1994199430.0low001000
sodium salicylate
1
organic molecular entity1956195668.0low010000
ubiquinone
15
1963201821.5low624270
k-strophanthin-beta
1
cardenolide glycoside;
steroid aldehyde		1955195569.0low010000
calpain
3
2011201910.0low000030
sapogenins
1
1997199727.0low001000
cpu 23
2
1993199729.0high002000
oxypaeoniflora
1
4-hydroxybenzoate ester;
beta-D-glucoside;
bridged compound;
cyclic acetal;
lactol;
monoterpene glycoside		plant metabolite1985198539.0low010000
xyloketal b
1
201520159.0low000010
chitosan
2
1998201219.0low001010
nnc 55-0396
1
hydrochlorideangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker		2013201311.0low000010
technetium tc 99m sestamibi
6
1995200723.8low004200
9-(tetrahydro-2-furyl)-adenine
1
201820186.0low000010
umirolimus
80
lactam;
macrolide		200720209.7high340015650
15-deoxyprostaglandin j2
2
2009200915.0low000200
mesna
1
organosulfonic acid1999199925.0low001000
bucladesine
4
3',5'-cyclic purine nucleotide1999200223.5low002200
tanshinone ii a sodium sulfonate
12
1981202126.5low343311
ro13-9904
2
1998201119.5low001010
sodium ethylxanthate
3
1961199344.0low021000
cortisol succinate, sodium salt
1
organic molecular entity2013201311.0low000010
almorexant
1
isoquinolines201620168.0low000010
picrotoxin
2
1962201237.0low010010
ethyl cellulose
2
glycoside201320179.0low000020
oxymatrine
2
2011201312.0low000020
quetiapine fumarate
1
fumarate salt202120213.0low000001
atb-346
1
201820186.0low000010
fibrinopeptide a
4
1987202024.8low020110
apelin-13 peptide
3
oligopeptideantihypertensive agent;
autophagy inhibitor;
biomarker;
human metabolite;
neuroprotective agent		201620196.7low000030
ldn 193189
1
pyrimidines2012201212.0low000010
pinane-thromboxane a2
1
1985198539.0low010000
9r-(9alpha(z),10alpha) of 3'-angeloyloxy-4'-acetoxy-3',4'-dihydroseselin
1
2011201113.0low000010
11,12-epoxy-5,8,14-eicosatrienoic acid
2
11,12-EEThuman xenobiotic metabolite2008201512.5low000110
glycolipids
3
2004201912.0low000120
alamandine
2
peptide201920214.0low000011
piperidines
48
1953201832.7low714161260
resolvin d1
1
hydroxy polyunsaturated fatty acid;
resolvin;
triol		anti-inflammatory agent201720177.0low000010
interleukin-8
2
201620196.5low000020
antcin a
1
ergostanoidmetabolite2012201212.0medium000010
hydroxocobalamin
2
2008201413.0low000110
fosinopril
2
2001202013.5low000110
sofosbuvir
1
isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug		201820186.0low000010
exenatide
2
2009201512.0low000110
benzoylpaeoniflorin
2
1985200628.5low010100
fructose-1,6-diphosphate
15
1991200921.5low3051000
methylcellulose
7
1954201338.4low030220
natriuretic peptide, brain
155
polypeptide1996202312.8low510664778
heme
2
2008201313.5low000110
ascorbic acid
22
ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent		1954201638.5low4103540
vericiguat
3
aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent		201920214.0low100021
tetracycline
4
1958200951.0low030100
oxytetracycline, anhydrous
1
1964196460.0low010000
salicylates
5
monohydroxybenzoateplant metabolite1953198560.6low050000
acenocoumarol
1
C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor		2011201113.0low000010
warfarin
45
benzenes;
hydroxycoumarin;
methyl ketone		1954202223.2low31176183
phenprocoumon
1
hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor		2002200222.0low000100
ethyl biscoumacetate
1
hydroxycoumarin1963196361.0low010000
dolutegravir
1
difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor202020204.0low000010
omega-agatoxin iva
1
201620168.0low000010
snx 230
1
2005200519.0low000100
epidermal growth factor
1
1996199628.0low001000
calca protein, human
1
2009200915.0low000100
kai 9803
1
2008200816.0medium100100
charybdotoxin
7
2000201518.6low001510
transforming growth factor beta
6
2006202112.0low000321
phytoestrogens
4
2002201318.2low000310
la 419
1
2009200915.0low000100
semaglutide
1
lipopeptide;
polypeptide		anti-obesity agent;
appetite depressant;
glucagon-like peptide-1 receptor agonist;
hypoglycemic agent;
neuroprotective agent		201920195.0low000010
pf-05231023
1
201820186.0low000010
ep 092
1
1985198539.0low010000
paeoniflorigenone
1
alicyclic ketone;
benzoate ester;
bridged compound;
cyclic acetal;
lactol;
monoterpenoid		neuromuscular agent;
plant metabolite		1985198539.0medium010000
rome
10
2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-olEC 2.7.1.91 (sphingosine kinase) inhibitor201120209.2low6000100
angiotensin i
2
angiotensin;
peptide zwitterion		antihypertensive agent;
cardioprotective agent;
human metabolite;
rat metabolite		201520187.5low000020
ym 758
1
2009200915.0medium100100
hirudin
3
2008201911.3low000120
cyclin d1
3
201220188.0low000030
caseins
2
1998200224.0low001100
teca
1
2014201410.0low000010
nitrophenols
1
1955195569.0low010000
snx 482
1
201620168.0low000010
angiotensin i
14
angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent		2000202111.3low0012101
hyaluronoglucosaminidase
19
1950202158.9low0170101
adrenomedullin
3
2000202114.0low101101
angiotensin iii
2
2004200519.5low100200
guan-fu base a
1
202120213.0low000001
d-ala(2),mephe(4),met(0)-ol-enkephalin
1
1996199628.0low001000
ginkgolide b
1
2010201014.0low100100
tridihexethyl
1
2009200915.0low000100
peoniflorin
1
1985198539.0low010000
vitamin b 12
1
2013201311.0low000010
aconitine
3
1981201123.7low010110
oxyntomodulin
1
201920195.0low000010
lysergic acid
12
1951196368.3low0120000
cyclosporine
12
1996201120.7low005610
peptide yy
1
201820186.0low000010
protopanaxadiol
1
1997199727.0low001000
gracillin
1
1998199826.0low001000
edifoligide
3
2007200717.0medium200300
carboxymethyl-beta-cyclodextrin
2
2005201713.0low000110
orabase
1
1954195470.0low010000
thromboplastin
8
1998202313.4low101421
muramidase
2
1959202134.0low010001
lutetium lu 177 dotatate
1
201920195.0low000010
exudates
11
201120217.7low4000101
plicamycin
1
202020204.0low000010
protopanaxatriol
1
1997199727.0low001000
acyclovir
1
2-aminopurines;
oxopurine		antimetabolite;
antiviral drug		2004200420.0low000100
levoleucovorin
1
5-formyltetrahydrofolic acidantineoplastic agent;
metabolite		2009200915.0low000100
cyclic gmp
44
3',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		1986202115.5low23616181
deoxyguanosine
1
purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2010201014.0low000100
guanosine monophosphate
1
guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite		2007200717.0low000100
guanosine triphosphate
2
guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor		1988199333.5low011000
guanosine
1
guanosines;
purines D-ribonucleoside		fundamental metabolite1997199727.0low001000
hypoxanthine
6
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite1993201025.2low105100
inosine
8
inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1989201025.8low115200
inosine diphosphate
2
inosine phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite1989200925.0low010100
sapropterin
7
5,6,7,8-tetrahydrobiopterincoenzyme;
cofactor;
diagnostic agent;
human metabolite		2007201910.9low200250
folic acid
9
folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient		1963201820.3low210710
3-methyladenine
2
202020223.0low000011
guanosine 5'-o-(3-thiotriphosphate)
4
nucleoside triphosphate analogue1999201218.2low002020
neopterin
1
2009200915.0low000100
rifampin
2
cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor		2002200819.0low000200
clozapine
4
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic		2004202011.5low000220
didanosine
1
purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor		2007200717.0low000100
valacyclovir
1
L-valyl esterantiviral drug2004200420.0low000100
olanzapine
1
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor		2013201311.0low000010
allopurinol
13
nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger		1985202217.8low131441
sapropterin dihydrochloride
2
hydrochloridecoenzyme;
diagnostic agent		1985199036.5high111000
bentazepam
1
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound		2006200618.0low000100
sildenafil citrate
21
citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		1998202116.1low1011361
aprepitant
1
(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist		202220222.0low100001
da 8159
1
sulfonamide2013201311.0low100010
vardenafil dihydrochloride
2
2003200719.0low000200
xav939
1
(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor201820186.0low000010
8-bromocyclic gmp
1
3',5'-cyclic purine nucleotide;
organobromine compound		muscle relaxant;
protein kinase G agonist		1999199925.0low001000
8-hydroxy-2'-deoxyguanosine
1
guanosinesbiomarker2010201014.0low000100
formycin b
1
formycin1991199133.0low001000
formycins
1
1991199133.0low001000
5-methyltetrahydrofolate
1
2009200915.0low100100
l 2286
1
2009200915.0medium000100
rvx 208
3
201920213.7low100012
carthamine
1
hydroxycinnamic acid2009200915.0low100100
cholestyramine resin
1
1988198836.0low010000
eye
8
1952200762.2low170100
ferric carboxymaltose
2
201620215.5low000011
acetylcellulose
1
2011201113.0low000010
cenderitide
2
201420188.0medium100020
phosphorus radioisotopes
1
1988198836.0low010000
leptin
5
2006202110.2low000131
pyrimidinones
5
200820219.6low000221
phenanthrenes
19
1981202124.7low355612
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
(pPNET) Peripheral Primitive Neuroectodermal Tumors0
1
1996199628.0low101000
2019 Novel Coronavirus Disease0
41
202020233.2low00001724
3-Methylglutaconic Aciduria, Type II0
2
2013201311.0low000020
47,XX,+210
1
1951195173.0low010000
48,XXYY Syndrome0
1
2008200816.0low000100
6th Nerve Palsy0
1
1959195965.0low010000
A-V Dissociation0
22
1956201925.2low153950
Abdomen, Acute0
1
1963196361.0low010000
Abdominal Aortic Aneurysm0
40
1996202011.6low30115240
Abdominal Cramps0
4
1952200547.5low030100
Abdominal Hernia0
1
201920195.0low000010
Abdominal Migraine0
64
1949201160.6low1572410
Abdominal Obesity0
2
2011201312.0low100020
Abdominal Pain0
2
2006201812.0low100110
Abnormal Deep Tendon Reflex0
4
1961201838.2low121010
Abnormal Movements0
3
1958201047.3low020100
Abnormalities, Autosome0
1
2011201113.0low000010
Abnormalities, Cardiovascular0
1
2010201014.0low000100
Abnormalities, Congenital0
2
201320217.0low000011
Abnormalities, Drug-Induced0
7
1964201231.0low031210
Abnormality, Heart0
59
1963202212.9low22416343
Abortion, Habitual0
2
201220217.5low000011
Abortion, Recurrent0
2
201220217.5low000011
Abortion, Spontaneous0
1
202120213.0low000001
Abortion, Tubal0
1
202120213.0low000001
Abruptio Placentae0
1
1952195272.0low010000
Abscess0
1
1961196163.0low010000
Abscess, Pulmonary0
1
1961196163.0low010000
Absence of Brain, Congenital0
1
1961196163.0low010000
Absence Seizure0
25
1950201947.4low1151540
Absence Status0
1
1959195965.0low010000
Acantholysis Bullosa0
2
1964196460.0low020000
Acathisia, Drug-Induced0
1
1998199826.0low001000
ACD-MPV0
3
2011201511.0low000030
Achalasia0
3
1951196365.0low030000
Ache0
41
1952201935.8low92038100
Achromatopsia0
1
2012201212.0low000010
Acid beta-Glucosidase Deficiency0
1
201620168.0low000010
Acid-Base Imbalance0
2
2003200321.0low000200
Acidosis0
6
1982201028.0low021300
Acidosis, Lactic0
3
2000201116.7low001020
Acidosis, Respiratory0
1
201520159.0low000010
Acoustic Perceptual Disorder0
1
1998199826.0low001000
Acoustic Trauma0
2
1963200639.5low010100
Acquired Immune Deficiency Syndrome0
4
1992201218.2low001120
Acquired Immunodeficiency Syndrome0
4
1992201218.2low001120
Acquired Language Disorders0
1
2012201212.0low000010
Acquired Nephrogenic Diabetes Insipidus0
1
2006200618.0low000100
Acrodynia0
1
1954195470.0low010000
Acropachy, Hereditary0
1
201720177.0low000010
Actinic Reticuloid Syndrome0
2
2005200917.0low000200
Action Tremor0
4
1961200152.8low030100
Active Hyperemia0
7
1995202013.9low101330
Acute Anterior Wall Myocardial Infarction0
10
1964201914.9low010090
Acute Brain Injuries0
13
1955201527.6low033430
Acute Chest Syndrome0
1
2014201410.0low000010
Acute Confusional Senile Dementia0
25
1993202113.0low20211102
Acute Coronary Syndrome0
251
200720239.4low51005218316
Acute Disease0
272
1955202315.7low278401011176
Acute Edematous Pancreatitis0
8
1953202133.9low031211
Acute Generalised Exanthematous Pustulosis0
1
201520159.0low000010
Acute Hemolytic Transfusion Reaction0
1
2004200420.0low000100
Acute Hepatic Failure0
3
200620239.0low000111
Acute Hypercapnic Respiratory Failure0
10
1964202128.9low040141
Acute Idiopathic Facial Neuropathy0
1
2008200816.0low000100
Acute Inferior Myocardial Infarction0
1
201920195.0low000010
Acute Ischemic Stroke0
3
201820214.0low100012
Acute Kidney Failure0
28
1987202314.4low2129151
Acute Kidney Injury0
28
1987202314.4low2129151
Acute Kidney Tubular Necrosis0
1
2001200123.0low000100
Acute Liver Injury, Drug-Induced0
18
1985202016.7low013680
Acute Lung Injury0
3
2012201510.3low000030
Acute Lymphoid Leukemia0
11
2001201517.8low2001010
Acute Mesenteric Arterial Embolus0
2
201420216.5low000011
Acute Myelogenous Leukemia0
4
1998201917.8low102110
Acute Onset Aura Migraine0
1
1962196262.0low010000
Acute Onset Vascular Dementia0
9
1997201316.7low301620
Acute Post-operative Pain0
3
1960200936.0low011100
Acute Post-Traumatic Stress Disorder0
3
2007201911.3low000120
Acute Promyelocytic Leukemia0
1
201820186.0low000010
Acute Respiratory Distress Syndrome0
5
2007202010.8low000230
Acute Rheumatic Fever0
4
1955201427.5low010120
Acute Symptom Flare0
3
201520178.0low200030
Adam-Stokes Attacks0
2
1960198054.0low020000
ADDH0
2
2007200916.0low000200
Adenocarcinoma0
3
1990201120.7low001110
Adenocarcinoma Of Kidney0
3
2006202111.7low000201
Adenocarcinoma of Lung0
1
2011201113.0low000010
Adenocarcinoma, Basal Cell0
3
1990201120.7low001110
Adenohypophyseal Diseases0
1
1958195866.0low010000
Adenohypophyseal Hyposecretion0
1
2005200519.0low000100
Adenoma0
1
2013201311.0low000010
Adenoma Sebaceum0
1
1965196559.0low010000
Adenoma, Basal Cell0
1
2013201311.0low000010
Adenoma, Prolactin-Secreting, Pituitary0
1
2012201212.0low000010
Adenoma, Prostatic0
3
2003202014.0low000210
Adenoviridae Infections0
1
201520159.0low000010
Adenovirus Infections0
1
201520159.0low000010
Adipocere0
3
1998202112.3low001011
Adjuvant Arthritis0
1
1952195272.0low010000
Adolescent Gynecomastia0
2
2000200820.0low001100
Adrenal Cancer0
1
1998199826.0low001000
Adrenal Cortex Cancer0
1
2013201311.0low000010
Adrenal Cortex Diseases0
1
1959195965.0low010000
Adrenal Cortex Neoplasms0
1
2013201311.0low000010
Adrenal Gland Hypofunction0
1
201920195.0low000010
Adrenal Insufficiency0
1
201920195.0low000010
Adult Onset Nemaline Myopathy0
1
201520159.0low000010
Adverse Drug Event0
188
1946202327.1low35615416115
Adverse Effects, Long Term0
3
201620215.0low000021
Affective Disorders0
3
1998201318.0low001110
Affective Disorders, Psychotic0
1
2009200915.0low100100
Affective Psychosis, Bipolar0
3
1952201431.7low010020
Age-Related Macular Degeneration0
1
2008200816.0low000100
Age-Related Memory Disorders0
2
2012201411.0low000020
Age-Related Osteoporosis0
15
1956201824.8low040560
Agenesis of Hemidiaphragm0
2
2009201512.0low000110
Aggression0
2
1955200842.5low110100
Aging0
100
1964202218.7low2121929382
Agitation, Psychomotor0
5
1952196466.8low050000
Agnosia0
1
1953195371.0low010000
Agranulocytosis0
4
1953199160.0low131000
AIDS-Related Opportunistic Infections0
1
2002200222.0low000100
Air Embolism0
4
2004202010.8low000130
Airflow Obstruction, Chronic0
37
2001201910.8low7009280
Airway Obstruction0
7
1965201027.1low021400
Akinetic-Rigid Variant of Huntington Disease0
1
202120213.0low000001
Alarm Clock Headache0
2
2006200916.5low000200
Alastrim0
1
2013201311.0low000010
Albuminuria0
7
2004201913.6low100520
Alcohol Abuse0
8
1954200646.2low050300
Alcohol Drinking0
20
1979201522.2low142950
Alcohol Problem0
1
2014201410.0low000010
Alcohol Withdrawal Associated Autonomic Hyperactivity0
2
1956195668.0low020000
Alcohol-Related Disorders0
1
2014201410.0low000010
Alcoholic Cardiomyopathy0
3
2000201018.7low001200
Alcoholic Cirrhosis0
1
1983198341.0low010000
Alcoholic Intoxication0
1
1991199133.0low001000
Alcoholism0
8
1954200646.2low050300
Aldosteronism0
4
2004201514.8low000310
Algodystrophic Syndrome0
3
1956201548.3low020010
Alkalosis0
1
1996199628.0low001000
Allergic Acute Coronary Syndrome0
1
202020204.0low000010
Allergic Angiitis0
1
2009200915.0low000100
Allergic Contact Dermatitis0
1
202020204.0low000010
Allergic Reaction0
12
1952201635.4low051510
Allergy, Drug0
12
1963202023.9low031440
Allergy, Food0
1
2003200321.0low000100
Allodynia0
5
2005201514.4low000320
Alloxan Diabetes0
31
1981202111.7low0118201
Alopecia0
1
1984198440.0low010000
Alopecia Cicatrisata0
1
1984198440.0low010000
alpha-Galactosidase A Deficiency0
3
2007201115.7low000210
ALS - Amyotrophic Lateral Sclerosis0
1
2008200816.0low000100
Altered Level of Consciousness0
1
2004200420.0low000100
Alveolar Bone Atrophy0
2
1999201716.0low001010
Alveolitis, Fibrosing0
3
1962201543.7low020010
Alzheimer Disease0
25
1993202113.0low20211102
Amaurosis0
6
1952201253.8low050010
Amaurosis Fugax0
1
2013201311.0low000010
Amblyopia0
5
1952195769.4low050000
Amblyopia, Developmental0
5
1952195769.4low050000
Ambulation Difficulty0
2
2007200717.0low000200
Amentia0
18
1992201914.7low102880
American Trypanosomiasis0
5
200720229.4low100221
Amnionitis0
1
2003200321.0low000100
Amniotic Fluid Embolism0
1
2010201014.0low000100
Amphetamine Abuse0
1
202120213.0low000001
Amphetamine-Related Disorders0
1
202120213.0low000001
Amyloid Neuropathies, Familial0
5
201920213.8low000032
Amyloid Neuropathy Type 10
5
201920213.8low000032
Amyloidosis0
3
1984200725.0low010200
Amyotonia Congenita0
10
1953199856.1low082000
Amyotrophic Lateral Sclerosis0
1
2008200816.0low000100
Amyotrophy, Thenar, Of Carpal Origin0
1
1959195965.0low010000
Anal Fissure0
1
1963196361.0low010000
Anaphylactic Reaction0
13
1957202023.7low031360
Anaphylaxis0
13
1957202023.7low031360
Anasarca0
31
1953202232.2low3133591
ANCA-Associated Vasculitides0
1
201720177.0low000010
Anemia0
19
1956201520.4low021880
Anemia, Aplastic0
1
1991199133.0low101000
Anemia, Cooley's0
2
2004201216.0low000110
Anemia, Hypoplastic0
1
1991199133.0low101000
Anemia, Iron-Deficiency0
2
2008201413.0low000110
Anemia, Sickle Cell0
2
201420178.5low000020
Anemias, Iron-Deficiency0
2
2008201413.0low000110
Anesthesia0
145
1947202350.9low2991220131
Aneurysm0
12
200220228.8low100282
Aneurysm, Anterior Cerebral Artery0
9
1995202110.3low101071
Aneurysm, Aortic0
37
2002202111.5low10016156
Aneurysm, Arteriovenous0
8
1982202310.0low310124
Aneurysm, Bacterial0
1
2007200717.0low000100
Aneurysm, Coronary0
34
2006202211.2low0009241
Aneurysm, False0
11
2006202011.7low000380
Aneurysm, Ruptured0
4
1995201813.5low101030
Aneurysm, Thoracic Aortic0
22
1998202012.0low0025150
Angiitis0
10
1999201911.4low001090
Angina at Rest0
122
1983202217.9low2052750382
Angina Pectoris0
471
1952202322.4low8782831721259
Angina Pectoris with Normal Coronary Arteriogram0
20
2002202011.7low3007130
Angina Pectoris, Stable0
102
200620227.7low270028911
Angina Pectoris, Variant0
13
1981201925.1low142430
Angina, Stable0
102
200620227.7low270028911
Angina, Unstable0
122
1983202217.9low2052750382
Angioblastic Meningioma0
1
2014201410.0low000010
Angioedema0
7
201220227.4low000052
Angioedema, Hereditary0
1
201520159.0low000010
Angioedemas, Hereditary0
1
201520159.0low000010
Angiogenesis, Pathologic0
12
1998202211.5low002181
Angiohemophilia0
1
2002200222.0low000100
Angioma0
5
2004201913.2low000320
Angioma, Cavernous0
1
2011201113.0low000010
Angioneurotic Edema0
7
201220227.4low000052
Angiospasm, Intracranial0
8
2007202012.1low100350
Angor Pectoris0
471
1952202322.4low8782831721259
Ankle Fractures0
1
2014201410.0low000010
Anomalous Ventricular Excitation Syndrome0
2
1994199529.5low002000
Anorexia Nervosa0
1
1987198737.0low010000
Anotia0
1
2013201311.0low000010
Anoxemia0
48
1951202119.9low25915181
Anoxia-Ischemia, Brain0
3
201020199.3low000120
Anoxia, Brain0
4
1992201916.0low001120
ANS (Autonomic Nervous System) Diseases0
21
1951201947.4low0132240
Anterior Cervical Pain0
1
1958195866.0low010000
Anterior Choroidal Artery Infarction0
14
1984202021.4low025340
Anterior Circulation Transient Ischemic Attack0
39
1988202212.0low4127263
Anterior Fascicular Block0
13
1984202016.6low212460
Anterior Ischemic Optic Neuropathy0
1
2006200618.0low000100
Anterior Optic Neuritis0
2
1946195772.5low020000
Anterior Wall Myocardial Infarction0
10
1964201914.9low010090
Anti-MuSK Myasthenia Gravis0
7
1951198459.4low070000
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis0
1
201720177.0low000010
Anti-Phospholipid Antibody Syndrome0
3
201120179.7low000030
Antibiotic-Associated Colitis0
2
1995200026.5low002000
Anticipation, Genetic0
1
2002200222.0low000100
Antiphospholipid Syndrome0
3
201120179.7low000030
Antithrombin 3 Deficiency0
1
2001200123.0low000100
Antithrombin III Deficiency0
1
2001200123.0low000100
Anuria0
1
1998199826.0low001000
Anxiety0
20
1952202223.9low3513101
Anxiety Disorders0
9
1952201737.1low240230
Anxiety Neuroses0
9
1952201737.1low240230
Aortic Aneurysm0
37
2002202111.5low10016156
Aortic Aneurysm, Abdominal0
40
1996202011.6low30115240
Aortic Aneurysm, Ruptured0
17
2006201912.1low0006110
Aortic Aneurysm, Thoracic0
22
1998202012.0low0025150
Aortic Arteritis, Giant Cell0
5
1963202023.0low010220
Aortic Coarctation0
4
2005201912.5low000220
Aortic Diseases0
46
1957202112.3low1118342
Aortic Dissection0
67
2004202111.0low20023395
Aortic Incompetence0
14
1993202013.9low002390
Aortic Stenosis0
39
1993202112.8low10410241
Aortic Valve Disease 10
5
201420217.6low000041
Aortic Valve Insufficiency0
14
1993202013.9low002390
Aortic Valve Stenosis0
39
1993202112.8low10410241
Aortitis Syndrome0
6
1992202013.8low001140
Aphthae0
1
2012201212.0low000010
Apical Ballooning Syndrome0
41
2007202111.0low00012272
Apnea0
8
1953199460.4low071000
Apnea, Central0
4
2004201415.8low300310
Apnea, Obstructive Sleep0
7
200920228.9low300151
Apnea, Sleep0
7
1995202116.4low001501
Apolipoprotein B-100, Familial Defective0
9
1988201813.2low110260
Apolipoprotein C-II Deficiency0
1
202120213.0low000001
Apoplexy0
244
2000202311.2low37027415810
Apoplexy, Pituitary0
1
202020204.0low000010
Appetite Disorders0
1
1955195569.0low010000
Arachnidism0
2
1962201038.0low010100
Arrhythmia0
250
1953202323.2low15524859829
Arrhythmias, Cardiac0
250
1953202323.2low15524859829
Arrhythmogenic Right Ventricular Cardiomyopathy0
3
2008201511.3low000120
Arrhythmogenic Right Ventricular Dysplasia0
3
2008201511.3low000120
Arterial Brain Diseases0
3
201220225.3low000012
Arterial Diseases, Carotid0
29
1989202211.4low6116201
Arterial Diseases, Cerebral0
1
2014201410.0low000010
Arterial Inflammation0
4
1957201726.5low011020
Arterial Obstructive Diseases0
80
1954201918.3low169934280
Arterial Occlusive Diseases0
80
1954201918.3low169934280
Arterio-Arterial Fistula0
2
2010201113.5low000110
Arteriosclerosis0
68
1952201829.7low415272330
Arteriosclerosis Obliterans0
13
1955202037.5low390220
Arteriosclerosis, Coronary0
1,337
1951202310.6low34081434390072
Arteriovenous Malformations0
1
2014201410.0low000010
Arteriovenous Malformations, Cerebral0
1
201620168.0low000010
Arthralgia0
2
2007201513.0low100110
Arthritis0
9
1952201847.9low061110
Arthritis, Degenerative0
5
2006202110.4low100221
Arthritis, Psoriatic0
3
2014201410.0low000030
Arthritis, Rheumatoid0
20
1955202122.1low250591
Arthropathies0
4
1961196561.2low040000
Arthus Phenomenon0
1
2000200024.0low001000
As If Personality0
2
1954195669.0low020000
Ascites0
1
2012201212.0low000010
Ascites, Chylous0
1
2011201113.0low000010
Ascorbic Acid Deficiency0
1
201620168.0low000010
Aseptic Necrosis of Femur Head0
1
2009200915.0low000100
Asialia0
10
1993201519.5low003520
Asphyxia Neonatorum0
2
1954196266.0low020000
Aspiration, Respiratory0
1
2006200618.0low000100
Asthenia0
2
2012201411.0low000020
Asthma0
45
1953201648.6low4323550
Asthma, Bronchial0
45
1953201648.6low4323550
Asthma, Cardiac0
1
1955195569.0low010000
Asthmatic Crisis0
1
1958195866.0low010000
Asymmetric Diabetic Proximal Motor Neuropathy0
6
2000201817.2low101410
Asymmetric Septal Hypertrophy, Familial0
5
2003201214.4low000230
Asymptomatic Conditions0
51
201020229.3low3007431
Asystole0
92
1952202120.3low518926372
Ataxia0
1
2004200420.0low000100
Ataxia of Gait0
1
2008200816.0low100100
Atheroembolism0
1
201720177.0low000010
Atherogenesis0
269
1952202312.2low73010814711
Atheroma0
84
201120237.7low8000768
Atherosclerosis0
269
1952202312.2low73010814711
Atherosclerotic Parkinsonism0
1
2011201113.0low000010
Athetoid Movements0
1
1959195965.0low010000
Athletic Injuries0
2
1962200242.0low010100
Atresia, Pulmonary0
1
201720177.0low000010
Atrial Ectopic Beats0
2
2001201615.5low000110
Atrial Ectopic Tachycardia0
2
1999200323.0low001100
Atrial Fibrillation0
238
1953202313.1low27316711399
Atrial Flutter0
14
1953202018.8low020480
Atrial Remodeling0
2
201420216.5low100011
Atrial Septal Defect0
4
2004201813.0low000220
Atrioventricular Block0
9
1946202218.2low010332
Atrioventricular Conduction Block0
9
1946202218.2low010332
Atrioventricular Nodal Re-Entrant Tachycardia0
48
1993202014.5low60914250
Atrioventricular Nodal Reentrant Tachycardia0
2
1994200922.5low001100
Atrophy0
4
1953200834.8low011200
Atrophy, Muscle0
1
2014201410.0low000010
Attachment Loss, Periodontal0
1
2005200519.0low000100
Attention Deficit Disorder with Hyperactivity0
2
2007200916.0low000200
Atypical Cluster Headache0
8
1953200948.6low050300
Atypical Hemolytic Uremic Syndrome0
1
201520159.0low000010
Atypical Hemolytic-Uremic Syndrome0
1
201520159.0low000010
Auditory Vertigo0
1
1952195272.0low010000
Aura0
21
1951202044.0low1113520
Auricular Fibrillation0
238
1953202313.1low27316711399
Auricular Flutter0
14
1953202018.8low020480
Autism0
2
2007201811.5low000110
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome0
1
2014201410.0low000010
Autistic Disorder0
2
2007201811.5low000110
Autoimmune Diabetes0
28
1987201815.6low1239140
Autoimmune Disease0
13
1981201716.2low010480
Autoimmune Diseases0
13
1981201716.2low010480
Autoimmune Thrombocytopenia0
1
2011201113.0low000010
Autosomal Dominant Juvenile Parkinson Disease0
25
1953201564.4low0240010
Autosomal Hemophilia A0
1
2001200123.0low000100
Autosomal Recessive Emery-Dreifuss Muscular Dystrophy0
1
2007200717.0low000100
Avian Diseases0
2
201620187.0low000020
B Virus Infection0
1
1992199232.0low001000
B-Cell Chronic Lymphocytic Leukemia0
1
2001200123.0low000100
B-Cell Lymphoma0
1
1999199925.0low001000
B. burgdorferi Infection0
2
1998200025.0low002000
Babesia Infection0
1
2011201113.0low000010
Back Ache0
6
1956200656.5low150100
Back Pain0
6
1956200656.5low150100
Bacteremia0
7
2003201812.6low000250
Bacterial Disease0
6
1951202032.7low020220
Bacterial Endocarditides0
8
1983201321.8low011420
Bacterial Infections0
6
1951202032.7low020220
Bacterial Infections, Gram-Negative0
1
2012201212.0low000010
Bacterial Skin Diseases0
1
2011201113.0low000010
Bagassosis0
1
2003200321.0low000100
Balkan Endemic Nephropathy0
1
1991199133.0low001000
Barth Syndrome0
2
2013201311.0low000020
Basal Ganglia Cerebrovascular Disease0
1
2006200618.0low000100
Basal Ganglia Diseases0
4
1958198160.0low040000
Basedow Disease0
1
2001200123.0low000100
Basilar Artery Insufficiency0
5
2007201312.8low100140
Basilar Steal Syndrome0
1
2013201311.0low000010
Batten Turner Congenital Myopathy0
2
1958201736.5low110010
Becker Muscular Dystrophy0
10
201020198.3low000190
Behavior Disorders0
47
1951202343.5low02651141
Bell Palsy0
1
2008200816.0low000100
Bends0
1
201520159.0low000010
Benign Meningeal Neoplasms0
1
2014201410.0low000010
Benign Monoclonal Gammopathies0
1
2011201113.0low000010
Benign Neoplasms0
115
1950202316.3low581030625
Benign Neoplasms, Brain0
2
1961201934.0low010010
Benign Paroxysmal Peritonitis0
1
1956195668.0low010000
Besnier-Boeck Disease0
6
1995201916.7low001320
beta-Thalassemia0
2
2004201216.0low000110
Bewilderment0
1
2013201311.0low000010
Bicuspid Aortic Valve Disease0
5
201420217.6low000041
Bilateral Headache0
41
1952200763.0low0391100
Bilateral Nasal Obstruction0
1
1960196064.0low010000
Bilateral Wilms Tumor0
1
2000200024.0low001000
Bile Duct Diseases0
1
1958195866.0low010000
Bile Duct Obstruction0
4
1988202020.8low011110
Bilharziasis0
1
201620168.0low000010
Biliary Calculi0
2
2011201212.5low000020
Biliary Dyskinesia0
1
1963196361.0low010000
Biliary or Urinary Stones0
3
1951195570.7low030000
Biliary Tract Cancer0
1
201520159.0low000010
Biliary Tract Diseases0
3
1954196264.7low030000
Biliary Tract Neoplasms0
1
201520159.0low000010
Bilirubin Encephalopathy0
1
1959195965.0low010000
Bimalleolar Ankle Fractures0
1
2014201410.0low000010
Biological Clock Disturbances0
2
2009201313.0low000110
Bipolar Disorder0
3
1952201431.7low010020
Birth Weight0
5
2002202014.6low000320
Bites0
1
201820186.0low000010
Blast Injuries0
1
2006200618.0low000100
Bleeding0
90
1952202122.0low181929591
Bleeding Between Periods0
4
1953197363.0low040000
Blepharoptosis0
1
1985198539.0low010000
Blepharospasm0
1
1985198539.0low010000
Blindness0
6
1952201253.8low050010
Blood Clot0
280
1952202315.7low671471471075
Blood Coagulation Disorders0
8
1982201817.0low010340
Blood Diseases0
9
1959201932.0low131320
Blood Loss, Postoperative0
7
2007201811.6low400250
Blood Loss, Surgical0
7
1953201822.4low111230
Blood Poisoning0
37
1951202319.9low35219101
Blood Pressure, High0
700
1950202336.9low232907216415816
Blood Pressure, Low0
93
1951202038.6low642815280
Blood Vessel Tumors0
1
2014201410.0low000010
Blunt Injuries0
8
1992201514.0low001160
Body Weight0
43
1962202120.0low54918111
Bone Diseases0
3
1958199851.0low021000
Bone Fractures0
10
1952201736.6low040420
Bone Loss, Osteoclastic0
2
2002200520.5low000200
Bone Loss, Perimenopausal0
4
1994201021.2low001300
Bone Tuberculosis0
1
1961196163.0low010000
BOOP0
2
2002200222.0low000200
Bordetella pertussis Infection, Respiratory0
1
1958195866.0low010000
Borrelia hermsii Infection0
1
2011201113.0low000010
Bouillaud Disease0
11
1963202131.7low150321
Bovine Diseases0
4
1955199159.2low031000
Bradyarrhythmia0
56
1963202316.1low45618225
Bradycardia0
56
1963202316.1low45618225
Bradykinesia0
1
202020204.0low000010
Brain Concussion0
1
1955195569.0low010000
Brain Damage, Chronic0
7
1995201915.1low001240
Brain Dead0
4
2005201614.0low000220
Brain Diseases0
1
2004200420.0low000100
Brain Disorders0
1
2004200420.0low000100
Brain Edema0
6
1952201128.7low011310
Brain Emboli0
4
2008201612.0low000130
Brain Hemorrhage0
5
2003201713.8low000230
Brain Hemorrhage, Cerebral0
13
1958202122.2low221631
Brain Inflammation0
1
1957195767.0low010000
Brain Injuries0
13
1955201527.6low033430
Brain Injuries, Traumatic0
1
201920195.0low000010
Brain Ischemia0
65
1956202016.6low73926270
Brain Neoplasms0
2
1961201934.0low010010
Brain Swelling0
6
1952201128.7low011310
Brain Thrombosis0
1
201920195.0low000010
Brain Vascular Disorders0
57
1962202218.4low89811263
Branch Vein Occlusion0
2
2003201813.5low000110
Breast Cancer0
35
1994202319.7low9017891
Breast Cancer, Male0
1
2008200816.0low000100
Breast Neoplasms0
35
1994202319.7low9017891
Breast Neoplasms, Male0
1
2008200816.0low000100
Breathlessness0
41
1955202114.1low103211241
Brill Disease0
1
1964196460.0low010000
Brill-Symmers Disease0
1
202020204.0low000010
Bronchial Diseases0
4
1951198759.2low040000
Bronchial Hyperreactivity0
1
1994199430.0low101000
Bronchial Spasm0
4
1992200922.8low001300
Bronchitis0
5
1955201350.4low040010
Bronchitis, Chronic0
1
2003200321.0low100100
Bronchopulmonary Dysplasia0
3
2002201116.0low000120
Bronchopulmonary Sequestration0
1
202020204.0low000010
Bronchospasm0
4
1992200922.8low001300
Brugada ECG Pattern0
12
1955202128.9low040161
Brugada Syndrome0
12
1955202128.9low040161
Buerger Disease0
11
1954201835.1low260050
Burning Mouth Syndrome0
1
2001200123.0low000100
Burns0
4
1957201840.5low020110
Cachexia0
7
1965201719.3low010420
Cacosmia0
1
1994199430.0low001000
CADASIL0
1
2008200816.0low000100
CADASILM0
1
2008200816.0low000100
Cadaver0
1
1952195272.0low010000
Calcification, Pathologic0
28
1998202114.0low30213121
Calcinosis0
28
1998202114.0low30213121
Calciphylaxes0
1
201720177.0low000010
Calculus, Dental0
1
2007200717.0low000100
Cancer of Colon0
2
2007200916.0low000200
Cancer of Esophagus0
2
2010201113.5low000110
Cancer of Head0
1
2012201212.0low100010
Cancer of Kidney0
4
2000202114.8low001201
Cancer of Larynx0
2
1990200228.0low001100
Cancer of Liver0
8
1989201815.9low010430
Cancer of Lung0
5
2009201710.8low000140
Cancer of Ovary0
1
1998199826.0low101000
Cancer of Pancreas0
1
2011201113.0low000010
Cancer of Pituitary0
1
2012201212.0low000010
Cancer of Prostate0
4
1954202026.0low010210
Cancer of Sigmoid0
1
2007200717.0low000100
Cancer of Skin0
4
200920226.8low000121
Cancer of Stomach0
1
2010201014.0low000100
Cancer of Testis0
2
200820219.5low000101
Cancer of the Uterus0
1
2000200024.0low001000
Cancer, Embryonal0
2
200820219.5low000101
Cancer, Second Primary0
1
2014201410.0low000010
Candida Infection0
2
1957200045.5low011000
Candidiasis0
2
1957200045.5low011000
Candidiasis, Cutaneous0
1
1957195767.0low010000
Cane-Cutter Fever0
1
1957195767.0low010000
Canine Diseases0
20
1953202118.4low122691
Cannabis Abuse0
1
201720177.0low000010
Capillary Leak Syndrome0
2
201120218.0low000011
Capillary Telangiectasia, Brain0
1
201620168.0low000010
Carbon Monoxide Poisoning0
1
2011201113.0low000010
Carcinoid Heart Disease0
1
2009200915.0low000100
Carcinoma, Epidermoid0
1
2002200222.0low000100
Carcinoma, Hepatocellular0
4
1989201219.8low010210
Carcinoma, Lewis Lung0
1
2004200420.0low000100
Carcinoma, Non-Small Cell Lung0
1
201520159.0low000010
Carcinoma, Non-Small-Cell Lung0
1
201520159.0low000010
Carcinoma, Renal Cell0
3
2006202111.7low000201
Carcinoma, Squamous Cell0
1
2002200222.0low000100
Cardiac Aneurysm0
5
1990202015.2low001130
Cardiac Arrest, Sudden0
116
1992202315.3low701553453
Cardiac Cancer0
2
1993201321.0low001010
Cardiac Complex, Premature0
1
1990199034.0low001000
Cardiac Conduction Defect0
8
1955202335.6low040031
Cardiac Death0
11
1952202228.1low130422
Cardiac Diseases0
356
1953202319.2low15445113111812
Cardiac Edema0
3
1959201726.3low010020
Cardiac Failure0
1,820
1953202314.7low19263223564867103
Cardiac Hypertrophy0
59
1991202213.9low10822254
Cardiac Murmurs0
4
1953201629.2low010210
Cardiac Neurosis0
6
1953198761.7low160000
Cardiac Output, Low0
38
1983201920.6low4382250
Cardiac Remodeling, Ventricular0
175
1998202211.6low1102699311
Cardiac Rupture, Post-Infarction0
3
2009202010.0low000120
Cardiac Rupture, Traumatic0
5
1992201518.4low001220
Cardiac Septal Defect0
3
201420179.0low000030
Cardiac Tamponade0
5
2004201712.4low000140
Cardiac Toxicity0
22
194620228.5low1100156
Cardio-Renal Syndrome0
18
201120229.4low1000162
Cardiomegaly0
59
1991202213.9low10822254
Cardiometabolic Syndrome0
47
2004202013.2low30026210
Cardiomyopathies0
167
1988202214.5low8227567111
Cardiomyopathies, Primary0
167
1988202214.5low8227567111
Cardiomyopathy, Chagas0
7
201020228.7low100151
Cardiomyopathy, Congestive0
88
1985202215.5low1431328404
Cardiomyopathy, Dilated0
88
1985202215.5low1431328404
Cardiomyopathy, Hypertrophic0
66
1990202312.8low50624297
Cardiomyopathy, Hypertrophic Obstructive0
66
1990202312.8low50624297
Cardiomyopathy, Restrictive0
5
2001201217.4low000320
Cardiotoxicity0
22
194620228.5low1100156
Cardiovascular Abnormalities0
1
2010201014.0low000100
Cardiovascular Diseases0
1,843
1950202313.7low7764123619909128
Cardiovascular Pregnancy Complications0
91
1963202117.8low1101225413
Cardiovascular Stroke0
1,484
1955202315.2low2866117650469944
Cardiovascular Tuberculosis0
1
1959195965.0low010000
Carditis0
44
1956202117.0low05314193
Caries, Cervical0
1
1997199727.0low001000
Caries, Dental0
3
1997201219.3low001110
Carotid Arteriopathies, Traumatic0
20
2007202011.2low0006140
Carotid Artery Diseases0
29
1989202211.4low6116201
Carotid Artery Narrowing0
89
2004202310.3low50025586
Carotid Artery Thrombosis0
1
2014201410.0low000010
Carotid Stenosis0
89
2004202310.3low50025586
Carpal Tunnel Syndrome0
1
1959195965.0low010000
Cat Diseases0
6
1995202112.7low001041
Cataleptic Attacks0
1
201520159.0low000010
Cataract0
4
1963199153.2low031000
Cataract, Membranous0
4
1963199153.2low031000
Catarrh0
4
1954196466.2low040000
Catastrophic Illness0
2
2010201113.5low000110
Catatonia0
1
1958195866.0low010000
Causalgia0
1
1956195668.0low010000
Causalgia Syndrome0
1
1956195668.0low010000
Cavernous Angioma, Central Nervous System0
1
201920195.0low000010
Celiac Artery Compression Syndrome0
1
202020204.0low000010
Celiac Disease0
3
1960201433.7low011010
Celiac Sprue0
3
1960201433.7low011010
Cell Transformation, Neoplastic0
1
201720177.0low000010
Cellulitis0
1
202020204.0low000010
Central Hypothyroidism0
6
1956201430.8low120220
Central Nervous System Disease0
6
1952201634.7low021120
Central Nervous System Diseases0
6
1952201634.7low021120
Central Nervous System Origin Vertigo0
4
1952201451.8low030010
Central Venous Catheter Thrombosis0
1
201520159.0low000010
Centriacinar Emphysema0
1
2013201311.0low000010
Cephalgia Syndromes0
2
1952200545.5low010100
Cephalgia, Vascular0
10
1953200460.1low090100
Cerebral Arterial Diseases0
1
2014201410.0low000010
Cerebral Arteriosclerosis0
5
1965202019.2low210130
Cerebral Cholesterinosis0
1
2012201212.0low000010
Cerebral Concussion0
1
1955195569.0low010000
Cerebral Hemorrhage0
13
1958202122.2low221631
Cerebral Infarction0
14
1984202021.4low025340
Cerebral Infarction, Middle Cerebral Artery0
5
201120199.8low100050
Cerebral Ischemia0
65
1956202016.6low73926270
Cerebral Palsy0
13
1952201260.5low0120010
Cerebral Palsy, Athetoid0
13
1952201260.5low0120010
Cerebrospinal Fluid Hypovolemia0
1
2010201014.0low000100
Cerebrovascular Disorders0
57
1962202218.4low89811263
Cerebrovascular Moyamoya Disease0
2
2014201410.0low000020
Chagas Cardiomyopathy0
7
201020228.7low100151
Chagas Disease0
5
200720229.4low100221
Chemical and Drug Induced Liver Injury0
18
1985202016.7low013680
Chemical Dependence0
15
1952201141.3low091320
Chest Injuries0
1
1992199232.0low001000
Chest Pain0
34
1964202115.2low31412152
Cheyne-Stokes Respiration0
1
2007200717.0low100100
Child Behavior Disorders0
1
2009200915.0low000100
Child Development Deviations0
1
2012201212.0low000010
Chills0
2
2001201715.0low000110
Cholecystitis0
2
1961196163.0low020000
Cholecystolithiasis0
1
2012201212.0low000010
Cholelithiasis0
1
1964196460.0low010000
Cholera0
1
2012201212.0low000010
Cholera Infantum0
34
1951202140.4low0164671
Cholestasis0
4
1988202020.8low011110
Chorea0
1
1963196361.0low010000
Chorea Disorders0
1
1963196361.0low010000
Chorioamnionitis0
1
2003200321.0low000100
Chronic Bronchitis0
1
2003200321.0low100100
Chronic Disease0
548
1952202314.5low82215218827017
Chronic Hepatitis C0
4
2001201815.0low000220
Chronic Idiopathic Intestinal Pseudo-Obstruction0
1
1957195767.0low010000
Chronic Illness0
548
1952202314.5low82215218827017
Chronic Insomnia0
3
1953201635.7low011010
Chronic Kidney Disease-Mineral and Bone Disorder0
2
2001201914.0low000110
Chronic Kidney Diseases0
49
200620228.8low3004414
Chronic Kidney Failure0
78
1979202216.9low77530342
Chronic Liver Failure0
1
201620168.0low000010
Chronic Lung Injury0
1
2013201311.0low000010
Chronic Pain0
1
201520159.0low000010
Churg-Strauss Syndrome0
1
2009200915.0low000100
Chylopericardium0
6
2000201712.5low001050
Chylothorax0
1
2002200222.0low000100
Cicatrix0
2
201220208.0low000020
Cicatrization0
2
201220208.0low000020
Circulatory Collapse0
35
1953202130.3low01524131
Cirrhoses, Experimental Liver0
1
2012201212.0low000010
Cirrhosis0
103
1998202310.7low80132646
Cirrhosis, Liver0
11
1984202115.3low010451
CKD-MBD0
2
2001201914.0low000110
Clasp-Knife Spasticity0
20
1951196566.1low0200000
Claustrophobia0
1
2005200519.0low000100
Click-Murmur Syndrome0
2
1994200624.0low101100
Clinical Deterioration0
1
202320231.0low000001
Clinically Isolated CNS Demyelinating Syndrome0
1
1980198044.0low010000
Closed Head Injuries0
2
1994201221.0low001010
Clostridium tetani Infection0
39
1951199265.1low0381000
Coagulation Disorders, Blood0
8
1982201817.0low010340
Coagulation, Disseminated Intravascular0
3
1984202123.0low011001
Coarctation of Aorta0
4
2005201912.5low000220
Cocaine Abuse0
4
1998201019.5low001300
Cocaine-Related Disorders0
4
1998201019.5low001300
Cochlear Hearing Loss0
3
1955201629.0low110020
Cockayne-Touraine Disease0
1
1964196460.0low010000
Cogan Syndrome0
2
2009200915.0low000200
Cognition Disorders0
21
1997201713.2low3017130
Cognitive Decline0
4
201720224.0low000022
Cognitive Dysfunction0
4
201720224.0low000022
Cold Fingers, Hereditary0
12
1964201529.8low052140
Cold Panniculitis0
1
201720177.0low000010
Colicky Pain0
2
2006201812.0low100110
Colitis0
6
1952201954.0low050010
Colitis Gravis0
3
1959196462.0low030000
Colitis, Ischemic0
2
2007201314.0low000110
Colitis, Ulcerative0
3
1959196462.0low030000
Collagen Diseases0
1
2009200915.0low000100
Colon Diverticula0
1
2011201113.0low000010
Colonic Diseases0
3
1954198557.7low030000
Colonic Inertia0
9
1952202052.9low070020
Colonic Neoplasms0
2
2007200916.0low000200
Colonic Polyps0
1
2007200717.0low000100
Color Vision Defects0
1
2012201212.0low000010
Colorectal Cancer0
3
2004201912.0low000120
Colorectal Neoplasms0
3
2004201912.0low000120
Coma0
5
1962201126.2low111210
Common Cold0
4
1954196466.2low040000
Common Migraine0
1
1963196361.0low010000
Communicable Diseases0
4
1961201140.5low021010
Compartment Syndromes0
1
2013201311.0low000010
Compensatory Hyperinsulinemia0
3
1956200440.0low011100
Complex Single Ventricle0
1
201920195.0low000010
Complication, Intraoperative0
24
1990201421.5low3012840
Complication, Postoperative0
149
1965202214.7low1661740833
Complications of Diabetes Mellitus0
117
1960201915.8low142969370
Complications, Infectious Pregnancy0
2
1964201136.5low010010
Complications, Labor0
14
1952200862.6low0130100
Complications, Neoplastic Pregnancy0
1
1998199826.0low001000
Complications, Pregnancy0
15
1953202043.3low080610
Concomitant Strabismus0
1
1954195470.0low010000
Congenital Familial Lymphedema0
2
1964200042.0low011000
Congenital Myotonic Dystrophy0
4
1956201153.8low030010
Congenitally Corrected Transposition0
1
202220222.0low000001
Conjugate Nystagmus0
1
1985198539.0low010000
Connective Tissue Diseases0
6
1953201921.8low010140
Consciousness, Loss of0
2
1998201119.5low001010
Constipation0
9
1952202052.9low070020
Constriction, Pathologic0
166
199520238.9low47012112915
Constriction, Pathological0
166
199520238.9low47012112915
Constrictive Pericarditis0
3
2010202110.0low000111
Contact Dermatitis0
1
1979197945.0low010000
Contracture0
1
1964196460.0low010000
Conus Medullaris Syndrome0
1
2012201212.0low000010
Convalescence0
1
2005200519.0low000100
Convulsions, Grand Mal0
1
201720177.0low000010
Cor Pulmonale0
6
1964200434.0low023100
Cor Triatriatum0
1
201720177.0low000010
Corneal Perforation0
1
2014201410.0low000010
Corneal Ulcer0
1
2014201410.0low000010
Coronary Artery Disease0
1,337
1951202310.6low34081434390072
Coronary Artery Stenosis0
291
2002202112.7low89001411491
Coronary Artery Vasospasm0
50
1986202316.7low121020162
Coronary Disease0
529
1951202123.9low591051391681125
Coronary Heart Disease0
529
1951202123.9low591051391681125
Coronary Occlusion0
81
200820239.3low150019584
Coronary Restenosis0
598
2002202311.7low1970023034325
Coronary Stenosis0
291
2002202112.7low89001411491
Coronary Thrombosis0
304
199520219.6low9902362633
Coronary Vasospasm0
50
1986202316.7low121020162
Coronary Vessel Anomalies0
32
2001202110.0low00010211
Coronavirus Infections0
14
202020204.0low0000140
Corynebacterium diphtheriae Infection0
1
1960196064.0low010000
Costen's Syndrome0
1
1961196163.0low010000
Cot Death0
1
2010201014.0low000100
Cough0
8
1954201740.1low041120
Coxsackie Virus Infections0
1
2005200519.0low000100
Cramp0
9
1960200055.7low181000
Cranial Nerve Diseases0
1
1984198440.0low010000
Craniocerebral Injuries0
2
1999200223.5low001100
Craniocerebral Trauma0
2
1999200223.5low001100
Craniofacial Microsomia0
1
2009200915.0low000100
Craniofacial Pain0
1
1991199133.0low001000
Critical Illness0
88
200120239.5low140022633
Cronobacter Infections0
2
2006201613.0low000110
Cross Infection0
1
2007200717.0low000100
Cross-Transfusion, Intrauterine0
1
2006200618.0low000100
Crossed Embolism0
3
201520187.7low000030
Crow-Fukase Syndrome0
1
2011201113.0low000010
Cruveilhier-Baumgarten Syndrome0
3
1993200626.0low002100
Cryoglobulinemia0
2
201320179.0low000020
Cryptogenic Fibrosing Alveolitis0
1
201920195.0low100010
Curling Ulcer0
4
1954201626.5low110210
Cushing Syndrome0
2
1957201339.0low010010
Cushing's Syndrome0
2
1957201339.0low010010
Cyanosis0
5
1952201428.8low011120
Cystic Fibrosis0
3
1960201727.0low010020
Cystic Fibrosis of Pancreas0
3
1960201727.0low010020
Cystic Kidney Diseases0
1
2007200717.0low000100
Cytomegalic Inclusion Disease0
2
1999201517.0low001010
Cytomegalovirus Infections0
2
1999201517.0low001010
Day Blindness0
1
2009200915.0low000100
Daytime Sleepiness0
1
2012201212.0low000010
DDD MPGNII0
1
2011201113.0low000010
Deaf Mutism0
2
1980201228.0low010010
Deafness0
2
1980201228.0low010010
Deafness Unilateral0
1
2014201410.0low000010
Deafness, Sudden0
2
201320169.5low100020
Deafness, Transitory0
2
2006202011.0low000110
Death, Sudden0
9
1981200433.1low044100
Death, Sudden, Cardiac0
116
1992202315.3low701553453
Debility0
4
201920223.5low000022
Decerebrate Posturing0
3
1990200327.7low002100
Decreased Muscle Tone0
1
1952195272.0low010000
Deep Vein Thrombosis0
8
2000201914.0low001430
Deficiency Diseases0
1
201620168.0low000010
Deficiency of Glucose-6-Phosphate Dehydrogenase0
1
201920195.0low000010
Deficiency, Ascorbic Acid0
1
201620168.0low000010
Deficiency, Magnesium0
5
1989201926.8low022010
Deficiency, Mental0
3
1951199554.0low021000
Deficiency, Protein0
1
2002200222.0low000100
Deficiency, Vitamin D0
3
201020179.3low000120
Deficiency, Vitamin E0
1
1984198440.0low010000
Degenerative Diseases, Central Nervous System0
4
200720188.8low000130
Deglutition Disorders0
1
1952195272.0low010000
Dehydration0
4
1953200748.5low030100
Delayed Effects, Prenatal Exposure0
2
2001200919.0low000200
Delayed Graft Function0
1
201620168.0low000010
Delayed Postpartum Hemorrhage0
7
1952201351.4low050110
Delirium0
3
2005200718.3low000300
Delirium of Mixed Origin0
3
2005200718.3low000300
Dementia0
18
1992201914.7low102880
Dementia Multi-Infarct0
1
1993199331.0low001000
Dementia Praecox0
7
1951202037.1low030220
Dementia, Vascular0
9
1997201316.7low301620
Demyelinating Diseases0
1
1980198044.0low010000
Dental Caries0
3
1997201219.3low001110
Depression0
37
1953202218.5low63612124
Depression, Endogenous0
17
1953201824.2low242650
Depression, Involutional0
4
200220219.8low100121
Depressive Disorder0
17
1953201824.2low242650
Depressive Disorder, Major0
4
200220219.8low100121
Dermatitis0
2
1962199844.0low111000
Dermatitis Medicamentosa0
14
1962201230.2low044510
Dermatitis, Allergic Contact0
1
202020204.0low000010
Dermatitis, Contact0
1
1979197945.0low010000
Dermatitis, Contact, Photoallergic0
3
2002200918.0low000300
Dermatitis, Contact, Phototoxic0
1
2009200915.0low000100
Dermatitis, Eczematous0
1
2009200915.0low000100
Dermatitis, Occupational0
1
2009200915.0low000100
Dermatomyositis0
1
2009200915.0low000100
Dermatomyositis, Adult Type0
1
2009200915.0low000100
Dermatoses0
8
1953200955.4low060200
Developmental Disabilities0
1
2012201212.0low000010
Dextro-Looped Transposition of the Great Arteries0
4
200920229.0low000121
Diabetes Mellitus0
201
1954202312.5low266124512315
Diabetes Mellitus, Adult-Onset0
212
1987202312.1low30277610918
Diabetes Mellitus, Gestational0
2
2013201510.0low000020
Diabetes Mellitus, Type 10
28
1987201815.6low1239140
Diabetes Mellitus, Type 20
212
1987202312.1low30277610918
Diabetes, Gestational0
2
2013201510.0low000020
Diabetic Angiopathies0
102
1964202114.9low186437541
Diabetic Cardiomyopathies0
27
201220217.0low3000234
Diabetic Feet0
5
2012201411.0low000050
Diabetic Foot0
5
2012201411.0low000050
Diabetic Glomerulosclerosis0
15
1999201913.5low101590
Diabetic Nephropathies0
15
1999201913.5low101590
Diabetic Neuropathies0
6
2000201817.2low101410
Diabetic Retinopathy0
7
2004202013.1low000430
Diaphragmatic Hernia0
1
2009200915.0low000100
Diaphragmatic Paralysis0
1
1952195272.0low010000
Diarrhea0
3
1962201232.7low011010
Diastolic Heart Failure0
19
2009201612.3low4005140
Diathesis0
16
1991201915.1low002680
Diffuse Large B-Cell Lymphoma0
1
1999199925.0low001000
Diffuse Mixed Small and Large Cell Lymphoma0
5
1960200729.4low111300
Diffuse Myofascial Pain Syndrome0
3
1957196264.3low030000
Diffuse Parenchymal Lung Disease0
3
2002200820.0low000300
Digestive System Fistula0
1
202020204.0low000010
Dilatation, Pathologic0
7
200020219.1low101051
Diphtheria0
1
1960196064.0low010000
Disbacteriosis0
2
201920204.5low000020
Disc, Herniated0
1
1964196460.0low010000
Disease0
33
1952196266.7low0330000
Disease Exacerbation0
249
1996202211.4low3103821559
Disease Models, Animal0
480
1984202211.7low362115327624
Disease, Pulmonary0
25
1953201827.6low066850
Diseases of Endocrine System0
6
1954200534.2low022200
Diseases of Immune System0
5
1957201923.2low011030
Diseases, Metabolic0
17
1993201913.2low0025100
Diseases, Peripheral Vascular0
96
1951201834.2low93445260
Disorders of Excessive Somnolence0
1
2012201212.0low000010
Disseminated Intravascular Coagulation0
3
1984202123.0low011001
Distorted Hearing0
3
1955195967.7low030000
Diverticular Bleeding0
1
202020204.0low000010
Diverticular Diseases0
1
202020204.0low000010
Diverticulitis0
1
1984198440.0low010000
Diverticulum, Colon0
1
2011201113.0low000010
Dizziness0
6
1996202013.8low301230
Dizzyness0
6
1996202013.8low301230
Down Syndrome0
1
1951195173.0low010000
DRESS Syndrome0
1
202020204.0low000010
Drop Attack0
40
1957202319.2low23913141
Drug Abuse, Intravenous0
2
201120189.5low000020
Drug Hypersensitivity0
12
1963202023.9low031440
Drug Overdose0
17
1989202016.2low014570
Drug Withdrawal Symptoms0
11
1979201421.1low131160
Drug-Induced Stevens Johnson Syndrome0
2
1958201537.5low010010
Drug-Related Side Effects and Adverse Reactions0
188
1946202327.1low35615416115
Ductus Arteriosus, Patent0
92
1984202016.2low62748350
Dumping Syndrome0
2
1964196460.0low020000
Duodenal Ulcer0
4
1954201626.5low110210
Dupuytren Contracture0
1
1998199826.0low001000
Dupuytren's Contracture0
1
1998199826.0low001000
Dwarfism0
1
2012201212.0low000010
Dysesthesia0
5
1951201054.8low040100
Dysgeusia0
1
2010201014.0low000100
Dyskinesia Syndromes0
7
1953201151.0low050110
Dyslipidemia0
55
2004202310.6low30018325
Dyslipidemias0
55
2004202310.6low30018325
Dysmenorrhea0
21
1952196466.0low0210000
Dysmyelopoietic Syndromes0
1
201720177.0low000010
Dyspareunia0
1
1964196460.0low010000
Dyspepsia0
1
1996199628.0low001000
Dysphagia0
1
1952195272.0low010000
Dysplastic Nevus Syndrome, Hereditary0
1
201920195.0low000010
Dyspnea0
41
1955202114.1low103211241
Dystocia0
12
1952196567.3low0120000
Dystonia0
3
1952195669.3low030000
Ear Diseases0
3
1958198256.7low030000
Ebola Hemorrhagic Fever0
1
2014201410.0low000010
Ebstein Anomaly0
2
201720177.0low000020
EBV Infections0
1
2011201113.0low000010
Eclampsia0
7
1951195670.6low070000
Ectopic Junctional Tachycardia0
4
201820234.2low000031
Eczema0
1
2009200915.0low000100
Edema0
31
1953202232.2low3133591
Edema-Proteinuria-Hypertension Gestosis0
26
1951202345.2low0151361
Edema, Cardiac0
3
1959201726.3low010020
Edema, Pulmonary0
26
1951202232.5low094571
Eisenmenger Complex0
2
201520178.0low000020
Eisenmenger Syndrome0
2
201520178.0low000020
Electric Injuries0
1
2013201311.0low000010
Electrocardiogram QT Prolonged0
37
1998202213.8low10123112
Electrolytes0
14
1953201841.2low280510
Electron Transport Chain Deficiencies, Mitochondrial0
4
2007201712.0low000220
Elevated Cholesterol0
56
1982201916.6low62528210
Elevated ICP (Intracranial Pressure)0
9
2001201914.2low100450
Embolism0
19
1954202216.2low111881
Embolism, Cholesterol0
1
201720177.0low000010
Embolism, Pulmonary0
15
1952202118.6low022452
Embolus0
19
1954202216.2low111881
Embryopathies0
4
1989200722.5low010300
Emergencies0
34
1981202026.1low11012570
Emesis0
5
1950201648.2low130110
Emphysema0
2
201720177.0low000020
Emphysema, Mediastinal0
1
202020204.0low000010
Emphysema, Subcutaneous0
1
202020204.0low000010
Empyema, Gall Bladder0
2
1961196163.0low020000
Encephalitis0
1
1957195767.0low010000
Encephalitis Lethargica Type Parkinsonism0
1
1952195272.0low010000
Encephalitis, Polio0
6
1952196468.3low060000
Encephalopathy, Hypertensive0
1
201720177.0low000010
Encephalopathy, Traumatic0
1
201920195.0low000010
End Stage Liver Disease0
1
201620168.0low000010
Endarteritis0
3
1954198457.0low030000
Endocardial Fibroelastosis0
1
2007200717.0low000100
Endocarditis0
9
1990201815.1low101350
Endocarditis, Bacterial0
8
1983201321.8low011420
Endocarditis, Loeffler0
3
2007201611.0low000120
Endocrine System Diseases0
6
1954200534.2low022200
Endometrial Diseases0
1
1954195470.0low010000
Endomyocardial Fibrosis0
4
1995202111.2low001021
Endotoxemia0
6
1999201416.2low001320
Endotoxin Shock0
34
1978202319.4low35313121
Enlarged Liver0
1
1979197945.0low010000
ENT Diseases0
2
1956195668.0low020000
Enteric Fever0
1
1963196361.0low010000
Enterobacteriaceae Infections0
2
2006201613.0low000110
Enterocele0
3
1955201447.3low020010
Enterocolitis, Necrotizing0
6
2003201117.5low000510
Enterocolitis, Pseudomembranous0
2
1995200026.5low002000
Envenomation, Snakebite0
1
2014201410.0low000010
Eosinophilia0
2
2004200917.5low000200
Eosinophilia, Pulmonary0
2
2002200222.0low000200
Eosinophilia, Tropical0
2
2004200917.5low000200
Epidermolysis Bullosa0
2
1964196460.0low020000
Epidermolysis Bullosa Dystrophica0
1
1964196460.0low010000
Epilepsy0
21
1951202044.0low1113520
Epilepsy, Tonic-Clonic0
1
201720177.0low000010
Epileptiform Neuralgia0
2
1955196365.0low020000
Epiphora0
1
201520159.0low000010
Epistaxis0
1
1954195470.0low010000
Epstein-Barr Virus Infections0
1
2011201113.0low000010
Epulides0
1
2010201014.0low000100
Equine Diseases0
5
1985201924.8low021110
Erectile Dysfunction0
39
1964202218.0low02419131
Ergot Poisoning0
7
1951196469.3low070000
Erythema0
2
1957200742.0low010100
Erythema Multiforme0
2
1957195866.5low020000
Erythema Nodosum0
1
201720177.0low000010
Erythermalgia0
1
1954195470.0low010000
Erythremia0
2
201420159.5low000020
Erythroblastosis Fetalis0
1
1959195965.0low010000
Erythromelalgia0
1
1954195470.0low010000
Esophageal Achalasia0
3
1951196365.0low030000
Esophageal and Gastric Varices0
5
1993201419.6low002120
Esophageal Neoplasms0
2
2010201113.5low000110
Esophageal Reflux0
2
2006201712.5low100110
Esophageal Stenosis0
2
1964196460.0low020000
Esophageal Stricture0
2
1964196460.0low020000
Esophageal Varices0
5
1993201419.6low002120
Esophagitis, Peptic0
1
2010201014.0low000100
Esophagitis, Reflux0
1
2010201014.0low000100
Essential Hypertension0
13
1951201365.5low0120010
Essential Polyarteritis0
1
2011201113.0low000010
Ewing Sarcoma0
1
1996199628.0low101000
Exanthem0
2
2000200521.5low001100
Exanthema0
2
2000200521.5low001100
Exfoliation Glaucoma0
1
2008200816.0low000100
Exfoliation Syndrome0
1
2008200816.0low000100
Exophthalmos0
1
2001200123.0low000100
Experimental Leukemia0
2
1984200430.0low010100
Experimental Lung Inflammation0
10
1958201824.9low221430
Experimental Mammary Neoplasms0
1
202020204.0low000010
Experimental Neoplasms0
4
1964200433.0low012100
Experimental Spinal Cord Ischemia0
1
2006200618.0low000100
Exsanguinating Hemorrhage0
1
202120213.0low000001
External Ear Inflammation0
1
1962196262.0low010000
External Ophthalmoplegia0
3
1962200440.3low020100
Extrasystole, Ventricular0
4
201120179.8low100040
Extravasation of Contrast Media0
3
2000200821.3low002100
Extravascular Hemolysis0
4
1957201936.8low020020
Eye Diseases0
9
1953200352.0low162100
Eye Disorders0
9
1953200352.0low162100
Eyelid Diseases0
1
1985198539.0low010000
Fabry Disease0
3
2007201115.7low000210
Facial Asymmetry0
1
2009200915.0low000100
Facial Neoplasms0
1
2014201410.0low000010
Facial Pain0
1
1991199133.0low001000
Facial Palsy0
1
2008200816.0low000100
Fallopian Tube Diseases0
1
1953195371.0low010000
Fallot's Tetralogy0
1
2014201410.0low000010
Familial Hypophosphatemic Rickets0
1
202020204.0low000010
Familial Mediterranean Fever0
1
1956195668.0low010000
Familial Primary Pulmonary Hypertension0
6
2011201411.7low100060
Familial Turner Syndrome0
2
2005201912.0low000110
Fasting Hypoglycemia0
5
1952199955.2low041000
Fatigue0
11
1999201913.9low301460
Fatigue, Mental0
1
2013201311.0low000010
Fatty Liver0
4
201220227.8low000031
Feeding and Eating Disorders0
1
1955195569.0low010000
Female Genital Diseases0
9
1953200461.1low080100
Female Genital Neoplasms0
1
201820186.0low000010
Female Genitourinary Diseases0
2
1996201618.0low001010
Femoral Neck Fractures0
1
2005200519.0low000100
Femur Neck Fractures0
1
2005200519.0low000100
Fetal Death0
2
1981201526.0low010010
Fetal Growth Restriction0
3
1981201818.3low010020
Fetal Growth Retardation0
3
1981201818.3low010020
Fever0
10
1954201737.6low050230
Fibroid0
1
2000200024.0low001000
Fibromuscular Dysplasia0
6
200720198.7low000150
Fibromyalgia0
3
1957196264.3low030000
Fibrosis0
103
1998202310.7low80132646
Fibrous Tissue Neoplasms0
1
1953195371.0low010000
Fissure in Ano0
1
1963196361.0low010000
Flushing0
3
1970199439.7low121000
FMR1-Related Primary Ovarian Insufficiency0
1
1994199430.0low001000
Focal Infection0
1
1953195371.0low010000
Focal Neurologic Deficits0
2
1964196460.0low020000
Folie a Deux0
1
1955195569.0low010000
Food Hypersensitivity0
1
2003200321.0low000100
Foot Diseases0
3
1955199951.7low021000
Foot Ulcer0
2
1956195668.0low020000
Foramen Ovale, Patent0
12
200820197.8low0001110
Foreign Bodies0
1
1956195668.0low010000
Foreign-Body Migration0
4
2011201611.0low000040
Fracture, Pathologic0
1
2008200816.0low000100
Fractures, Bone0
10
1952201736.6low040420
Frigidity0
3
2003201315.7low000210
Frostbite0
5
1952199862.0low041000
Fusiform Aneurysm0
12
200220228.8low100282
Gait Disorders, Animal0
1
201620168.0low000010
Gall Bladder Diseases0
5
1954196563.2low050000
Gallbladder Dyskinesia0
1
1963196361.0low010000
Gallstone Disease0
1
1964196460.0low010000
Gallstones0
2
2011201212.5low000020
Gambling0
1
201520159.0low000010
Gambling, Pathologic0
1
201520159.0low000010
Gangrene0
10
1952202150.6low070201
Gas Poisoning0
1
1958195866.0low010000
Gasser Syndrome0
1
2013201311.0low000010
Gastric Ulcer0
6
1964201719.2low110230
Gastric Volvulus0
1
1964196460.0low010000
Gastroduodenal Ulcer0
15
1951200960.4low0130200
Gastroenteritis0
1
1960196064.0low010000
Gastroesophageal Reflux0
2
2006201712.5low100110
Gastrointestinal Hemorrhage0
12
1985202116.6low012261
Gaucher Disease0
1
201620168.0low000010
Generalized Resistance To 1,25-Dihydroxyvitamin D0
1
202020204.0low000010
Genetic Diseases0
2
201420188.0low000020
Genetic Diseases, Inborn0
2
201420188.0low000020
Genetic Predisposition0
81
1991202111.2low30127494
Genital Diseases, Female0
9
1953200461.1low080100
Genital Diseases, Male0
1
2004200420.0low000100
Genital Neoplasms, Female0
1
201820186.0low000010
Germinoblastoma0
1
202320231.0low100001
Gestational Hypertension0
3
201220197.7low000030
Giant Cell Arteritis0
5
1963202023.0low010220
Gingival Diseases0
1
2010201014.0low000100
Gingival Hemorrhage0
1
2005200519.0low000100
Gingival Hyperplasia0
1
2005200519.0low000100
Gingival Overgrowth0
1
202020204.0low000010
Gingivitis0
1
2005200519.0low000100
Glaucoma0
9
1953201338.1low042210
Glaucoma, Suspect0
4
1985201723.2low011110
Glomerulonephritis, Lupus0
1
2005200519.0low000100
Glomerulonephritis, Membranoproliferative0
1
2011201113.0low000010
Glucose Intolerance0
4
2009201412.5low000220
Glucose Metabolic Disorder0
1
201920195.0low000010
Glucosephosphate Dehydrogenase Deficiency0
1
201920195.0low000010
Goiter0
1
1952195272.0low010000
Goiter, Nodular0
1
2001200123.0low000100
Goldblatt Syndrome0
9
1998201515.3low001620
Gonadal Disorders0
1
2006200618.0low000100
Gonorrhea0
1
1958195866.0low010000
Gout0
5
1957201335.4low020120
Graft Occlusion, Vascular0
88
1996202310.4low1805215210
Gram-Negative Bacterial Infections0
1
2012201212.0low000010
Granulocytic Leukemia0
2
1996199827.0low002000
Granuloma0
2
1960201238.0low010010
Granuloma, Hodgkin0
4
1960200242.5low120200
Granulomas0
2
1960201238.0low010010
Graves Disease0
1
2001200123.0low000100
Grippe0
10
1958202128.6low031231
Groenblad-Strandberg Syndrome0
1
202020204.0low000010
Group A Strep Infection0
2
2003201415.5low000110
Gynecomastia0
2
2000200820.0low001100
Hair Diseases0
1
201920195.0low000010
Hallucination of Body Sensation0
4
1954199851.0low031000
Hallucinations0
4
1954199851.0low031000
Hansen Disease0
2
1956195668.0low020000
Hay Fever0
1
1960196064.0low010000
HbS Disease0
2
201420178.5low000020
Head and Neck Neoplasms0
1
2012201212.0low100010
Headache0
41
1952200763.0low0391100
Headache Disorders0
2
1952200545.5low010100
Headache, Tension0
2
1962200739.5low010100
Health Care Associated Infection0
1
2007200717.0low000100
Hearing Loss0
2
2006202011.0low000110
Hearing Loss, Noise-Induced0
2
1963200639.5low010100
Hearing Loss, Sensorineural0
3
1955201629.0low110020
Heart Arrest0
92
1952202120.3low518926372
Heart Defects, Congenital0
59
1963202212.9low22416343
Heart Disease, Ischemic0
433
1992202216.9low6501211511538
Heart Diseases0
356
1953202319.2low15445113111812
Heart Failure0
1,820
1953202314.7low19263223564867103
Heart Failure, Diastolic0
19
2009201612.3low4005140
Heart Failure, Systolic0
69
200820239.3low180012516
Heart Septal Defects, Ventricular0
5
1998202214.2low101211
Heart Valve Diseases0
40
1983202215.5low3446242
Heat Collapse0
1
1952195272.0low010000
Heavy Menstrual Bleeding0
4
1953197363.0low040000
Heavy Metal Poisoning0
1
1957195767.0low010000
Helicobacter Infections0
2
2009201014.5low000200
Hemangioma0
5
2004201913.2low000320
Hemangioma, Capillary0
1
201720177.0low000010
Hemangioma, Cavernous, Central Nervous System0
1
201920195.0low000010
Hematochezia0
12
1985202116.6low012261
Hematologic Diseases0
9
1959201932.0low131320
Hematologic Malignancies0
2
2003200619.5low100200
Hematologic Neoplasms0
2
2003200619.5low100200
Hematoma0
9
1958202118.4low010341
Hematoma, Subdural0
2
1993199430.5low002000
Hematuria0
1
1955195569.0low010000
Hemiplegia0
1
1951195173.0low010000
Hemiplegia, Crossed0
1
1951195173.0low010000
Hemisensory Neglect0
1
1985198539.0low010000
Hemolysis0
4
1957201936.8low020020
Hemolytic-Uremic Syndrome0
1
2013201311.0low000010
Hemophilia A0
1
2001200123.0low000100
Hemoptysis0
1
2005200519.0low000100
Hemorrhage0
90
1952202122.0low181929591
Hemorrhage, Gingival0
1
2005200519.0low000100
Hemorrhage, Intracranial, Traumatic0
1
2009200915.0low100100
Hemorrhage, Retinal0
1
2004200420.0low000100
Hemorrhage, Subarachnoid0
12
1995202111.2low301281
Hemorrhage, Uterine0
2
1961197357.0low020000
Hemorrhage, Vitreous0
1
2004200420.0low000100
Hemorrhagic Diathesis0
1
1953195371.0low010000
Hemorrhagic Disorders0
1
1953195371.0low010000
Hemorrhagic Fever, Ebola0
1
2014201410.0low000010
Hemorrhagic Shock0
7
1982202220.0low011311
Hemorrhagic Thrombocythemia0
1
2014201410.0low000010
Hemorrhoids0
5
1963198055.2low050000
Hepatic Failure0
3
2004201811.0low000120
Hepatic Insufficiency0
1
2012201212.0low000010
Hepatitis0
3
1960200042.7low021000
Hepatitis A0
1
1960196064.0low010000
Hepatitis B0
2
2008201214.0low000110
Hepatitis B Virus Infection0
2
2008201214.0low000110
Hepatitis C0
1
201920195.0low000010
Hepatitis C, Chronic0
4
2001201815.0low000220
Hepatitis, Infectious0
1
1960196064.0low010000
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0
1
201920195.0low000010
Hepato-Pulmonary Syndrome0
1
2008200816.0low000100
Hepatocellular Carcinoma0
4
1989201219.8low010210
Hepatopulmonary Syndrome0
1
2008200816.0low000100
Hepatorenal Syndrome0
2
2004200818.0low000200
Heritable Pulmonary Arterial Hypertension0
6
2011201411.7low100060
Hernia0
3
1955201447.3low020010
Hernia, Inguinal0
1
1955195569.0low010000
Hernias, Diaphragmatic, Congenital0
2
2009201512.0low000110
Herpes Simplex Keratitis0
1
1952195272.0low010000
Herpes Zoster0
7
1953195869.1low070000
Herpes Zoster Ophthalmicus0
1
1953195371.0low010000
Herpes Zoster, Ocular0
1
1953195371.0low010000
Hibernation, Myocardial0
12
1994201520.4low206330
Hip Fractures0
3
2003201613.3low100120
HIV0
3
201120169.7low000030
HIV Coinfection0
23
200420239.3low2005153
HIV Infections0
23
200420239.3low2005153
Hives0
4
1959201227.8low010210
Hodgkin Disease0
4
1960200242.5low120200
Hospital-Acquired Condition0
17
1947201437.4low081440
Hot Flashes0
1
2002200222.0low000100
Humeral Fractures0
1
2010201014.0low000100
Huntington Disease0
1
202120213.0low000001
Hyperaldosteronism0
4
2004201514.8low000310
Hyperammonemia0
1
2014201410.0low100010
Hypercalcemia0
5
1962201728.0low020120
Hypercapnia0
8
2001201415.1low400530
Hypercholesterolemia0
56
1982201916.6low62528210
Hypercoagulability0
8
2007201512.8low000350
Hyperemia0
7
1995202013.9low101330
Hypereosinophilic Syndrome0
3
2007201611.0low000120
Hyperglycemia0
22
1959202118.7low322972
Hyperglycemia, Postprandial0
22
1959202118.7low322972
Hypergonadotropic Hypogonadism0
4
2004201216.2low100310
Hyperhomocysteinemia0
8
2004201614.6low000620
Hyperinsulinism0
3
1956200440.0low011100
Hyperkalemia0
13
1984202114.7low110651
Hyperkeratosis Palmaris et Plantaris0
1
201920195.0low000010
Hyperlipemia0
45
1993202217.9low10924111
Hyperlipidemias0
45
1993202217.9low10924111
Hyperlipoproteinemia0
3
1985199635.0low021000
Hyperlipoproteinemia Type I0
1
202120213.0low000001
Hyperlipoproteinemia Type II0
9
1988201813.2low110260
Hyperlipoproteinemias0
3
1985199635.0low021000
Hypermelanosis0
1
2008200816.0low000100
Hypernatremia0
1
2012201212.0low000010
Hyperostosis Frontalis Interna0
1
1953195371.0low010000
Hyperoxia0
1
1996199628.0low001000
Hyperparathyroidism0
1
2001200123.0low000100
Hyperparathyroidism, Secondary0
2
2005201315.0low000110
Hyperphosphatemia0
2
201420159.5low000020
Hyperpigmentation0
1
2008200816.0low000100
Hyperplasia0
110
1997202312.8low250348581
Hyperpotassemia0
13
1984202114.7low110651
Hypersensitivity0
12
1952201635.4low051510
Hypersensitivity, Type III0
1
2010201014.0low000100
Hypersomnia, Post-Traumatic0
1
2007200717.0low000100
Hypertension0
700
1950202336.9low232907216415816
Hypertension, Essential0
13
1951201365.5low0120010
Hypertension, Malignant0
8
1954201755.6low061010
Hypertension, Portal0
3
1993200626.0low002100
Hypertension, Pregnancy-Induced0
3
201220197.7low000030
Hypertension, Pulmonary0
91
1954202315.2low45634433
Hypertension, Renal0
5
1995201818.8low002210
Hypertension, Renovascular0
9
1998201515.3low001620
Hyperthyroid0
10
1952200153.8low172100
Hyperthyroidism0
10
1952200153.8low172100
Hypertriglyceridemia0
4
1996202115.2low101111
Hypertrophic Pyloric Stenosis0
1
1964196460.0low010000
Hypertrophy0
7
1964201819.0low110330
Hypertrophy, Left Ventricular0
71
1990202114.7low20735263
Hypertrophy, Right Ventricular0
6
201020189.8low000150
Hyperuricemia0
2
201220179.5low000020
Hyperventilation0
3
2001201317.3low100210
Hypoalbuminemia0
1
2005200519.0low000100
Hypoascorbemia0
1
1961196163.0low010000
Hypocalcemia0
3
1984200725.7low010200
Hypocapnia0
3
1996201318.0low101110
Hypoglycemia0
5
1952199955.2low041000
Hypogonadism0
4
2004201216.2low100310
Hypokalemia0
8
1984201823.6low013310
Hypolipoproteinemia0
1
1986198638.0low010000
Hypomenorrhea0
1
1973197351.0low010000
Hyponatremia0
6
200820219.2low100231
Hypopituitarism0
1
2005200519.0low000100
Hypoplastic Left Heart Syndrome0
2
2005202111.0low000101
Hypotension0
93
1951202038.6low642815280
Hypotension, Orthostatic0
25
1954202321.1low2275101
Hypotension, Postural0
25
1954202321.1low2275101
Hypothermia0
7
1956202343.9low041101
Hypothermia, Accidental0
7
1956202343.9low041101
Hypothyroidism0
6
1956201430.8low120220
Hypovolemia0
1
2009200915.0low000100
Hypovolemic0
1
2009200915.0low000100
Hypoxia0
48
1951202119.9low25915181
Hypoxia-Ischemia, Brain0
3
201020199.3low000120
Icterus0
3
1962200439.3low020100
Idiopathic Inflammatory Myopathies0
1
201920195.0low000010
Idiopathic Parkinson Disease0
43
1952202165.8low0420001
Idiopathic Pulmonary Fibrosis0
1
201920195.0low100010
Immune System Diseases0
5
1957201923.2low011030
Impaired Glucose Tolerance0
4
2009201412.5low000220
Impotence0
39
1964202218.0low02419131
Impotence, Arteriogenic0
5
1997201319.6low001310
Inborn Errors of Metabolism0
2
201820214.5low000011
Incompetence, Pulmonary Valve0
3
2011201610.3low000030
Indigestion0
1
1996199628.0low001000
Infant Malnutrition0
1
1955195569.0low010000
Infant, Newborn, Diseases0
5
1964201624.2low010310
Infant, Premature, Diseases0
27
2000201917.1low1041490
Infantile Respiratory Distress Syndrome0
5
2000201019.8low001400
Infarct0
1
2003200321.0low100100
Infarct, Lacunar0
1
2014201410.0low100010
Infarction, Middle Cerebral Artery0
5
201120199.8low100050
Infection0
7
1959201921.7low010330
Infection, Postoperative Wound0
2
2007201214.5low000110
Infection, Wound0
2
201420188.0low000020
Infections0
7
1959201921.7low010330
Infections, Coronavirus0
14
202020204.0low0000140
Infections, Helicobacter0
2
2009201014.5low000200
Infections, Meningococcal0
2
1983198540.0low020000
Infections, Parvoviridae0
2
2007201513.0low000110
Infections, Pasteurella0
2
1953201142.0low010010
Infections, Prosthesis-Related0
1
2007200717.0low000100
Infections, Pseudomonas0
1
2008200816.0low000100
Infections, Respiratory0
2
1962200739.5low010100
Infections, Respiratory Syncytial Virus0
1
2009200915.0low000100
Infections, Roseolovirus0
1
201720177.0low000010
Infections, Serratia0
1
2007200717.0low000100
Infections, Spirochaetales0
1
1949194975.0low010000
Infections, Staphylococcal0
3
2007201412.7low000120
Infectious Diseases0
4
1961201140.5low021010
Infective Endocarditis0
9
1990201815.1low101350
Inferior Dislocation0
3
1952196068.7low030000
Infertility0
3
1954196464.3low030000
Infertility, Female0
1
1964196460.0low010000
Infertility, Male0
2
1961201038.5low110100
Inflammation0
125
1956202313.1low542555212
Inflammatory Response Syndrome, Systemic0
6
2001202116.3low300501
Influenza, Human0
10
1958202128.6low031231
Inguinal Hernia0
1
1955195569.0low010000
Injuries0
15
1955202035.8low070260
Injuries, Multiple0
1
2009200915.0low000100
Injuries, Neck0
1
1961196163.0low010000
Injuries, Radiation0
4
1959201823.2low010120
Injuries, Spinal Cord0
6
1960201725.2low012120
Injuries, Tendon0
1
1962196262.0low010000
Injuries, Whiplash0
1
1961196163.0low010000
Injury, Ischemia-Reperfusion0
52
1990202216.7low101519153
Injury, Myocardial Reperfusion0
221
1988202215.1low1253492828
Innate Inflammatory Response0
125
1956202313.1low542555212
Inner Ear Disease0
2
1959198054.5low020000
Insect Bites0
1
2012201212.0low000010
Insect Bites and Stings0
1
2012201212.0low000010
Insulin Resistance0
27
1992202114.7low00214101
Insulin Sensitivity0
27
1992202114.7low00214101
Intellectual Disability0
3
1951199554.0low021000
Intermittent Claudication0
78
1951202113.9low195221473
Interstitial Cell Tumor0
1
2008200816.0low000100
Intertrochanteric Fractures0
3
2003201613.3low100120
Intervertebral Disc Displacement0
1
1964196460.0low010000
Intestinal Diseases0
1
1995199529.0low001000
Intestinal Obstruction0
3
1957201946.3low020010
Intestinal Perforation0
5
1985202018.6low010220
Intestinal Pseudo-Obstruction0
1
1957195767.0low010000
Intracranial Aneurysm0
9
1995202110.3low101071
Intracranial Arteriosclerosis0
5
1965202019.2low210130
Intracranial Arteriovenous Malformations0
1
201620168.0low000010
Intracranial Hemorrhages0
5
2003201713.8low000230
Intracranial Hypertension0
9
2001201914.2low100450
Intraocular Pressure0
4
2006201714.5low100310
Intraventricular Septal Defects0
5
1998202214.2low101211
Iron Overload0
3
2004201513.7low000120
Ischemia0
159
1962202313.0low2681044898
Ischemic Attack, Transient0
39
1988202212.0low4127263
Ischemic Stroke0
3
201820214.0low100012
Isolated Non-compaction of the Ventricular Myocardium0
7
2011201711.0low000070
Jactatio Capitis Nocturna0
2
1961196461.5low020000
Jaundice0
3
1962200439.3low020100
Jaundice, Cholestatic0
1
1962196262.0low010000
Jaundice, Obstructive0
1
1962196262.0low010000
Jaw, Edentulous, Partially0
1
1999199925.0low001000
Joint Diseases0
4
1961196561.2low040000
Joint Pain0
2
2007201513.0low100110
Kahler Disease0
4
1961201736.2low020020
Kawasaki Disease0
4
200420199.8low000130
Keratitis0
1
1952195272.0low010000
Keratitis, Herpetic0
1
1952195272.0low010000
Keratitis, Ulcerative0
1
2014201410.0low000010
Keratoderma Blennorrhagicum0
1
202020204.0low000010
Keratosis0
1
202020204.0low000010
Kernicterus0
1
1959195965.0low010000
Kidney Calculi0
1
1954195470.0low010000
Kidney Diseases0
86
1954202117.1low96441332
Kidney Diseases, Cystic0
1
2007200717.0low000100
Kidney Failure0
45
1957202114.6low71117242
Kidney Failure, Chronic0
78
1979202216.9low77530342
Kidney Neoplasms0
4
2000202114.8low001201
Kidney Stones0
1
1954195470.0low010000
Kidney Tubular Necrosis, Acute0
1
2001200123.0low000100
Klinefelter Syndrome0
1
2008200816.0low000100
Koch's Disease0
9
1953196165.4low090000
Koehler Disease0
2
1961196262.5low020000
Labor Pain0
2
1952195371.5low020000
Labor, Premature0
4
1960200850.0low130100
Labyrinth Diseases0
2
1959198054.5low020000
Lacrimal Apparatus Diseases0
1
201520159.0low000010
Lactic Acidosis0
3
2000201116.7low001020
Language Disorders0
1
2012201212.0low000010
Laryngeal Neoplasms0
2
1990200228.0low001100
Lassitude0
11
1999201913.9low301460
Leanness0
2
2011201113.0low000020
Left Heart Hypoplasia Syndrome0
2
2005202111.0low000101
Left Ventricular Dysfunction0
251
1994202214.2low35031951169
Left Ventricular Hypertrophy0
71
1990202114.7low20735263
Left Ventricular Outflow Obstruction0
15
1996202114.3low002661
Leg Ulcer0
11
1953201731.3low341510
Leiomyoma0
1
2000200024.0low001000
Lens Dislocation0
1
2008200816.0low000100
Leprosy0
2
1956195668.0low020000
Leptospirosis0
1
1957195767.0low010000
Leriche Syndrome0
1
1964196460.0low010000
Leucocythaemia0
1
1963196361.0low010000
Leukemia0
1
1963196361.0low010000
Leukemia P3880
2
1984199136.5low011000
Leukemia, Acute Monocytic0
1
2005200519.0low000100
Leukemia, Lymphocytic0
1
2007200717.0low000100
Leukemia, Lymphocytic, Chronic, B-Cell0
1
2001200123.0low000100
Leukemia, Lymphoid0
1
2007200717.0low000100
Leukemia, Monocytic, Acute0
1
2005200519.0low000100
Leukemia, Myeloid0
2
1996199827.0low002000
Leukemia, Myeloid, Acute0
4
1998201917.8low102110
Leukemia, Promyelocytic, Acute0
1
201820186.0low000010
Leukocytopenia0
2
1995200524.0low001100
Leukocytosis0
1
2006200618.0low000100
Leukoencephalopathy Syndrome, Posterior0
1
201820186.0low000010
Leukopenia0
2
1995200524.0low001100
Libman-Sacks Disease0
11
1960202017.5low120180
Lichen Planus0
1
2005200519.0low000100
Lichen Planus, Oral0
1
2007200717.0low000100
Lichen Ruber Planus0
1
2005200519.0low000100
Lichen Simplex Chronicus0
1
1955195569.0low010000
Licheniform Eruptions0
3
2002201017.7low000300
Limb-Girdle Muscular Dystrophies0
1
202020204.0low000010
Lip Diseases0
1
2007200717.0low000100
Lipid Metabolism, Inborn Error0
2
201520216.0low000011
Lipodystrophy0
1
1957195767.0low010000
Lipodystrophy, Intestinal0
1
1957195767.0low010000
Liver Cirrhosis0
11
1984202115.3low010451
Liver Cirrhosis, Alcoholic0
1
1983198341.0low010000
Liver Diseases0
23
1960202028.5low292660
Liver Dysfunction0
23
1960202028.5low292660
Liver Failure0
3
2004201811.0low000120
Liver Failure, Acute0
3
200620239.0low000111
Liver Neoplasms0
8
1989201815.9low010430
Liver Steatosis0
4
201220227.8low000031
Local Neoplasm Recurrence0
4
201420237.5low000031
Loeys-Dietz Aortic Aneurysm Syndrome0
1
202220222.0low000001
Long QT Syndrome0
37
1998202213.8low10123112
Long Sleeper Syndrome0
6
1953201345.8low132010
Low Back Ache0
1
1960196064.0low010000
Low Back Pain0
1
1960196064.0low010000
Lung Abscess0
1
1961196163.0low010000
Lung Adenocarcinoma0
1
2011201113.0low000010
Lung Diseases0
25
1953201827.6low066850
Lung Diseases, Interstitial0
3
2002200820.0low000300
Lung Diseases, Obstructive0
4
1984201025.2low111200
Lung Injury, Acute0
3
2012201510.3low000030
Lung Injury, Ventilator-Induced0
1
201520159.0low000010
Lung Neoplasms0
5
2009201710.8low000140
Lupus Erythematosus, Cutaneous0
1
2011201113.0low000010
Lupus Erythematosus, Cutaneous, Subacute0
1
2011201113.0low000010
Lupus Erythematosus, Systemic0
11
1960202017.5low120180
Lupus Nephritis0
1
2005200519.0low000100
Lyme Disease0
2
1998200025.0low002000
Lymph Node Metastasis0
1
1964196460.0low010000
Lymphatic Diseases0
1
1995199529.0low001000
Lymphedema0
2
1964200042.0low011000
Lymphocytopenia0
1
2013201311.0low000010
Lymphoma0
1
202320231.0low100001
Lymphoma, B-Cell0
1
1999199925.0low001000
Lymphoma, Follicular0
1
202020204.0low000010
Lymphoma, Large B-Cell, Diffuse0
1
1999199925.0low001000
Lymphoma, Non-Hodgkin0
5
1960200729.4low111300
Lymphopenia0
1
2013201311.0low000010
Macular Degeneration0
1
2008200816.0low000100
Magnesium Deficiency0
5
1989201926.8low022010
Male Genitourinary Diseases0
1
1996199628.0low001000
Malignant Carcinoid Syndrome0
1
1970197054.0low010000
Malignant Hypertension0
8
1954201755.6low061010
Malignant Melanoma0
1
201920195.0low000010
Malnourishment0
3
2007201712.3low000120
Malnutrition0
3
2007201712.3low000120
Mandibular Diseases0
1
201720177.0low000010
Mandibular Fractures0
1
2009200915.0low000100
Marfan Syndrome0
10
2002201913.9low000640
Marfan Syndrome, Type I0
10
2002201913.9low000640
Marijuana Abuse0
1
201720177.0low000010
Mast Cell Activation Disease0
1
201720177.0low000010
Mastocytosis0
1
201720177.0low000010
Mediastinal Cyst0
1
2008200816.0low000100
Melanoma0
1
201920195.0low000010
Memory Disorders0
2
2012201411.0low000020
Meniere Disease0
1
1952195272.0low010000
Meningeal Neoplasms0
1
2014201410.0low000010
Meningioma0
1
2014201410.0low000010
Meningitis0
2
1960202034.0low010010
Meningitis, Tuberculous0
1
1961196163.0low010000
Meningococcal Infections0
2
1983198540.0low020000
Meniscitis0
4
1958196462.8low040000
Menopause0
3
1997201320.0low001110
Menopause, Premature0
2
1994199529.5low002000
Menorrhagia0
4
1953197363.0low040000
Menstruation, Painful0
21
1952196466.0low0210000
Mental Disorders0
47
1951202343.5low02651141
Mesenteric Vascular Occlusion0
5
2005202113.8low000401
Metabolic Acidosis0
6
1982201028.0low021300
Metabolic Diseases0
17
1993201913.2low0025100
Metabolic Syndrome0
47
2004202013.2low30026210
Metabolically Benign Obesity0
1
201520159.0low000010
Metabolism, Inborn Errors0
2
201820214.5low000011
Metastase0
4
1996200823.2low002200
Methemoglobinemia0
3
1952195868.3low030000
Metrorrhagia0
4
1953197363.0low040000
Microbial Superinvasion0
1
2010201014.0low000100
Microscopic Polyangiitis0
1
2010201014.0low000100
Middle Ear Inflammation0
2
1958201040.0low010100
Migraine Disorders0
64
1949201160.6low1572410
Migraine with Aura0
1
1962196262.0low010000
Migraine without Aura0
1
1963196361.0low010000
Milk-Alkali Syndrome0
5
1962201728.0low020120
Mitochondrial Diseases0
4
2007201712.0low000220
Mitral Incompetence0
46
1992202311.3low60111322
Mitral Stenosis0
13
1954201920.4low222180
Mitral Valve Insufficiency0
46
1992202311.3low60111322
Mitral Valve Stenosis0
13
1954201920.4low222180
MODS0
16
1995202311.8low101681
Mood Disorders0
3
1998201318.0low001110
Morbid Obesity0
6
2000201914.0low001230
Mouth Breathing0
1
1994199430.0low001000
Mouth Diseases0
7
1987201525.4low013210
Mouth Ulcer0
1
1999199925.0low001000
Movement Disorders0
7
1953201151.0low050110
MS (Multiple Sclerosis)0
14
1953201644.2low281230
Mucocutaneous Lymph Node Syndrome0
4
200420199.8low000130
Mucositis0
1
2007200717.0low000100
Mucositis, Oral0
1
2007200717.0low000100
Multiple Myeloma0
4
1961201736.2low020020
Multiple Organ Failure0
16
1995202311.8low101681
Multiple Primary Neoplasms0
1
2001200123.0low000100
Multiple Sclerosis0
14
1953201644.2low281230
Mumps0
5
1957200754.8low040100
Muscle Contraction0
50
1952201829.3low01618880
Muscle Cramp0
9
1960200055.7low181000
Muscle Disorders0
13
1952201550.7low091030
Muscle Pain0
4
1954201538.0low120020
Muscle Relaxation0
31
1948201334.8low0138910
Muscle Spasm0
30
1951201959.3low0260220
Muscle Spasticity0
20
1951196566.1low0200000
Muscle Weakness0
1
1959195965.0low010000
Muscular Atrophy0
1
2014201410.0low000010
Muscular Diseases0
13
1952201550.7low091030
Muscular Dystrophies0
2
201220217.5low000011
Muscular Dystrophies, Limb-Girdle0
1
202020204.0low000010
Muscular Dystrophy0
2
201220217.5low000011
Muscular Dystrophy, Animal0
1
201620168.0low000010
Muscular Dystrophy, Duchenne0
10
201020198.3low000190
Muscular Weakness0
1
1959195965.0low010000
Musculoskeletal Diseases0
5
1956200549.0low031100
Mushroom Poisoning0
1
1956195668.0low010000
Myalgia0
4
1954201538.0low120020
Myasthenia Gravis0
7
1951198459.4low070000
Myelodysplastic Syndromes0
1
201720177.0low000010
Myocardial Bridging0
5
2009201512.8low000230
Myocardial Infarction0
1,484
1955202315.2low2866117650469944
Myocardial Ischemia0
433
1992202216.9low6501211511538
Myocarditis0
44
1956202117.0low05314193
Myoclonic Jerk0
1
1996199628.0low001000
Myopathies, Nemaline0
1
201520159.0low000010
Myositis0
1
201920195.0low000010
Myotonia0
2
1954195868.0low020000
Myotonic Dystrophy0
4
1956201153.8low030010
Nanism0
1
2012201212.0low000010
Narcosis0
4
1952195371.8low040000
Nasal Bleeding0
1
1954195470.0low010000
Nasal Catarrh0
1
1953195371.0low010000
Nasal Obstruction0
1
1960196064.0low010000
Nausea0
6
1954202034.8low131020
Neck Pain0
1
1958195866.0low010000
Necrosis0
57
1982202115.1low113818262
Necrotizing Enterocolitis0
6
2003201117.5low000510
Neisseria gonorrhoeae Infection0
1
1958195866.0low010000
Neointima0
177
201220218.9low500001752
Neonatal Early-Onset Sepsis0
1
202020204.0low000010
Neonatal Sepsis0
1
202020204.0low000010
Neoplasm Metastasis0
4
1996200823.2low002200
Neoplasms0
115
1950202316.3low581030625
Neoplasms, Germ Cell and Embryonal0
2
200820219.5low000101
Neoplasms, Vascular0
1
202020204.0low000010
Nephrosclerosis0
1
2013201311.0low000010
Nephrosis0
1
1960196064.0low010000
Nerve Degeneration0
3
1980201630.7low020010
Nerve Pain0
6
1955201532.8low020220
Nervous System Diseases0
27
1954202131.9low0111591
Nervous System Disorders0
27
1954202131.9low0111591
Neuralgia0
6
1955201532.8low020220
Neuralgia, Sciatic0
3
1962196361.7low030000
Neurally Mediated Faint0
12
1997202215.7low301641
Neuritis0
1
1955195569.0low010000
Neurodegenerative Diseases0
4
200720188.8low000130
Neurodermatitis0
1
1955195569.0low010000
Neuroectodermal Tumors, Primitive, Peripheral0
1
1996199628.0low101000
Neuromuscular Blockade0
11
1953201061.6low0100100
Neuromuscular Diseases0
10
1953199856.1low082000
Neuropathy, Paraneoplastic0
1
1958195866.0low010000
Neuroses0
3
1953196068.3low030000
Neurotic Disorders0
3
1953196068.3low030000
Neutropenia0
4
2004200718.5low100400
Nicotine Addiction0
2
201820186.0low100020
No-Reflow Phenomenon0
19
2008202110.3low2004132
Nodular Goiter0
1
2001200123.0low000100
Non-ST Elevated Myocardial Infarction0
33
201620235.6low8000276
Non-ST-Elevation Myocardial Infarction0
33
201620235.6low8000276
Noonan Syndrome0
2
2005201912.0low000110
Nutrition Disorders0
1
1982198242.0low010000
Nutritional Disorders0
1
1982198242.0low010000
Obesity0
82
1999202312.8low10336394
Obesity, Morbid0
6
2000201914.0low001230
Obstructive Lung Diseases0
4
1984201025.2low111200
Ocular Hypertension0
4
1985201723.2low011110
Oliguria0
1
2005200519.0low000100
Onycholysis0
1
2009200915.0low000100
Optic Atrophy0
1
1998199826.0low001000
Optic Neuritis0
2
1946195772.5low020000
Optic Neuropathy, Ischemic0
1
2006200618.0low000100
Oral Ulcer0
1
1999199925.0low001000
Orphan Diseases0
2
201520197.0low000020
Orthopedic Disorders0
5
1956200549.0low031100
Osteoarthritis0
5
2006202110.4low100221
Osteomyelitis0
1
2013201311.0low000010
Osteoporosis0
15
1956201824.8low040560
Osteoporosis, Postmenopausal0
4
1994201021.2low001300
Osteoporotic Fractures0
1
2013201311.0low000010
Otitis Externa0
1
1962196262.0low010000
Otitis Media0
2
1958201040.0low010100
Out-of-Hospital Cardiac Arrest0
10
201520235.3low000082
Ovarian Neoplasms0
1
1998199826.0low101000
Overweight0
8
2007201810.6low000260
Ozena0
1
1953195371.0low010000
P carinii Pneumonia0
2
1958196065.0low020000
Pachymeningitis0
2
1960202034.0low010010
Pain0
41
1952201935.8low92038100
Pain, Chronic0
1
201520159.0low000010
Pain, Postoperative0
3
1960200936.0low011100
Palmoplantaris Pustulosis0
7
2008201511.9low000250
Palsy0
11
1953196565.4low0110000
Pancreatic Diseases0
1
1952195272.0low010000
Pancreatic Neoplasms0
1
2011201113.0low000010
Pancreatitis0
8
1953202133.9low031211
Papulosquamous Disorders0
1
2002200222.0low000100
Paraganglioma0
3
1952201947.7low020010
Paraganglioma, Gangliocytic0
3
1952201947.7low020010
Paralysis0
11
1953196565.4low0110000
Paralysis, Legs0
2
1960200641.0low010100
Paranoia0
1
1956195668.0low010000
Paraparesis0
1
2006200618.0low000100
Paraplegia0
2
1960200641.0low010100
Parkinson Disease0
43
1952202165.8low0420001
Parkinson Disease, Postencephalitic0
1
1952195272.0low010000
Parkinson Disease, Secondary0
1
2011201113.0low000010
Parkinsonian Disorders0
25
1953201564.4low0240010
Parodontosis0
5
2003201515.6low000320
Paroxysmal Reciprocal Tachycardia0
6
1955201629.0low013110
Patency of the Ductus Arteriosus0
92
1984202016.2low62748350
Patent Foramen Ovale0
12
200820197.8low0001110
Pelvic Pain0
1
2007200717.0low100100
Peptic Ulcer0
15
1951200960.4low0130200
Perceptual Disorders0
1
1985198539.0low010000
Pericardial Effusion0
6
2000201712.5low001050
Pericarditis0
18
1984202113.7low111691
Pericarditis, Tuberculous0
2
1959201039.5low010100
Periodontal Diseases0
5
2003201515.6low000320
Periodontal Pocket0
1
2005200519.0low000100
Peripheral Arterial Disease0
423
195220237.4low7760333381
Peripheral Arterial Diseases0
423
195220237.4low7760333381
Peripheral Nerve Diseases0
6
1979202025.3low020310
Peripheral Nerve Injuries0
1
2005200519.0low000100
Peripheral Nerve Injury0
1
2005200519.0low000100
Peripheral Nervous System Diseases0
6
1979202025.3low020310
Peripheral Vascular Diseases0
96
1951201834.2low93445260
Peritoneal Diseases0
1
1956195668.0low010000
Peritonitis0
2
1982201127.5low010010
Persistent Fetal Circulation Syndrome0
3
2011201511.0low000030
Petechiae0
5
1955199858.2low041000
Pharyngitis0
1
2014201410.0low000010
Pheochromocytoma0
3
1952199841.3low012000
Pheochromocytoma, Extra-Adrenal0
3
1952199841.3low012000
Phlegmasia Alba Dolens0
4
1965199439.8low022000
Phlegmon0
1
202020204.0low000010
Phobic Disorders0
1
2005200519.0low000100
Pituitary Diseases0
1
1958195866.0low010000
Pituitary Neoplasms0
1
2012201212.0low000010
Placenta, Retained0
1
2010201014.0low000100
Placental Abruption0
1
1952195272.0low010000
Plant Poisoning0
1
201820186.0low000010
Pleural Diseases0
3
1987200430.7low020100
Pleural Effusion0
7
1985201022.9low011500
Pleurisy0
1
1983198341.0low010000
Pleuropericarditis0
18
1984202113.7low111691
Pneumatosis Cystoides Intestinalis0
1
2013201311.0low000010
Pneumoconiosis0
1
2003200321.0low000100
Pneumonia0
10
1958201824.9low221430
Pneumonia, Pneumocystis0
2
1958196065.0low020000
Pneumonia, Ventilator-Associated0
2
2008202010.0low000110
Pneumonia, Viral0
14
202020204.0low0000140
Pneumopericardium0
1
202020204.0low000010
Pneumoperitoneum0
1
202020204.0low000010
Pneumothorax0
2
1953202037.5low010010
Pneumothorax, Primary Spontaneous0
2
1953202037.5low010010
Pocket, Periodontal0
1
2005200519.0low000100
POEMS Syndrome0
1
2011201113.0low000010
Poisoning0
44
1953202245.1low0292562
Poliomyelitis0
6
1952196468.3low060000
Polyarthritis0
9
1952201847.9low061110
Polycystic Ovarian Syndrome0
2
2012201311.5low000020
Polycystic Ovary Syndrome0
2
2012201311.5low000020
Polycythemia Vera0
2
201420159.5low000020
Polyneuropathies0
1
1984198440.0low010000
Polyneuropathy, Acquired0
1
1984198440.0low010000
Polyploid0
1
2002200222.0low000100
Polyuria0
1
2008200816.0low100100
Post Exercise Hypotension0
1
201920195.0low000010
Post-Cardiac Arrest Syndrome0
1
202020204.0low000010
Post-Dural Puncture Headache0
1
2007200717.0low000100
Post-operative Vasoplegic Syndrome0
3
1952202028.0low010020
Postcommissurotomy Syndrome0
2
2007201811.5low100110
Postoperative Complications0
149
1965202214.7low1661740833
Postpartum Hemorrhage0
7
1952201351.4low050110
Postpericardiotomy Syndrome0
2
2007201811.5low100110
Postthrombotic Syndrome0
1
1955195569.0low010000
Postural Orthostatic Tachycardia Syndrome0
10
201220215.8low100091
Potassium Deficiency0
2
1956195668.0low020000
Pre-Eclampsia0
26
1951202345.2low0151361
Pre-Excitation Syndromes0
1
2009200915.0low000100
Precordial Catch0
34
1964202115.2low31412152
Precursor Cell Lymphoblastic Leukemia-Lymphoma0
11
2001201517.8low2001010
Prediabetes0
5
2004201413.6low000230
Prediabetic State0
5
2004201413.6low000230
Pregnancy0
379
1950202344.0low221821597011
Pregnancy in Diabetes0
2
2013201311.0low000020
Pregnancy, Prolonged0
1
1965196559.0low010000
Premature Birth0
3
200420239.0low000111
Preterm Birth0
3
200420239.0low000111
Priapism0
1
1998199826.0low001000
Primary Graft Dysfunction0
2
2011201710.0low000020
Primary Ovarian Insufficiency0
1
1994199430.0low001000
Primary Peritonitis0
2
1982201127.5low010010
Prinzmetal Angina0
13
1981201925.1low142430
Proctitis0
2
1963196460.5low020000
Proliferative Vitreoretinopathy0
1
202320231.0low000001
Prostatic Hyperplasia0
3
2003202014.0low000210
Prostatic Neoplasms0
4
1954202026.0low010210
Prosthesis Durability0
62
2004202011.3low50017450
Proteinuria0
6
2004201217.0low100510
Pruritus Ani0
1
1963196361.0low010000
Pseudomonas Infections0
1
2008200816.0low000100
Pseudoxanthoma Elasticum0
1
202020204.0low000010
Psoriasis0
7
2008201511.9low000250
Psoriasis Arthropathica0
3
2014201410.0low000030
Psychomotor Agitation0
5
1952196466.8low050000
Psychoses0
14
1952202259.4low0120011
Psychoses, Alcoholic0
2
1956195668.0low020000
Psychoses, Drug0
2
1956195867.0low020000
Psychotic Disorders0
14
1952202259.4low0120011
Ptosis, Eyelid0
1
1985198539.0low010000
Puerperal Disorders0
14
2000202111.7low002291
Pulmonary Arterial Hypertension0
2
201920233.0low100011
Pulmonary Arterial Remodeling0
29
201420216.3low4000254
Pulmonary Consumption0
4
1953196267.2low040000
Pulmonary Disease, Chronic Obstructive0
37
2001201910.8low7009280
Pulmonary Edema0
26
1951202232.5low094571
Pulmonary Embolism0
15
1952202118.6low022452
Pulmonary Eosinophilia0
2
2002200222.0low000200
Pulmonary Fibrosis0
3
1962201543.7low020010
Pulmonary Hypertension0
91
1954202315.2low45634433
Pulmonary Sarcoidosis0
1
201520159.0low000010
Pulmonary Stenoses0
2
1955200146.0low010100
Pulmonary Veno Occlusive Disease0
2
2009200915.0low000200
Pulmonary Veno-Occlusive Disease0
2
2009200915.0low000200
Pulsatile Tinnitus0
4
1955201624.5low110030
Purpura0
5
1955199858.2low041000
Purpura, Thrombocytopenic0
1
1962196262.0low010000
Purpura, Thrombocytopenic, Idiopathic0
1
2011201113.0low000010
Purpura, Thrombopenic0
1
1962196262.0low010000
Pyloric Stenosis0
1
1964196460.0low010000
Pyoderma Gangrenosum0
1
201720177.0low000010
Pyrexia0
10
1954201737.6low050230
Radius Fractures0
1
2009200915.0low000100
Raynaud Disease0
12
1964201529.8low052140
Recrudescence0
388
1956202211.6low864317726115
Rectovaginal Fistula0
1
201620168.0low000010
Reflex Sympathetic Dystrophy0
3
1956201548.3low020010
Reflex, Abnormal0
4
1961201838.2low121010
Remission, Spontaneous0
7
2006201912.7low000340
Renal Artery Obstruction0
28
2002202113.0low20017101
Renal Artery Stenosis0
28
2002202113.0low20017101
Renal Insufficiency0
45
1957202114.6low71117242
Renal Insufficiency, Chronic0
49
200620228.8low3004414
Reperfusion Injury0
52
1990202216.7low101519153
Reproductive Sterility0
3
1954196464.3low030000
Respiration Disorders0
6
2000201516.7low101320
Respiratory Distress Syndrome0
5
2007202010.8low000230
Respiratory Distress Syndrome, Newborn0
5
2000201019.8low001400
Respiratory Insufficiency0
10
1964202128.9low040141
Respiratory Syncytial Virus Infections0
1
2009200915.0low000100
Respiratory Tract Diseases0
9
1952201246.6low062010
Respiratory Tract Infections0
2
1962200739.5low010100
Retinal Degeneration0
4
1952200157.5low030100
Retinal Detachment0
2
1955202335.0low010001
Retinal Diseases0
2
2001202013.5low000110
Retinal Pigment Epithelial Detachment0
2
1955202335.0low010001
Retinal Vein Occlusion0
2
2003201813.5low000110
Retinopathy of Prematurity0
2
201920204.5low000020
Retrolental Fibroplasia0
2
201920204.5low000020
Rett Syndrome0
1
2014201410.0low000010
Rhabdomyolysis0
3
2002201414.3low000120
Rhabdomyosarcoma0
1
1996199628.0low101000
Rheumatic Diseases0
16
1952201654.3low0130120
Rheumatic Heart Disease0
11
1963202131.7low150321
Rheumatism0
16
1952201654.3low0130120
Rheumatoid Arthritis0
20
1955202122.1low250591
Rheumatoid Vasculitis0
2
2014201410.0low000020
Rhinitis0
1
1953195371.0low010000
Rhinitis, Allergic, Seasonal0
1
1960196064.0low010000
Rhinitis, Atrophic0
1
1953195371.0low010000
Rhinitis, Vasomotor0
1
1960196064.0low010000
Right Ventricular Dysfunction0
25
1997202013.0low10210130
Rupture0
5
2008201215.0low000410
Rupture, Spontaneous0
16
1999201811.4low2012130
Salmonella Infections, Animal0
1
2003200321.0low000100
Sarcoidosis0
6
1995201916.7low001320
Sarcoidosis, Pulmonary0
1
201520159.0low000010
Sarcoma0
5
1996200622.8low302300
Sarcoma, Epithelioid0
5
1996200622.8low302300
Sarcoma, Ewing0
1
1996199628.0low101000
Sarcopenia0
2
2011201710.0low000020
Scarlet Fever0
1
1963196361.0low010000
Schistosomiasis0
1
201620168.0low000010
Schizophrenia0
7
1951202037.1low030220
Sciatica0
3
1962196361.7low030000
Scleroderma, Systemic0
17
1961201721.9low151380
Sclerosis0
2
1951199949.0low011000
Sclerosis, Systemic0
17
1961201721.9low151380
Scoliosis0
1
1995199529.0low001000
Scotoma0
1
2001200123.0low000100
Scurvy0
1
1961196163.0low010000
Secondary Hyperparathyroidism0
2
2005201315.0low000110
Seizures0
25
1950201947.4low1151540
Sensitivity and Specificity0
65
1991201917.2low1201625240
Sepsis0
37
1951202319.9low35219101
Serum Sickness0
1
1980198044.0low010000
Sex Disorders0
7
1980201920.1low011320
Sexual Dysfunction, Physiological0
7
1980201920.1low011320
Sexual Dysfunctions, Psychological0
3
2003201315.7low000210
Shingles0
7
1953195869.1low070000
Shock0
35
1953202130.3low01524131
Shock, Cardiogenic0
75
1980202117.3low481023322
Shock, Septic0
34
1978202319.4low35313121
Shock, Traumatic0
1
201820186.0low000010
Short Bowel Syndrome0
1
2004200420.0low000100
Sick Sinus Node Syndrome0
7
1979202219.0low020131
Sinoatrial Block0
1
2000200024.0low001000
Sinoatrial Nodal Reentry Tachycardia0
1
1996199628.0low001000
Sinus Infections0
1
1960196064.0low010000
Sinus Tachycardia0
13
201020217.0low2001102
Sinusitis0
1
1960196064.0low010000
Skin Aging0
3
2009201611.7low000120
Skin Diseases0
8
1953200955.4low060200
Skin Diseases, Bacterial0
1
2011201113.0low000010
Skin Neoplasms0
4
200920226.8low000121
Skin Ulcer0
3
2011201411.0low000030
Sleep Apnea Syndromes0
7
1995202116.4low001501
Sleep Apnea, Central0
4
2004201415.8low300310
Sleep Apnea, Obstructive0
7
200920228.9low300151
Sleep Initiation and Maintenance Disorders0
3
1953201635.7low011010
Sleep Wake Disorders0
6
1953201345.8low132010
Smallpox0
1
2013201311.0low000010
Smoking Cessation0
81
1997202112.9low150529461
Soft Tissue Neoplasms0
1
1996199628.0low101000
Sore Throat0
1
2014201410.0low000010
Spasm0
30
1951201959.3low0260220
Spasmophilia0
1
1962196262.0low010000
Spider Veins0
1
201620168.0low000010
Spinal Cord Injuries0
6
1960201725.2low012120
Spinal Diseases0
4
1955196264.8low040000
Spondylitis0
2
1964196460.0low020000
Sprains0
1
1962196262.0low010000
Sprains and Strains0
1
1962196262.0low010000
ST Elevated Myocardial Infarction0
79
201620235.4low150006910
ST Elevation Myocardial Infarction0
79
201620235.4low150006910
Stammering0
1
2006200618.0low000100
Staphylococcal Infections0
3
2007201412.7low000120
Stasis Ulcer0
19
1958202019.5low4314110
Status Asthmaticus0
1
1958195866.0low010000
Status Epilepticus0
1
1959195965.0low010000
Steatorrhea0
2
1960196163.5low020000
Stenosis, Pulmonary Vein0
1
202320231.0low000001
Sterility, Female0
1
1964196460.0low010000
Sterility, Male0
2
1961201038.5low110100
Stevens-Johnson Syndrome0
2
1958201537.5low010010
Stomach Neoplasms0
1
2010201014.0low000100
Stomach Ulcer0
6
1964201719.2low110230
Stomatitis0
1
2007200717.0low000100
Stomatitis, Aphthous0
1
2012201212.0low000010
Strabismus0
1
1954195470.0low010000
Streptococcal Infections0
2
2003201415.5low000110
Stress Disorders, Post-Traumatic0
3
2007201911.3low000120
Stroke0
244
2000202311.2low37027415810
Stuttering0
1
2006200618.0low000100
Subarachnoid Hemorrhage0
12
1995202111.2low301281
Substance Withdrawal Syndrome0
11
1979201421.1low131160
Substance-Related Disorders0
15
1952201141.3low091320
Suicidal Ideation0
3
1964201243.7low020010
Surgical Incision0
1
201720177.0low000010
Swine Diseases0
1
1983198341.0low010000
Symptom Cluster0
65
1952202223.3low3101027153
Syncope0
40
1957202319.2low23913141
Syndrome0
65
1952202223.3low3101027153
Systemic Inflammatory Response Syndrome0
6
2001202116.3low300501
Systemic Vasculitis0
5
2011201410.8low000050
Systolic Heart Failure0
69
200820239.3low180012516
Tachyarrhythmia0
47
1954202120.9low27717142
Tachycardia0
47
1954202120.9low27717142
Tachycardia, Paroxysmal0
6
1955201629.0low013110
Tachycardia, Supraventricular0
16
1995202113.6low003571
Tachycardia, Ventricular0
48
1993202014.5low60914250
Tachypnea0
1
2014201410.0low000010
Takayasu Arteritis0
6
1992202013.8low001140
Takotsubo Cardiomyopathy0
41
2007202111.0low00012272
Taste Disorder, Anterior Tongue0
3
1994202017.0low001110
Telangiectasis0
1
201620168.0low000010
Temporomandibular Disorders0
2
1960196163.5low020000
Temporomandibular Joint Disorders0
2
1960196163.5low020000
Tension-Type Headache0
2
1962200739.5low010100
Testicular Neoplasms0
2
200820219.5low000101
Tetanus0
39
1951199265.1low0381000
Tetralogy of Fallot0
1
2014201410.0low000010
Tetraploid0
1
1954195470.0low010000
Thrombocythemia0
1
2012201212.0low000010
Thrombocythemia, Essential0
1
2014201410.0low000010
Thrombocytopenia0
6
1962201531.5low031110
Thromboembolism0
21
1956202129.0low171661
Thromboembolism, Venous0
5
2008201711.6low000140
Thrombopenia0
6
1962201531.5low031110
Thrombophilia0
8
2007201512.8low000350
Thrombophlebitis0
4
1965199439.8low022000
Thrombosis0
280
1952202315.7low671471471075
Thrombotic Microangiopathies0
3
2008201512.0low000120
Thyroid Diseases0
1
2008200816.0low000100
Thyrotoxicosis0
4
1962201227.5low010120
Tinnitus0
4
1955201624.5low110030
Tobacco Use Disorder0
2
201820186.0low100020
Tooth Diseases0
1
202020204.0low000010
Tooth Loss0
1
1997199727.0low001000
Torsade de Pointes0
25
1993202214.0low1031273
Toxemia0
2
1951195471.5low020000
Transfusion Reaction0
1
2004200420.0low000100
Transposition of Great Vessels0
4
200920229.0low000121
Tremor0
4
1961200152.8low030100
Tricuspid Incompetence0
12
2004201911.2low100390
Tricuspid Valve Stenosis0
1
2012201212.0low000010
Trigeminal Neuralgia0
2
1955196365.0low020000
Tuberculosis0
9
1953196165.4low090000
Tuberculosis, Meningeal0
1
1961196163.0low010000
Tuberculosis, Miliary0
1
1960196064.0low010000
Tuberculosis, Pulmonary0
4
1953196267.2low040000
Tuberculosis, Urogenital0
1
201820186.0low000010
Tuberous Sclerosis0
1
1965196559.0low010000
Typhoid Fever0
1
1963196361.0low010000
Typhus, Epidemic Louse-Borne0
1
1964196460.0low010000
Ulcer0
13
1953202143.4low180041
Uremia0
2
1991200128.0low001100
Ureteral Calculi0
4
1955200547.5low030100
Ureteral Diseases0
2
1954201838.0low010010
Ureterolithiasis0
3
1954196267.0low030000
Urinary Calculi0
1
1962196262.0low010000
Urinary Incontinence0
1
2010201014.0low000100
Urinary Retention0
2
1962200640.0low110100
Urinary Tract Diseases0
9
1952201360.1low080010
Urinary Tract Infections0
4
1954202025.0low010120
Urination Disorders0
1
1962196262.0low010000
Urticaria0
4
1959201227.8low010210
Uterine Atony0
1
1957195767.0low010000
Uterine Diseases0
1
1954195470.0low010000
Uterine Hemorrhage0
2
1961197357.0low020000
Uterine Inertia0
1
1957195767.0low010000
Uterine Neoplasms0
1
2000200024.0low001000
Varices0
22
1958201926.3low162590
Varicocele0
1
2010201014.0low100100
Varicose Ulcer0
19
1958202019.5low4314110
Varicose Veins0
22
1958201926.3low162590
Vascular Calcification0
49
201120227.8low9000481
Vascular Diseases0
118
1951202328.8low741417533
Vascular Fistula0
1
2009200915.0low000100
Vascular Injuries0
15
2011201910.5low1000150
Vascular Malformations0
3
201020208.3low000120
Vasculitis0
10
1999201911.4low001090
Vasomotor Rhinitis0
1
1960196064.0low010000
Vasospasm, Intracranial0
8
2007202012.1low100350
Vein Of Galen Malformation0
1
201820186.0low000010
Venous Insufficiency0
40
1973202115.5low10278221
Venous Thromboembolism0
5
2008201711.6low000140
Venous Thrombosis0
8
2000201914.0low001430
Ventilator-Associated Pneumonia0
2
2008202010.0low000110
Ventricular Dysfunction0
6
1995201820.2low002310
Ventricular Dysfunction, Left0
251
1994202214.2low35031951169
Ventricular Fibrillation0
57
1957202019.2low551416220
Ventricular Septal Perforation0
3
2007202110.7low000111
Vertigo0
4
1952201451.8low030010
Vibrio cholerae Infection0
1
2012201212.0low000010
Viral Diseases0
4
2003201516.2low000310
Virus Diseases0
4
2003201516.2low000310
Vitamin D Deficiency0
3
201020179.3low000120
Vitreoretinopathy, Proliferative0
1
202320231.0low000001
Vitreous Hemorrhage0
1
2004200420.0low000100
Vomiting0
5
1950201648.2low130110
von Willebrand Diseases0
1
2002200222.0low000100
Water-Electrolyte Imbalance0
10
1984201518.6low010630
Weight Gain0
6
1999201913.2low002040
Weight Loss0
15
1997201814.2low401590
Weight Reduction0
15
1997201814.2low401590
Whooping Cough0
1
1958195866.0low010000
Wilms Tumor0
1
2000200024.0low001000
Wolff-Parkinson-White Syndrome0
2
1994199529.5low002000
Wounds and Injuries0
15
1955202035.8low070260
Wounds, Gunshot0
1
1994199430.0low001000
Wounds, Penetrating0
1
1992199232.0low001000
Xanthomatosis, Cerebrotendinous0
1
2012201212.0low000010
Xerostomia0
10
1993201519.5low003520

Safety/Toxicity (286)

ArticleYear
Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: First-in-man trial (REFORM).
Cardiovascular revascularization medicine : including molecular interventions, , Volume: 56		2023
Thirty years of telemetry-based data acquisition for cardiovascular drug safety evaluation: Applications and optimization.
Journal of pharmacological and toxicological methods, , Volume: 122
Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Artery Disease.
Journal of vascular and interventional radiology : JVIR, , Volume: 34, Issue:7		2023
Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis.
PloS one, , Volume: 17, Issue:10		2022
Network Analysis for Signal Detection in Spontaneous Adverse Event Reporting Database: Application of Network Weighting Normalization to Characterize Cardiovascular Drug Safety.
Drug safety, , Volume: 45, Issue:11		2022
Comparing the efficacy and safety of two different drug-coated balloons in in-stent restenosis: Two-year clinical outcomes of the RESTORE ISR China randomized trial.
Journal of cardiology, , Volume: 81, Issue:1		2023
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
JAMA cardiology, , 09-01, Volume: 7, Issue:9		2022
Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis.
Advances in therapy, , Volume: 39, Issue:9		2022
Safety and efficacy of 48 mm Xience Xpedition everolimus-eluting stent for the treatment of long coronary lesions.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 100, Issue:2		2022
Interactions of selected cardiovascular active natural compounds with CXCR4 and CXCR7 receptors: a molecular docking, molecular dynamics, and pharmacokinetic/toxicity prediction study.
BMC complementary medicine and therapies, , Feb-04, Volume: 22, Issue:1		2022
Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
European radiology experimental, , 11-17, Volume: 5, Issue:1		2021
Ultraviolet photolysis of four typical cardiovascular drugs: mechanisms, influencing factors, degradation pathways, and toxicity trends.
Environmental science and pollution research international, , Volume: 28, Issue:43		2021
PRospective Observational Registry Evaluating the Safety and Effectivenessof Orsiro Stent in Chilean Patients - ROSES Registry.
Cardiovascular revascularization medicine : including molecular interventions, , Volume: 36		2022
Safety and efficacy of Everolimus-Eluting bioabsorbable Polymer-Coated stent in patients with long coronary lesions: The EVOLVE 48 study.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 99, Issue:2		2022
Efficacy and safety of Shenfuqiangxin pills in complementary treatment of chronic heart failure: A protocol for systematic review and meta-analysis.
Medicine, , Apr-16, Volume: 100, Issue:15		2021
Toward a broader view of mechanisms of drug cardiotoxicity.
Cell reports. Medicine, , 03-16, Volume: 2, Issue:3		2021
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
The Journal of pharmacology and experimental therapeutics, , Volume: 377, Issue:2		2021
Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial.
Journal of vascular surgery, , Volume: 74, Issue:3		2021
A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Cardiovascular drugs and therapy, , Volume: 36, Issue:2		2022
Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients.
Anatolian journal of cardiology, , Volume: 25, Issue:2		2021
Safety and Efficacy of Paclitaxel-Eluting Balloon Angioplasty for Dysfunctional Hemodialysis Access: A randomized trial Comparing with Angioplasty Alone.
Journal of vascular and interventional radiology : JVIR, , Volume: 32, Issue:3		2021
Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment.
Archivos de cardiologia de Mexico, , Dec-20, Volume: 91, Issue:Suplemento		2021
Gender differences in the adverse events associated with cardiovascular drugs in a spontaneous reporting system in South Korea.
International journal of clinical pharmacy, , Volume: 43, Issue:4		2021
Rationale and Design of the SAFE-PAD Study.
Circulation. Cardiovascular quality and outcomes, , Volume: 14, Issue:1		2021
Efficacy and safety of a magnesium stearate paclitaxel coated balloon catheter in the porcine coronary model.
International journal of cardiology, , 05-15, Volume: 331		2021
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 81		2021
Effectiveness and safety of Yufengningxin for treating coronary heart disease angina: A protocol for a systematic review and meta-analysis.
Medicine, , Dec-24, Volume: 99, Issue:52		2020
Efficacy and safety of Qishen granules for chronic heart failure: A protocol for systematic review and meta-analysis.
Medicine, , Dec-24, Volume: 99, Issue:52		2020
The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: A brief review.
Cardiology journal, , Volume: 29, Issue:1		2022
Ursolic acid: A systematic review of its pharmacology, toxicity and rethink on its pharmacokinetics based on PK-PD model.
Fitoterapia, , Volume: 147		2020
Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline.
Toxicology in vitro : an international journal published in association with BIBRA, , Volume: 69		2020
Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 96, Issue:5		2020
Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction.
Cardiovascular drugs and therapy, , Volume: 34, Issue:4		2020
Cardiovascular drugs and lipid regulating agents in surface waters at global scale: Occurrence, ecotoxicity and risk assessment.
The Science of the total environment, , Aug-10, Volume: 729		2020
Safety and Performance of the Orsiro Sirolimus-Eluting Stent in the Treatment of All-Comers Patient Population in Daily Clinical Practice.
Cardiovascular revascularization medicine : including molecular interventions, , Volume: 21, Issue:11		2020
Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis.
Drugs, , Volume: 80, Issue:7		2020
Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial.
BMC complementary and alternative medicine, , Dec-11, Volume: 19, Issue:1		2019
Drug related adverse events due to cardiotropic agents : Epidemiology and prognosis in the emergency department.
La Tunisie medicale, , Volume: 97, Issue:5		2019
Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
Journal of vascular surgery, , Volume: 71, Issue:1		2020
Comparison of efficacy and safety between ultrathin bioresorbable polymer sirolimus-eluting stents and thin durable polymer drug-eluting stents: a systematic review and meta-analysis of the literature.
Coronary artery disease, , Volume: 30, Issue:8		2019
Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.
European heart journal, , 10-07, Volume: 41, Issue:38		2020
Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
JACC. Cardiovascular interventions, , 12-23, Volume: 12, Issue:24		2019
Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?
Current cardiology reports, , 09-07, Volume: 21, Issue:10		2019
Late-term safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: Final 4-year results from the evaluation of the XIENCE coronary stent, Performance, and Technique in Chronic Total Occlusions (EXPERT CT
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Oct-01, Volume: 94, Issue:4		2019
The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial.
Trials, , Aug-20, Volume: 20, Issue:1		2019
Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure　- J-SHIFT Study.
Circulation journal : official journal of the Japanese Circulation Society, , 09-25, Volume: 83, Issue:10		2019
Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , 02-15, Volume: 95, Issue:3		2020
Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Cardiovascular research, , 03-01, Volume: 116, Issue:3		2020
Association Between Medication Adherence and 1-Year Major Cardiovascular Adverse Events After Acute Myocardial Infarction in China.
Journal of the American Heart Association, , 05-07, Volume: 8, Issue:9		2019
Two-year safety evaluation of a biodegradable polymer sirolimus-eluting stent with increased drug elution and polymer absorption kinetics in complex patient and lesion cohort.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 95, Issue:2		2020
Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , 02-15, Volume: 93, Issue:S1		2019
Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
European journal of heart failure, , Volume: 21, Issue:3		2019
Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan.
Clinical pharmacology and therapeutics, , Volume: 105, Issue:6		2019
Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Medicine, , Volume: 97, Issue:51		2018
Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
Drug safety, , Volume: 42, Issue:5		2019
Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , 02-15, Volume: 93, Issue:S1		2019
Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.
Cardiovascular toxicology, , Volume: 19, Issue:4		2019
Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, , Sep-20, Volume: 15, Issue:7		2019
Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 108, Issue:6		2019
Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
Clinical drug investigation, , Volume: 38, Issue:11		2018
Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials.
BMC cardiovascular disorders, , 08-15, Volume: 18, Issue:1		2018
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.
Indian journal of experimental biology, , Volume: 54, Issue:10		2016
A human population-based organotypic in vitro model for cardiotoxicity screening.
ALTEX, , Volume: 35, Issue:4		2018
Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
Cardiovascular revascularization medicine : including molecular interventions, , Volume: 20, Issue:3		2019
Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
Basic & clinical pharmacology & toxicology, , Volume: 123, Issue:5		2018
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
BMC cardiovascular disorders, , 05-08, Volume: 18, Issue:1		2018
A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects.
Journal of clinical pharmacology, , Volume: 58, Issue:11		2018
Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
Toxicological sciences : an official journal of the Society of Toxicology, , 08-01, Volume: 164, Issue:2		2018
Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
Acta pharmacologica Sinica, , Volume: 39, Issue:10		2018
Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.
Neurogastroenterology and motility, , Volume: 30, Issue:6		2018
Treatment with 48-mm everolimus-eluting stents : Procedural safety and 12-month patient outcome.
Herz, , Volume: 44, Issue:5		2019
The SAFE pathway for cardioprotection: is this a promising target?
Basic research in cardiology, , 01-15, Volume: 113, Issue:2		2018
Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
ESC heart failure, , Volume: 5, Issue:3		2018
A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.
Clinical pharmacology and therapeutics, , Volume: 104, Issue:3		2018
Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank.
American heart journal, , Volume: 194		2017
Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.
JACC. Cardiovascular interventions, , 12-11, Volume: 10, Issue:23		2017
Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model.
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, , Volume: 25, Issue:1		2018
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, , 03-20, Volume: 13, Issue:16		2018
Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
Journal of clinical pharmacy and therapeutics, , Volume: 43, Issue:3		2018
Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China.
Scientific reports, , 10-23, Volume: 7, Issue:1		2017
Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
Trials, , Oct-10, Volume: 18, Issue:1		2017
Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry.
European journal of heart failure, , Volume: 20, Issue:2		2018
Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , 08-01, Volume: 92, Issue:2		2018
Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials.
JACC. Cardiovascular interventions, , 09-25, Volume: 10, Issue:18		2017
Nullification of aspirin induced gastrotoxicity and hepatotoxicity by prior administration of wheat germ oil in Mus musculus: histopathological, ultrastructural and molecular studies.
Cellular and molecular biology (Noisy-le-Grand, France), , 08-30, Volume: 63, Issue:8		2017
Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients.
Diabetes & vascular disease research, , Volume: 14, Issue:5		2017
Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy.
JACC. Cardiovascular interventions, , 08-28, Volume: 10, Issue:16		2017
Pilot Study to Determine Safety and Efficacy of Paclitaxel Infusion in De Novo Peripheral Lesions Using the Atrium ClearWay Balloon.
South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 70, Issue:3		2017
A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
European journal of heart failure, , Volume: 19, Issue:10		2017
Safety and efficacy outcomes of second-generation everolimus-eluting stents in octogenarians compared to non-octogenarians.
Cardiovascular revascularization medicine : including molecular interventions, , Volume: 19, Issue:1 Pt A		2018
Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Circulation. Cardiovascular interventions, , Volume: 10, Issue:5		2017
[Comparative Assessment of Antianginal Efficacy and Safety of Nicorandil at the Background of Therapy With -Adrenoblockers in Ischemic Heart Disease Patients With Stable Angina].
Kardiologiia, , Volume: 56, Issue:10		2016
Potential functional and pathological side effects related to off-target pharmacological activity.
Journal of pharmacological and toxicological methods, , Volume: 87		2017
Anthracycline Chemotherapy and Cardiotoxicity.
Cardiovascular drugs and therapy, , Volume: 31, Issue:1		2017
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Journal of cardiovascular pharmacology, , Volume: 69, Issue:5		2017
Efficacy and safety of a biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: A pooled analysis of the CREDIT II and CREDIT III trials.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 89, Issue:S1		2017
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
JACC. Cardiovascular interventions, , 02-13, Volume: 10, Issue:3		2017
Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
JACC. Cardiovascular interventions, , 01-09, Volume: 10, Issue:1		2017
IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease.
Advanced drug delivery reviews, , Volume: 112		2017
Impact of the implementation of vasoactive drug protocols on safety and efficacy in the treatment of critically ill patients.
Journal of clinical pharmacy and therapeutics, , Volume: 41, Issue:6		2016

Long-term Use (53)

ArticleYear
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.
Acta pharmacologica Sinica, , Volume: 43, Issue:9		2022
Macrophage-Based Therapies for Atherosclerosis Management.
Journal of immunology research, , Volume: 2020		2020
Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities.
European journal of heart failure, , Volume: 21, Issue:12		2019
Myocardial Phosphodiesterases and Their Role in cGMP Regulation.
Journal of cardiovascular pharmacology, , Volume: 75, Issue:6		2020
Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine.
Current cardiology reports, , 06-14, Volume: 20, Issue:8		2018
Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol.
American heart journal, , Volume: 190		2017
The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.
European journal of preventive cardiology, , Volume: 24, Issue:9		2017
Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
BMC cardiovascular disorders, , 05-31, Volume: 16		2016
Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction.
International journal of cardiology, , Aug-15, Volume: 217		2016
Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study.
BMJ open, , 05-13, Volume: 6, Issue:5		2016
Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI).
American heart journal, , Volume: 170, Issue:5		2015
Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care.
Journal of the American College of Cardiology, , Sep-15, Volume: 66, Issue:11		2015
Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
Therapeutic drug monitoring, , Volume: 38, Issue:1		2016
Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).
Clinical pharmacokinetics, , Volume: 53, Issue:12		2014
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
European heart journal, , Volume: 35, Issue:6		2014
The pediatric cardiology pharmacopeia: 2013 update.
Pediatric cardiology, , Volume: 34, Issue:1		2013
Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat.
American journal of physiology. Heart and circulatory physiology, , Sep-15, Volume: 303, Issue:6		2012
Delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI): protocol for a pragmatic, cluster-randomized controlled trial.
Implementation science : IS, , Jun-09, Volume: 7		2012
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Lancet (London, England), , Oct-01, Volume: 378, Issue:9798		2011
Mildronate treatment alters γ-butyrobetaine and l-carnitine concentrations in healthy volunteers.
The Journal of pharmacy and pharmacology, , Volume: 63, Issue:9		2011
Xanthine derivatives in the heart: blessed or cursed?
Current medicinal chemistry, , Volume: 18, Issue:24		2011
Drug therapies for tardive dyskinesia: part 2.
Journal of psychosocial nursing and mental health services, , Volume: 49, Issue:7		2011
Patients' satisfaction with information and experiences with counseling on cardiovascular medication received at the pharmacy.
Patient education and counseling, , Volume: 83, Issue:3		2011
Vascular protection by natural product-derived polyphenols: in vitro and in vivo evidence.
Planta medica, , Volume: 77, Issue:11		2011
Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris.
Atherosclerosis, , Volume: 214, Issue:2		2011
Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization.
Archives of cardiovascular diseases, , Volume: 103, Issue:6-7
The challenge of polypharmacy in cardiovascular medicine.
Fundamental & clinical pharmacology, , Volume: 24, Issue:1		2010
The influence of medication on salivary flow of the elderly: preliminary study.
Gerodontology, , Volume: 27, Issue:4		2010
Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database.
Archives of cardiovascular diseases, , Volume: 102, Issue:4		2009
Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors.
European heart journal, , Volume: 30, Issue:8		2009
1-Methylnicotinamide (MNA) prevents endothelial dysfunction in hypertriglyceridemic and diabetic rats.
Pharmacological reports : PR, , Volume: 60, Issue:1
Non-ST segment elevation acute coronary syndromes: treatment guidelines for the nurse practitioner.
Journal of the American Academy of Nurse Practitioners, , Volume: 19, Issue:6		2007
Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management.
Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2		2007
Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction.
Journal of cardiovascular pharmacology, , Volume: 48, Issue:6		2006
Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS.
Pharmacy world & science : PWS, , Volume: 28, Issue:5		2006
[Change of concentration of L-carnitine in blood and other tissues in rats on a background of the alcohol intake and influence of mildronate on its level].
Georgian medical news, , Issue:137		2006
The effect of medication on sleep.
Respiratory care clinics of North America, , Volume: 12, Issue:1		2006
Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure.
Journal of cardiovascular pharmacology, , Volume: 44 Suppl 1		2004
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
European journal of heart failure, , Volume: 6, Issue:4		2004
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
American heart journal, , Volume: 147, Issue:5		2004
Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
American journal of nephrology, , Volume: 22, Issue:4
Gender and drug treatment as determinants of mortality in a cohort of heart failure patients.
European journal of epidemiology, , Volume: 17, Issue:4		2001
Drug-induced respiratory disorders: incidence, prevention and management.
Drug safety, , Volume: 23, Issue:2		2000
Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents.
Gastroenterology clinics of North America, , Volume: 24, Issue:4		1995
Intraindividual reproducibility of postprandial and orthostatic blood pressure changes in older nursing-home patients: relationship with chronic use of cardiovascular medications.
Journal of the American Geriatrics Society, , Volume: 44, Issue:4		1996
Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure.
European heart journal, , Volume: 16 Suppl F		1995
What to try while congestive heart failure patients are still ambulatory.
Postgraduate medicine, , Volume: 94, Issue:5		1993
[Nitrates in heart failure: the hemodynamic effects and clinical implications].
Cardiology, , Volume: 84 Suppl 1		1994
Mechanical factors involved in the growth of the heart and its blood vessels.
Cellular & molecular biology research, , Volume: 40, Issue:2		1994
Diuretics in cardiovascular therapy. Perusing the past, practising in the present, preparing for the future.
Zeitschrift fur Kardiologie, , Volume: 74 Suppl 2		1985
[Drug treatment of heart insufficiency].
Schweizerische medizinische Wochenschrift, , Dec-17, Volume: 118, Issue:50		1988
Pharmacokinetics of newer drugs in patients with renal impairment (Part II).
Clinical pharmacokinetics, , Volume: 20, Issue:5		1991
Poisoning in the elderly. Epidemiological, clinical and management considerations.
Drugs & aging, , Volume: 1, Issue:1		1991

Pharmacokinetics (146)

ArticleYear
Guiding future paediatric drug studies based on existing pharmacokinetic and efficacy data: Cardiovascular drugs as a proof of concept.
British journal of clinical pharmacology, , Volume: 89, Issue:9		2023
Interactions of selected cardiovascular active natural compounds with CXCR4 and CXCR7 receptors: a molecular docking, molecular dynamics, and pharmacokinetic/toxicity prediction study.
BMC complementary medicine and therapies, , Feb-04, Volume: 22, Issue:1		2022
Evaluation of the effect of Shengxian Decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 144		2021
LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study.
Biomedical chromatography : BMC, , Volume: 35, Issue:7		2021
Estimated plasma volume status in heart failure: clinical implications and future directions.
Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 110, Issue:8		2021
Ursolic acid: A systematic review of its pharmacology, toxicity and rethink on its pharmacokinetics based on PK-PD model.
Fitoterapia, , Volume: 147		2020
Peculiarities of Pharmacokinetics and Bioavailability of Some Cardiovascular Drugs under Conditions of Antiorthostatic Hypokinesia.
Bulletin of experimental biology and medicine, , Volume: 168, Issue:4		2020
Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products.
Cardiovascular therapeutics, , Volume: 2019		2019
Cut-off value of mal-apposition volume and depth for resolution at early phase of acute incomplete stent apposition after CoCr-EES implantation.
The international journal of cardiovascular imaging, , Volume: 35, Issue:11		2019
Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Traditional Medicine-based Cardiovascular Drug Research.
Current drug metabolism, , Volume: 20, Issue:7		2019
Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Renal failure, , Volume: 41, Issue:1		2019
Meldonium long-term excretion period and pharmacokinetics in blood and urine of healthy athlete volunteers.
Drug testing and analysis, , Volume: 11, Issue:4		2019
Pharmacokinetics of intramuscular alfaxalone and its echocardiographic, cardiopulmonary and sedative effects in healthy dogs.
PloS one, , Volume: 13, Issue:9		2018
The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.
British journal of clinical pharmacology, , Volume: 85, Issue:1		2019
Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
Clinical drug investigation, , Volume: 38, Issue:11		2018
Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
Basic & clinical pharmacology & toxicology, , Volume: 123, Issue:5		2018
A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects.
Journal of clinical pharmacology, , Volume: 58, Issue:11		2018
Cardiovascular Drug Therapy for Human Newborn: Review of Pharmacodynamic Data.
Current pharmaceutical design, , Volume: 23, Issue:38		2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Circulation, , Sep-19, Volume: 136, Issue:12		2017
Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics.
Circulation. Cardiovascular imaging, , Volume: 10, Issue:6		2017
Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule.
Journal of Zhejiang University. Science. B, , Volume: 18, Issue:4
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7		2017
The influence of targeted temperature management on the pharmacokinetics of drugs administered during and after cardiac arrest: a systematic review.
Acta clinica Belgica, , Volume: 72, Issue:2		2017
What is the impact of obtaining medical clearance to participate in a randomised controlled trial examining a physical activity intervention on the socio-demographic and risk factor profiles of included participants?
Trials, , 12-07, Volume: 17, Issue:1		2016
Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure.
International journal of cardiology, , Dec-01, Volume: 224		2016
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Clinical pharmacology in drug development, , Volume: 4, Issue:2		2015
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 44, Issue:7		2016
Clearance of cardiovascular medications during hemodialysis.
Current opinion in nephrology and hypertension, , Volume: 25, Issue:3		2016
Single- and Multiple-dose Pharmacokinetic, Safety and Tolerability Study of Mildronate Injection in Healthy Chinese Subjects Pharmacokinetic of Mildronate Injection.
Drug research, , Volume: 66, Issue:5		2016
Relationship of Provider and Practice Volume to Performance Measure Adherence for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation: Results From the National Cardiovascular Data Registry.
Circulation. Cardiovascular quality and outcomes, , Volume: 9, Issue:1		2016
Pharmacodynamics and potential synergistic effects of Mai-Luo-Ning injection on cardiovascular protection, based on molecular docking.
Chinese journal of natural medicines, , Volume: 13, Issue:11		2015
Quantifying the shape of maximal expiratory flow-volume curves in healthy humans and asthmatic patients.
Respiratory physiology & neurobiology, , Volume: 220		2016
Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.
Journal of cardiovascular pharmacology and therapeutics, , Volume: 21, Issue:1		2016
Tanshinone IIA - loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Aug-30, Volume: 76		2015
Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers.
Journal of cardiovascular pharmacology, , Volume: 65, Issue:4		2015
Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
British journal of clinical pharmacology, , Volume: 79, Issue:6		2015
Recent Pharmacokinetic Studies in Combination Therapies for Diabetes and Related Vascular Complications.
Current vascular pharmacology, , Volume: 13, Issue:4		2015
Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).
Clinical pharmacokinetics, , Volume: 53, Issue:12		2014
The effect of clopidogrel on pharmacokinetics of ivabradine and its metabolite in rats.
Drug development and industrial pharmacy, , Volume: 41, Issue:9		2015
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).
Clinical pharmacokinetics, , Volume: 53, Issue:12		2014
[Pharmacokinetics of anesthesia related drugs in patients with chronic kidney disease].
Masui. The Japanese journal of anesthesiology, , Volume: 62, Issue:11		2013
Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.
British journal of pharmacology, , Volume: 171, Issue:3		2014
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 13, Issue:5		2013
Stroke prevention in patients with non-valvular atrial fibrillation: new insight in selection of rhythm or rate control therapy and impact of mean platelet volume.
Current pharmaceutical design, , Volume: 19, Issue:32		2013
Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Jan-01, Volume: 83, Issue:1		2014
Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 83, Issue:2		2014
Radix Puerariae: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use.
Journal of clinical pharmacology, , Volume: 53, Issue:8		2013
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).
Clinical pharmacokinetics, , Volume: 52, Issue:3		2013
Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:2		2013
Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
Circulation. Cardiovascular interventions, , Volume: 5, Issue:6		2012
Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Nov-01, Volume: 908		2012
Survival in patients with severe ischemic cardiomyopathy undergoing revascularization versus medical therapy: association with end-systolic volume and viability.
Circulation, , Sep-11, Volume: 126, Issue:11 Suppl 1		2012
A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics.
Therapeutic delivery, , Volume: 2, Issue:11		2011
Sinomenium acutum: a review of chemistry, pharmacology, pharmacokinetics, and clinical use.
Pharmaceutical biology, , Volume: 50, Issue:8		2012
Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?
Circulation. Cardiovascular interventions, , Volume: 5, Issue:3		2012
Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits.
Die Pharmazie, , Volume: 67, Issue:4		2012
Integrated pharmacokinetics of major bioactive components in MCAO rats after oral administration of Huang-Lian-Jie-Du-Tang.
Journal of ethnopharmacology, , May-07, Volume: 141, Issue:1		2012
Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.
Clinical therapeutics, , Volume: 33, Issue:12		2011
Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature.
Journal of vascular surgery, , Volume: 55, Issue:2		2012
Quantification of leonurine, a novel potential cardiovascular agent, in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats.
Biomedical chromatography : BMC, , Volume: 26, Issue:4		2012
The effect of Compound Danshen Dripping Pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats.
Journal of ethnopharmacology, , Oct-11, Volume: 137, Issue:3		2011
Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats.
Journal of ethnopharmacology, , Sep-01, Volume: 137, Issue:1		2011
Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 17, Issue:15		2011
Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.
Clinical journal of the American Society of Nephrology : CJASN, , Volume: 6, Issue:6		2011
Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Dec-01, Volume: 78, Issue:7		2011
Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems.
Current drug metabolism, , Volume: 12, Issue:7		2011
Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis, , Jul-15, Volume: 55, Issue:5		2011
Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries.
Journal of vascular and interventional radiology : JVIR, , Volume: 22, Issue:5		2011
Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
Therapeutic drug monitoring, , Volume: 33, Issue:2		2011
Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers.
Journal of clinical pharmacy and therapeutics, , Volume: 36, Issue:2		2011
Reproducibility of Shin's method for necrotic core and calcium content in atherosclerotic coronary lesions treated with bioresorbable everolimus-eluting vascular scaffolds using volumetric intravascular ultrasound radiofrequency-based analysis.
The international journal of cardiovascular imaging, , Volume: 28, Issue:1		2012
Pharmacokinetics of oral ivabradine in healthy cats.
Journal of veterinary pharmacology and therapeutics, , Volume: 34, Issue:5		2011
Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment.
International journal of pharmaceutics, , Jan-17, Volume: 403, Issue:1-2		2011
Relationship of resting hemoglobin concentration to peak oxygen uptake in heart failure patients.
American journal of hematology, , Volume: 85, Issue:6		2010
Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Journal of clinical pharmacology, , Volume: 51, Issue:5		2011
High volume-rate three-dimensional stress echocardiography to assess inducible myocardial ischemia: a feasibility study.
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, , Volume: 23, Issue:6		2010
Determination of mildronate by LC-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Feb-15, Volume: 878, Issue:5-6		2010
Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans.
Phytotherapy research : PTR, , Volume: 24, Issue:3		2010
Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis, , Mar-11, Volume: 51, Issue:4		2010
TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload.
American journal of physiology. Heart and circulatory physiology, , Volume: 297, Issue:4		2009
Does extreme prematurity affect kidney volume at term corrected age?
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, , Volume: 22, Issue:5		2009
Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties.
Current pharmaceutical design, , Volume: 15, Issue:6		2009
Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
Clinical therapeutics, , Volume: 30, Issue:12		2008
The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Dec-01, Volume: 72, Issue:7		2008
Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza).
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 38, Issue:4		2008
Case volume and hospital compliance with evidence-based processes of care.
International journal for quality in health care : journal of the International Society for Quality in Health Care, , Volume: 20, Issue:2		2008
Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome.
Therapeutic drug monitoring, , Volume: 29, Issue:6		2007
Pharmacodynamics in older adults: a review.
The American journal of geriatric pharmacotherapy, , Volume: 5, Issue:3		2007
Pharmacokinetic-pharmacodynamic crisis in the elderly.
American journal of therapeutics, , Volume: 14, Issue:5
Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Oct-15, Volume: 858, Issue:1-2		2007
Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs.
Current drug metabolism, , Volume: 8, Issue:5		2007
Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs.
Journal of pharmacokinetics and pharmacodynamics, , Volume: 34, Issue:3		2007
[Pharmacokinetics of cardiovascular drugs in the elderly].
Bulletin de l'Academie nationale de medecine, , Volume: 190, Issue:4-5
Drug-eluting stents: factors governing local pharmacokinetics.
Advanced drug delivery reviews, , Jun-03, Volume: 58, Issue:3		2006
Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 67, Issue:2		2006
Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.
Drugs & aging, , Volume: 22, Issue:11		2005
Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Clinical pharmacology and therapeutics, , Volume: 78, Issue:3		2005
Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
International journal of clinical pharmacology and therapeutics, , Volume: 43, Issue:4		2005
Relationship between prolongation of QTc and prolongation of the peak of T (Tp) to the end of T (Te).
Journal of pharmacological and toxicological methods, , Volume: 52, Issue:1
Prescribing patterns in high-need Health Authority populations: how does an ethnically mixed composition affect volume and cost?
Journal of clinical pharmacy and therapeutics, , Volume: 29, Issue:6		2004

Bioavailability (112)

ArticleYear
Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 23, Issue:3		2023
Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators.
Proceedings of the National Academy of Sciences of the United States of America, , 12-28, Volume: 118, Issue:52		2021
Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology - A new chance for causative therapy?
Journal of controlled release : official journal of the Controlled Release Society, , 05-10, Volume: 333		2021
Ursolic acid: A systematic review of its pharmacology, toxicity and rethink on its pharmacokinetics based on PK-PD model.
Fitoterapia, , Volume: 147		2020
Metabolism and pharmacological activities of the natural health-benefiting compound diosmin.
Food & function, , Oct-21, Volume: 11, Issue:10		2020
Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
Current pharmaceutical biotechnology, , Volume: 22, Issue:7		2021
The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: From molecular mechanisms to clinical applications.
Pharmacological research, , Volume: 159		2020
Nanocrystal technology for improving therapeutic efficacy of flavonoids.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 71		2020
Nitric Oxide in Post-cardiac Arrest Syndrome.
Journal of cardiovascular pharmacology, , Volume: 75, Issue:6		2020
Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis.
Drugs, , Volume: 80, Issue:7		2020
Peculiarities of Pharmacokinetics and Bioavailability of Some Cardiovascular Drugs under Conditions of Antiorthostatic Hypokinesia.
Bulletin of experimental biology and medicine, , Volume: 168, Issue:4		2020
In Vitro Demonstration of Drug-Reagent Interactions Among Commonly Used Parenteral Drugs in Cardiology.
Cardiovascular & hematological agents in medicinal chemistry, , Volume: 19, Issue:1		2021
Ultrasound controlled paclitaxel releasing system-A novel method for improving the availability of coronary artery drug coated balloon.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Volume: 96, Issue:2		2020
Nanoparticle Therapy for Vascular Diseases.
Arteriosclerosis, thrombosis, and vascular biology, , Volume: 39, Issue:4		2019
Therapeutic Versatility of Resveratrol Derivatives.
Nutrients, , Oct-29, Volume: 9, Issue:11		2017
The vascular endothelium: A regulator of arterial tone and interface for the immune system.
Critical reviews in clinical laboratory sciences, , Volume: 54, Issue:7-8
Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy.
Current vascular pharmacology, , 01-26, Volume: 16, Issue:2		2018
The potential of stimulating nitric oxide formation in the treatment of hypertension.
Expert opinion on therapeutic targets, , Volume: 21, Issue:5		2017
Carvedilol-loaded nanocapsules: Mucoadhesive properties and permeability across the sublingual mucosa.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 114		2017
Small molecule absorption by PDMS in the context of drug response bioassays.
Biochemical and biophysical research communications, , Jan-08, Volume: 482, Issue:2		2017
Quercetin and Its Role in Chronic Diseases.
Advances in experimental medicine and biology, , Volume: 929		2016
Arginase Inhibition Improves Microvascular Endothelial Function in Patients With Type 2 Diabetes Mellitus.
The Journal of clinical endocrinology and metabolism, , Volume: 101, Issue:11		2016
Drug-coated balloons are replacing the need for nitinol stents in the superficial femoral artery.
The Journal of cardiovascular surgery, , Volume: 57, Issue:4		2016
Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, , Volume: 23, Issue:2		2016
Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy.
Methodist DeBakey cardiovascular journal, , Volume: 11, Issue:3
Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy.
Pharmacological reports : PR, , Volume: 67, Issue:4		2015
Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.
Drug design, development and therapy, , Volume: 9		2015
Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment.
Pharmacology & therapeutics, , Volume: 154		2015
The potential benefits of red beetroot supplementation in health and disease.
Nutrients, , Apr-14, Volume: 7, Issue:4		2015
Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.
Marine drugs, , Apr-14, Volume: 13, Issue:4		2015
Age-related changes and effects of mild hypothermia on carotid artery reactivity in newborn rats.
CNS & neurological disorders drug targets, , Volume: 14, Issue:1		2015
[News in lipid lowering treatment].
Vnitrni lekarstvi, , Volume: 60, Issue:11		2014
Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects.
International journal of molecular sciences, , Nov-14, Volume: 15, Issue:11		2014
Overview of green tea interaction with cardiovascular drugs.
Current pharmaceutical design, , Volume: 21, Issue:9		2015
Endothelial NADPH oxidases: which NOX to target in vascular disease?
Trends in endocrinology and metabolism: TEM, , Volume: 25, Issue:9		2014
Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases.
Journal of controlled release : official journal of the Controlled Release Society, , Nov-10, Volume: 193		2014
Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.
The Journal of pharmacy and pharmacology, , Volume: 66, Issue:7		2014
Astaxanthin: sources, extraction, stability, biological activities and its commercial applications--a review.
Marine drugs, , Jan-07, Volume: 12, Issue:1		2014
Danshen diversity defeating dementia.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 24, Issue:3		2014
In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule.
Drug development and industrial pharmacy, , Volume: 41, Issue:2		2015
Nitric oxide, a protective molecule in the cardiovascular system.
Nitric oxide : biology and chemistry, , Nov-30, Volume: 35		2013
Current status of NADPH oxidase research in cardiovascular pharmacology.
Vascular health and risk management, , Volume: 9		2013
[Quantum-pharmacological aspects of cardiovascular drugs studying].
Likars'ka sprava, , Issue:1
Pterostilbene: Biomedical applications.
Critical reviews in clinical laboratory sciences, , Volume: 50, Issue:3
Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Cellular signalling, , Volume: 25, Issue:9		2013
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.
Current pharmaceutical design, , Volume: 19, Issue:34		2013
Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?
Cardiovascular research, , Jun-01, Volume: 98, Issue:3		2013
Berberine and its derivatives: a patent review (2009 - 2012).
Expert opinion on therapeutic patents, , Volume: 23, Issue:2		2013
Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:2		2013
Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women.
Nutrition journal, , Nov-12, Volume: 11		2012
A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics.
Therapeutic delivery, , Volume: 2, Issue:11		2011
The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B.
Fitoterapia, , Volume: 83, Issue:4		2012
Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases.
Vascular pharmacology, , Volume: 57, Issue:5-6
Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.
Clinical therapeutics, , Volume: 33, Issue:12		2011
Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 80, Issue:2		2012
Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.
Drug delivery, , Volume: 18, Issue:8		2011
Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats.
Journal of ethnopharmacology, , Sep-01, Volume: 137, Issue:1		2011
Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy.
American journal of physiology. Heart and circulatory physiology, , Volume: 301, Issue:3		2011
Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.
Clinical journal of the American Society of Nephrology : CJASN, , Volume: 6, Issue:6		2011
Dehydroepiandrosterone protects against oxidative stress-induced endothelial dysfunction in ovariectomized rats.
The Journal of physiology, , May-15, Volume: 589, Issue:Pt 10		2011
Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers.
Journal of clinical pharmacy and therapeutics, , Volume: 36, Issue:2		2011
Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment.
International journal of pharmaceutics, , Jan-17, Volume: 403, Issue:1-2		2011
Specific coronary drug-eluting stents interfere with distal microvascular function after single stent implantation in pigs.
JACC. Cardiovascular interventions, , Volume: 3, Issue:7		2010
Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, , Volume: 6, Issue:1		2010
Dual modulation of nitric oxide production in the heart during ischaemia/reperfusion injury and inflammation.
Thrombosis and haemostasis, , Volume: 104, Issue:2		2010
Beneficial effect of the oligomerized polyphenol oligonol on high glucose-induced changes in eNOS phosphorylation and dephosphorylation in endothelial cells.
British journal of pharmacology, , Volume: 159, Issue:4		2010
Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans.
Phytotherapy research : PTR, , Volume: 24, Issue:3		2010
Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.
Drug development and industrial pharmacy, , Volume: 35, Issue:12		2009
Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.
Current vascular pharmacology, , Volume: 8, Issue:2		2010
Wine, resveratrol and health: a review.
Natural product communications, , Volume: 4, Issue:5		2009
Arginase and vascular aging.
Journal of applied physiology (Bethesda, Md. : 1985), , Volume: 105, Issue:5		2008
Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
Circulation, , Aug-19, Volume: 118, Issue:8		2008
Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease.
American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:5		2008
Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza).
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 38, Issue:4		2008
Endothelial dysfunction in heart failure.
Pharmacological reports : PR, , Volume: 60, Issue:1
Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
Clinical pharmacology and therapeutics, , Volume: 83, Issue:3		2008
Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome.
Therapeutic drug monitoring, , Volume: 29, Issue:6		2007
The enhancing effect of synthetical borneol on the absorption of tetramethylpyrazine phosphate in mouse.
International journal of pharmaceutics, , Jun-07, Volume: 337, Issue:1-2		2007
Hydrophilic carotenoid amphiphiles: methods of synthesis and biological applications.
Mini reviews in medicinal chemistry, , Volume: 6, Issue:9		2006
Paediatric formulations--getting to the heart of the problem.
International journal of pharmaceutics, , Aug-26, Volume: 300, Issue:1-2		2005
Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction.
International journal of cardiology, , Volume: 98, Issue:1		2005
Interactions between grapefruit juice and cardiovascular drugs.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 4, Issue:5		2004
Nitric oxide, an iceberg in cardiovascular physiology: far beyond vessel tone control.
Archives of medical research, , Volume: 35, Issue:1
Alginate-diltiazem hydrochloride beads: optimization of formulation factors, in vitro and in vivo availability.
Journal of microencapsulation, , Volume: 20, Issue:2
Effect of concomitant colestipol hydrochloride administration on the bioavailability of diltiazem from immediate- and sustained-release formulations.
Biopharmaceutics & drug disposition, , Volume: 23, Issue:9		2002
Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
British journal of clinical pharmacology, , Volume: 54, Issue:2		2002
Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors.
Journal of cardiovascular pharmacology, , Volume: 38 Suppl 3		2001
Effect of administration route and length of exposure on pharmacokinetics and metabolism of diltiazem in dogs.
Drug metabolism and drug interactions, , Volume: 18, Issue:3-4		2001
Rapid determination of partition coefficients between n-octanol/water for cardiovascular therapies.
American journal of therapeutics, , Volume: 9, Issue:1
Complexation of Ginkgo biloba extract with phosphatidylcholine improves cardioprotective activity and increases the plasma antioxidant capacity in the rat.
Planta medica, , Volume: 67, Issue:4		2001
Medications in the breast-feeding mother.
American family physician, , Jul-01, Volume: 64, Issue:1		2001
Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers.
American journal of therapeutics, , Volume: 5, Issue:3		1998
Thermally reversible xyloglucan gels as vehicles for rectal drug delivery.
Journal of controlled release : official journal of the Controlled Release Society, , Dec-04, Volume: 56, Issue:1-3		1998
[Rationale for the pharmacologic treatment of cardiovascular diseases].
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, , Volume: 17, Issue:5		1998
[Cardiological drugs and the elderly].
Annales de cardiologie et d'angeiologie, , Volume: 46, Issue:7
Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats.
Journal of veterinary internal medicine, , Volume: 10, Issue:5
Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential.
General pharmacology, , Volume: 27, Issue:4		1996
Radioimmunoassay for the chemical stable prostacyclin analog, 15AU81: a preliminary pharmacokinetics study in the dog.
Prostaglandins, leukotrienes, and essential fatty acids, , Volume: 48, Issue:2		1993
Pharmacokinetic drug interactions with ACE inhibitors.
Clinical pharmacokinetics, , Volume: 25, Issue:1		1993
Inhibitors of enkephalin-degrading enzymes as potential therapeutic agents.
Progress in medicinal chemistry, , Volume: 30		1993

Dosage (398)

ArticleYear
The Effect of Anesthesia Type Applied in Transcatheter Aortic Valve Implantation.
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, , Volume: 51, Issue:6		2023
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
JAMA, , 09-19, Volume: 330, Issue:11		2023
Guiding future paediatric drug studies based on existing pharmacokinetic and efficacy data: Cardiovascular drugs as a proof of concept.
British journal of clinical pharmacology, , Volume: 89, Issue:9		2023
Comparison Between Clinical Outcomes of Low- and High-Dose Paclitaxel Drug-Coated Balloon in Endovascular Therapy for Femoropopliteal Lesion.
Cardiovascular and interventional radiology, , Volume: 46, Issue:5		2023
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
Journal of the American College of Cardiology, , 08-09, Volume: 80, Issue:6		2022
Select drug-drug interactions with colchicine and cardiovascular medications: A review.
American heart journal, , Volume: 252		2022
Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients with standard treatment.
BMC cardiovascular disorders, , 12-28, Volume: 21, Issue:1		2021
Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018.
BMC cardiovascular disorders, , 10-20, Volume: 21, Issue:1		2021
Mortality Following Treatment with Paclitaxel-Coated Devices in Real World Utilization: Correlation to Total Lifetime Dosage?
Journal of vascular and interventional radiology : JVIR, , Volume: 32, Issue:12		2021
Medication adherence in cardiovascular medicine.
BMJ (Clinical research ed.), , 08-11, Volume: 374		2021
Assessment of Drugs Approved by Public Knowledge-Based Applications (Kouchi-shinsei) During the Last Two Decades in Japan.
Clinical pharmacology and therapeutics, , Volume: 110, Issue:4		2021
Pharmacogenetics to guide cardiovascular drug therapy.
Nature reviews. Cardiology, , Volume: 18, Issue:9		2021
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
The Journal of pharmacology and experimental therapeutics, , Volume: 377, Issue:2		2021
Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
European journal of pharmacology, , Apr-15, Volume: 897		2021
Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis.
Molecular nutrition & food research, , Volume: 65, Issue:6		2021
Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency.
Vascular pharmacology, , Volume: 137		2021
Post hoc study to investigate the potential causes of poor quality of cardiovascular medicines collected in sub-Saharan countries.
BMJ open, , 11-09, Volume: 10, Issue:11		2020
Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.
Reviews in cardiovascular medicine, , Jun-30, Volume: 21, Issue:2		2020
[Perioperative pharmacological circulatory support in daily clinical routine].
Der Anaesthesist, , Volume: 69, Issue:11		2020
Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
Croatian medical journal, , Apr-30, Volume: 61, Issue:2		2020
Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure.
Circulation. Heart failure, , Volume: 13, Issue:5		2020
Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial.
BMJ open, , 03-25, Volume: 10, Issue:3		2020
Body surface area and medication dosing in patients with heart failure with reduced ejection fraction.
Trends in cardiovascular medicine, , Volume: 31, Issue:2		2021
[Evaluation of the antianginal effectiveness of trimetazidine in a new dosage form for a single dose, depending on the region of the Russian Federation. ODA trial results].
Kardiologiia, , Sep-11, Volume: 59, Issue:10S		2019
Improving Appropriate Dosing of Intravenous dilTIAZem in Patients With Atrial Fibrillation or Flutter With Rapid Ventricular Response in the Emergency Department.
Journal of emergency nursing, , Volume: 46, Issue:2		2020
Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
JACC. Cardiovascular interventions, , 12-23, Volume: 12, Issue:24		2019
Optimizing heart failure treatment following cardiac resynchronization therapy.
Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 109, Issue:5		2020
Drug-related problems in prescribing for coronary artery diseases in Vietnam: cross-sectional study.
Tropical medicine & international health : TM & IH, , Volume: 24, Issue:11		2019
Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 20, Issue:1		2020
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Cardiovascular diabetology, , 06-03, Volume: 18, Issue:1		2019
Orthostatic blood pressure drop and cardiovascular and psychotropic medication dosages in acutely ill geriatric inpatients.
Acta clinica Belgica, , Volume: 75, Issue:5		2020
Rationale and Design of the VITALITY-HFpEF Trial.
Circulation. Heart failure, , Volume: 12, Issue:5		2019
Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial.
BMC complementary and alternative medicine, , May-06, Volume: 19, Issue:1		2019
Controlled infusion of intravenous cardiac drugs using global optimization.
Indian journal of pharmacology, , Volume: 51, Issue:1
Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
European journal of heart failure, , Volume: 21, Issue:7		2019
Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Renal failure, , Volume: 41, Issue:1		2019
Anti-anginal medication titration among patients with residual angina 6-months after chronic total occlusion percutaneous coronary intervention: insights from OPEN CTO registry.
European heart journal. Quality of care & clinical outcomes, , 10-01, Volume: 5, Issue:4		2019
[Cardiovascular drugs and renal function: Pitfall of renal adaptation].
Nephrologie & therapeutique, , Volume: 15, Issue:2		2019
A mobile device application to reduce medication errors and time to drug delivery during simulated paediatric cardiopulmonary resuscitation: a multicentre, randomised, controlled, crossover trial.
The Lancet. Child & adolescent health, , Volume: 3, Issue:5		2019
Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Journal of neurology, , Volume: 267, Issue:6		2020
Ginkgo biloba Extract Protects Mesenteric Arterioles of Old Rats via Improving Vessel Elasticity through Akt/FoxO3a Signaling Pathway.
Annals of vascular surgery, , Volume: 57		2019
Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
Cardiovascular drugs and therapy, , Volume: 33, Issue:1		2019
Innate immunity as a target for acute cardioprotection.
Cardiovascular research, , 06-01, Volume: 115, Issue:7		2019
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.
European journal of heart failure, , Volume: 21, Issue:3		2019
Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine.
Current cardiology reports, , 06-14, Volume: 20, Issue:8		2018
Self-Reported Non-adherence to Medication in Japanese Patients with Cardiovascular Diseases.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 18, Issue:4		2018
Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry.
BMC cardiovascular disorders, , 05-03, Volume: 18, Issue:1		2018
Anesthesia Management of Modified Ex Vivo Liver Resection and Autotransplantation.
Annals of transplantation, , Apr-27, Volume: 23		2018
Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction.
Clinical cardiology, , Volume: 41, Issue:6		2018
10 years EU regulation of pediatric medicines - impact on cardiovascular drug formulations.
Expert opinion on drug delivery, , Volume: 15, Issue:3		2018
Effect of characteristics of pharmacotherapy on non-adherence in chronic cardiovascular disease: A systematic review and meta-analysis of observational studies.
International journal of clinical practice, , Volume: 72, Issue:1		2018
Adherence to guidelines in patients with chronic heart failure in primary health care.
Scandinavian journal of primary health care, , Volume: 35, Issue:4		2017
The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.
Journal of the American College of Cardiology, , Nov-07, Volume: 70, Issue:19		2017
Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 18, Issue:1		2018
In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.
Heart failure reviews, , Volume: 23, Issue:1		2018
Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
International journal of cardiology, , Dec-15, Volume: 249		2017
Cardiac microphysiological devices with flexible thin-film sensors for higher-throughput drug screening.
Lab on a chip, , 10-25, Volume: 17, Issue:21		2017
Identification of Ion Currents Components Generating Field Potential Recorded in MEA From hiPSC-CM.
IEEE transactions on bio-medical engineering, , Volume: 65, Issue:6		2018
[Balance between cardiovascular pharmacological and hemolytic effects of saponins of Panax notogenseng].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 41, Issue:5		2016
Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Journal of the American College of Cardiology, , Sep-05, Volume: 70, Issue:10		2017
The effects of intravenous lignocaine on depth of anaesthesia and intraoperative haemodynamics during open radical prostatectomy.
BMC research notes, , Jul-06, Volume: 10, Issue:1		2017
Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
Pharmacotherapy, , Volume: 37, Issue:9		2017
Fighting fake medicines: First quality evaluation of cardiac drugs in Africa.
International journal of cardiology, , Sep-15, Volume: 243		2017
The frequency and nature of medication errors in hospitalized patients with acute coronary syndrome.
International journal of clinical pharmacy, , Volume: 39, Issue:3		2017
Current Pharmacological Therapies in Heart Failure Patients.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 24, Issue:2		2017
[Management of different cardiovascular risk factors with a combination tablet (polypill)].
Herz, , Volume: 43, Issue:3		2018
Establishment of one-step approach to detoxification of hypertoxic aconite based on the evaluation of alkaloids contents and quality.
Chinese journal of natural medicines, , Volume: 15, Issue:1		2017
Anthracycline Chemotherapy and Cardiotoxicity.
Cardiovascular drugs and therapy, , Volume: 31, Issue:1		2017
Carvedilol-loaded nanocapsules: Mucoadhesive properties and permeability across the sublingual mucosa.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 114		2017
Awareness and knowledge among internal medicine house-staff for dose adjustment of commonly used medications in patients with CKD.
BMC nephrology, , 01-17, Volume: 18, Issue:1		2017
Translational Applications of Tissue Engineering in Cardiovascular Medicine.
Current pharmaceutical design, , 03-26, Volume: 23, Issue:6		2017
Plant-derived cardiac glycosides: Role in heart ailments and cancer management.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 84		2016
Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure.
International journal of cardiology, , Dec-01, Volume: 224		2016
Pleiotropic mechanisms of action of perhexiline in heart failure.
Expert opinion on therapeutic patents, , Volume: 26, Issue:9		2016
Discontinued cardiovascular drugs in 2015.
Expert opinion on investigational drugs, , Volume: 25, Issue:9		2016
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, , Volume: 25, Issue:10		2016
Pharmacologic Issues in Liver Disease.
Critical care clinics, , Volume: 32, Issue:3		2016
New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
Journal of pharmacy practice, , Volume: 30, Issue:5		2017
Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study.
BMJ open, , 05-13, Volume: 6, Issue:5		2016
Clinical research in neonates and infants: Challenges and perspectives.
Pharmacological research, , Volume: 108		2016
CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury.
Journal of cardiovascular pharmacology and therapeutics, , Volume: 21, Issue:6		2016
Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
European journal of heart failure, , Volume: 18, Issue:5		2016
Global cardiovascular protection in chronic kidney disease.
Nature reviews. Cardiology, , Volume: 13, Issue:10		2016
First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure.
Clinical therapeutics, , Volume: 38, Issue:5		2016
Ginsenoside Rg1 ameliorates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress-induced apoptosis in a streptozotocin-induced diabetes rat model.
Journal of cellular and molecular medicine, , Volume: 20, Issue:4		2016
Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014.
Prostaglandins, leukotrienes, and essential fatty acids, , Volume: 107		2016
Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
Progress in cardiovascular diseases, , Volume: 58, Issue:5
Preconditioning is hormesis part I: Documentation, dose-response features and mechanistic foundations.
Pharmacological research, , Volume: 110		2016
Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 18, Issue:8		2015
Multi-wave cohort study of sedentary work and risk of ischemic heart disease.
Scandinavian journal of work, environment & health, , Volume: 42, Issue:1		2016
Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Non-Institutionalized Elderly Patients.
Basic & clinical pharmacology & toxicology, , Volume: 118, Issue:6		2016
Effects of five preoperative cardiovascular drugs on mortality after coronary artery bypass surgery: A retrospective analysis of an observational study of 16, 192 patients.
European journal of anaesthesiology, , Volume: 33, Issue:1		2016
General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study.
Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 105, Issue:5		2016
Influence of bariatric surgery on the use of medication.
European journal of clinical pharmacology, , Volume: 72, Issue:2		2016
[Cardiovascular drugs in aged and multimorbid patients].
Praxis, , Sep-16, Volume: 104, Issue:19		2015
An Observational Study on a Protocol for Withdrawal of Life-Sustaining Measures on Two Non-Academic Intensive Care Units in The Netherlands: Few Signs of Distress, No Suffering?
Journal of pain and symptom management, , Volume: 50, Issue:5		2015
Consumption of high-dose vitamin C (1250 mg per day) enhances functional and structural properties of serum lipoprotein to improve anti-oxidant, anti-atherosclerotic, and anti-aging effects via regulation of anti-inflammatory microRNA.
Food & function, , Volume: 6, Issue:11		2015
[Clinical and Economic Efficacy of Ivabradine in Patients Suffered Myocardial Infarction].
Kardiologiia, , Volume: 55, Issue:3		2015
Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.
Drug design, development and therapy, , Volume: 9		2015
Gender Differences in Cardiovascular Drugs.
Cardiovascular drugs and therapy, , Volume: 29, Issue:4		2015

Interactions (89)

ArticleYear
Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.
Journal of the American College of Cardiology, , 11-15, Volume: 80, Issue:20		2022
Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis.
Advances in therapy, , Volume: 39, Issue:9		2022
Select drug-drug interactions with colchicine and cardiovascular medications: A review.
American heart journal, , Volume: 252		2022
Vortex-assisted liquid-liquid microextraction combined with liquid chromatography tandem mass spectrometry for simultaneous determination of cardiovascular drugs in human plasma.
Journal of pharmaceutical and biomedical analysis, , Aug-05, Volume: 217		2022
Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI).
Pakistan journal of pharmaceutical sciences, , Volume: 34, Issue:5(Special)		2021
HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
Current drug metabolism, , Volume: 22, Issue:5		2021
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 81		2021
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Fundamental & clinical pharmacology, , Volume: 34, Issue:5		2020
Major Cardiac-Psychiatric Drug-Drug Interactions: a Systematic Review of the Consistency of Drug Databases.
Cardiovascular drugs and therapy, , Volume: 35, Issue:3		2021
Drug-Drug Interactions Between Lithium and Cardiovascular as Well as Anti-Inflammatory Drugs.
Pharmacopsychiatry, , Volume: 53, Issue:5		2020
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
AIDS (London, England), , 05-01, Volume: 34, Issue:6		2020
Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs.
Critical reviews in oncology/hematology, , Volume: 145		2020
Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Cardiovascular revascularization medicine : including molecular interventions, , Volume: 21, Issue:6		2020
Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans.
Annals of vascular surgery, , Volume: 64		2020
Assessment of the cardiovascular adverse effects of drug-drug interactions through a combined analysis of spontaneous reports and predicted drug-target interactions.
PLoS computational biology, , Volume: 15, Issue:7		2019
Rationale, design, and methodology of the EPIC (Epidemiology of Polypharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients) study.
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, , Volume: 47, Issue:5		2019
Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications.
The Canadian journal of cardiology, , Volume: 35, Issue:3		2019
Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Medicine, , Volume: 97, Issue:51		2018
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
Alimentary pharmacology & therapeutics, , Volume: 48, Issue:11-12		2018
Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine.
Current cardiology reports, , 06-14, Volume: 20, Issue:8		2018
Aspects influencing patients' preferences for the management of drug-drug interactions: A focus group study.
Patient education and counseling, , Volume: 101, Issue:4		2018
Preferences of Patients and Pharmacists with Regard to the Management of Drug-Drug Interactions: A Choice-Based Conjoint Analysis.
Drug safety, , Volume: 41, Issue:2		2018
Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions.
JACC. Cardiovascular interventions, , 03-27, Volume: 10, Issue:6		2017
[Assessment of Efficiency of Medicamentous Therapy in Correction of Structurally Functional Changes of The Cardiac Muscle at Patients With Arterial Hypertension in Combination With Bronchial Asthma].
Kardiologiia, , Volume: 56, Issue:6		2016
Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein.
The AAPS journal, , Volume: 19, Issue:2		2017
Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?
Journal of clinical pharmacology, , Volume: 56 Suppl 7		2016
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Clinical pharmacology in drug development, , Volume: 4, Issue:2		2015
Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug-drug interactions.
Molecular genetics and metabolism, , Volume: 117, Issue:2		2016
Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial.
International journal of cardiology, , Jan-15, Volume: 203		2016
Ivabradine in Combination with Metoprolol Improves Symptoms and Quality of Life in Patients with Stable Angina Pectoris: A post hoc Analysis from the ADDITIONS Trial.
Cardiology, , Volume: 133, Issue:2		2016
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
European journal of pharmacology, , Oct-15, Volume: 765		2015
Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.
Advances in therapy, , Volume: 32, Issue:2		2015
Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).
Clinical pharmacokinetics, , Volume: 53, Issue:12		2014
Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
Experimental gerontology, , Volume: 59		2014
ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.
Clinical pharmacology and therapeutics, , Volume: 96, Issue:3		2014
Cardiac structure and function improvements in coronary artery disease combined with severe obstructive sleep apnea/hypopnea syndrome patients via noninvasive positive pressure ventilation therapy.
Coronary artery disease, , Volume: 25, Issue:6		2014
A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal.
Indian journal of pharmacology, , Volume: 46, Issue:2
The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
JACC. Cardiovascular interventions, , Volume: 6, Issue:11		2013
Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal.
Journal of the neurological sciences, , Jan-15, Volume: 336, Issue:1-2		2014
Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Aug-01, Volume: 84, Issue:2		2014
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 13, Issue:5		2013
Absorptive constituents and their metabolites in drug-containing urine samples from Wuzhishan miniature pigs orally administered with Buyang Huanwu decoction.
Journal of natural medicines, , Volume: 68, Issue:1		2014
[Cerebral blood flow and endothelial functional activity in patients with coronary heart disease and arterial hypertension during therapy with ivabradine in combination with perindopril].
Terapevticheskii arkhiv, , Volume: 84, Issue:12		2012
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, , Sep-01, Volume: 82, Issue:3		2013
Comparative effectiveness research: drug-drug comparisons in heart failure.
Heart failure clinics, , Volume: 9, Issue:1		2013
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.
Journal of hepatology, , Volume: 58, Issue:4		2013
Drug interaction networks: an introduction to translational and clinical applications.
Cardiovascular research, , Mar-15, Volume: 97, Issue:4		2013
Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population.
AIDS (London, England), , Jul-31, Volume: 26 Suppl 1		2012
The mechanisms responsible for garlic - drug interactions and their in vivo relevance.
Current drug metabolism, , Volume: 14, Issue:1		2013
Cytochrome P450-mediated cardiovascular drug interactions.
Expert opinion on drug metabolism & toxicology, , Volume: 7, Issue:9		2011
Ageing with HIV: medication use and risk for potential drug-drug interactions.
The Journal of antimicrobial chemotherapy, , Volume: 66, Issue:9		2011
Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.
Expert opinion on drug metabolism & toxicology, , Volume: 7, Issue:4		2011
Successful surgical treatment of Nicolau's syndrome combined with intravenous iloprost.
VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 38, Issue:4		2009
Early goal-directed hemodynamic optimization combined with therapeutic hypothermia in comatose survivors of out-of-hospital cardiac arrest.
Resuscitation, , Volume: 80, Issue:4		2009
Updates on cytochrome P450-mediated cardiovascular drug interactions.
American journal of therapeutics, , Volume: 16, Issue:2
[Cytochrome P-450 3A4--the most important arena for drug interactions in the body].
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Dec-18, Volume: 128, Issue:24		2008
Update on rifampin and rifabutin drug interactions.
The American journal of the medical sciences, , Volume: 335, Issue:2		2008
Herbal and dietary supplement--drug interactions in patients with chronic illnesses.
American family physician, , Jan-01, Volume: 77, Issue:1		2008
Risk and predictability of drug interactions in the elderly.
International review of neurobiology, , Volume: 81		2007
Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions.
Drug safety, , Volume: 29, Issue:8		2006
The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge.
Drug safety, , Volume: 29, Issue:1		2006
Drug-drug interactions in oncology: why are they important and can they be minimized?
Critical reviews in oncology/hematology, , Volume: 55, Issue:2		2005
Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction.
International journal of cardiology, , Volume: 98, Issue:1		2005
Herb-drug interactions: an overview of the clinical evidence.
Fundamental & clinical pharmacology, , Volume: 19, Issue:1		2005
Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest.
Resuscitation, , Volume: 63, Issue:3		2004
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Kardiologiia, , Volume: 43, Issue:12		2003
Fructose-1,6-diphosphate alone and in combination with cyclosporine potentiates rat cardiac allograft survival and inhibits lymphocyte proliferation and interleukin-2 expression.
Transplantation, , Dec-15, Volume: 74, Issue:11		2002
Rifampin and rifabutin drug interactions: an update.
Archives of internal medicine, , May-13, Volume: 162, Issue:9		2002
Cardiac drug and psychotropic drug interactions: significance and recommendations.
Heart disease (Hagerstown, Md.), , Volume: 3, Issue:4
Cytochrome p450-mediated cardiovascular drug interactions.
Heart disease (Hagerstown, Md.), , Volume: 2, Issue:3
Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents.
BJU international, , Volume: 88, Issue:6		2001
An evaluation of risperidone drug interactions.
Journal of clinical psychopharmacology, , Volume: 21, Issue:4		2001
Cardiovascular drug-drug interactions.
Cardiology clinics, , Volume: 19, Issue:2		2001
Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.
Cardiovascular drugs and therapy, , Volume: 14, Issue:6		2000
Avoiding psychotropic drug interactions in the cardiovascular patient.
Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1		2000
Cardiac drug and psychotropic drug interactions: significance and recommendations.
General hospital psychiatry, , Volume: 21, Issue:6
Intravenous hydroxyethylrutosides combined with long-term oral anticoagulation in atherosclerotic nonreconstructable critical leg ischemia: a retrospective study.
Angiology, , Volume: 50, Issue:6		1999
Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.
Drug safety, , Volume: 19, Issue:6		1998
Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients.
Journal of the American Geriatrics Society, , Volume: 44, Issue:8		1996
beta-blockers. Drug interactions of clinical significance.
Drug safety, , Volume: 13, Issue:6		1995
Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Apr-15, Volume: 154, Issue:8		1996
Pharmacokinetic drug interactions with ACE inhibitors.
Clinical pharmacokinetics, , Volume: 25, Issue:1		1993
ACE inhibitors. Drug interactions of clinical significance.
Drug safety, , Volume: 12, Issue:5		1995
Calcium antagonists. Drug interactions of clinical significance.
Drug safety, , Volume: 13, Issue:3		1995
Drug interactions in psychopharmacology.
The Psychiatric clinics of North America, , Volume: 7, Issue:3		1984
Complications of alcohol use combined with drug therapy in the elderly.
Journal of the American Geriatrics Society, , Volume: 30, Issue:11 Suppl		1982
Drug interactions with the calcium-entry blockers.
Circulation, , Volume: 75, Issue:6 Pt 2		1987
[Drug interactions in the prescriptions of patients before and after a heart infarct: results of the MONICA Augsburg heart infarct registry].
Sozial- und Praventivmedizin, , Volume: 36, Issue:1		1991
[Drug interactions of cyclosporine. Literature review].
Therapie, , Volume: 46, Issue:2

Natural Sources (1)

ArticleYear
Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction.
Circulation, , 03-03, Volume: 141, Issue:9		2020